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Abstract 
Amyloids are fibrous peptide/protein nanostructures characterized by self-assembled cross-β-
sheet molecular networks. Amyloid formation is typically associated with protein misfolding 
pathologies, including Alzheimer’s and Parkinson’s diseases. However, in recent years, 
growing evidence supported amyloid formation under normal physiological conditions, where 
these nanostructures perform host native functions.  
 
According to recent findings, a range of human neuropeptides and peptide/protein hormones 
are stored as amyloid-like nanostructures within intracellular secretory granules of brain cells. 
Upon appropriate stimulation, these neuropeptides are released into the extracellular matrix, 
where functional amyloids dissociate into monomeric peptides to perform biological functions.  
 
This thesis focuses on three functional amyloid-forming human neuropeptides: substance P, 
luteinizing hormone-releasing hormone (LHRH) and somatostatin-14. After providing a 
review of known structures and properties of amyloids (Chapter 1), biophysical techniques and 
cell experiments (Chapter 2) were used to characterise unreported nanostructures formed by 
substance P and LHRH under conditions relevant to secretory granules (Chapter 3). Substance 
P is shown to self-assemble into nanotubes with a diameter of 6 nm, while LHRH forms 
nanofibrils arranged in a hexagonal network. Both these features are novel. 
 
The influence of glycosaminoglycans, thought to be protein/peptide aggregation helpers, was 
investigated on the self-assembly mechanisms of all three model neuropeptides (Chapter 4). 
Glycosaminoglycans are shown to not only change self-assembling kinetics but also to alter 
the structure of the assemblies formed. This result is directly relevant to research methodology, 
indicating a potential danger of using such aggregation modifiers blindly in fundamental 
amyloid research. 
 
For the three model neuropeptides, the cytotoxicity of the amyloid structures and soluble 
species was assessed towards brain cell lines (Chapter 5). Concentration- and structure-
dependent cytotoxicity was found. Peptide soluble species and liquid crystalline arrays of 
neuropeptide nanostructures are non-toxic. However, aggregates/precipitates formed at high 
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neuropeptide concentration in cell culture media were correlated to cytotoxicity to 
neuroblastoma cells and microglia.  
 
The last results chapter is dedicated to exploring the use of the neuropeptide nanostructures as 
biotemplates to fabricate inorganic nanomaterials (Chapter 6). The neuropeptides are shown to 
catalyse the synthesis of silica nanotubes, gold nanoparticles, gold crystals and silver 
nanostructures. These materials offer novel perspectives of sol-gel synthesis pathways for 
inorganic nanostructures under soft conditions. 
 
Overall, the results presented in this thesis contribute to enhancing the current understanding 
of functional amyloid formation. The bio-nanomaterials developed in this thesis could be 
developed into nanotechnology applications by further research, including nanoneedles for 
drug delivery and inorganic nanomaterials for diagnostic tools or nanoelectronics.  
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Chapter 1 
General introduction 
 
1.1 Amyloids 
Amyloids are fibrous peptide/protein nanostructures often characterized by a cross-β-sheet 
structure. Even though amyloid formation is typically associated with protein misfolding 
diseases, in recent years growing evidence has shown that amyloid formation can also take 
place under physiological conditions where these amyloids perform native functions of the 
host. Amyloids that grant advantages to the host organism are known as functional amyloids. 
The discovery of functional amyloids supports the fact that amyloid formation is a generic 
property of polypeptide sequences under suitable conditions [1, 2]. Furthermore, the amyloid 
state has been characterized as the energetically most favorable state even compared to a 
native form of the peptide/protein [3]. Amyloid fibrils possess a high level of mechanical 
properties which are similar to steel and dragline silk [4].  Indeed, it has been hypothesized 
that the amyloid structure has existed as long as protein and was probably a prominent fold 
early in the evolution of life [5]. 
 
1.1.1 Structural features of amyloid fibrils 
The structural features of amyloid fibrils are surprisingly similar at the atomic level, whereas 
significantly variable at the mesoscopic level. Depending on differences in aggregation 
mechanisms mesoscopic structure of amyloid fibrils shows vast variability in shape and 
topologies [6, 7]. Nanotubes, nanofibrils, nanoparticles, ribbons, and nanosheets were 
identified as prominent amyloid morphologies [8-10]. The internal supramolecular structure 
of amyloids depends on their β-sheet hydrogen-bond networks. Amino acids are organized 
into β-strands running orthogonal to the fibril axis, while β-strands firmly packed into β-
sheets which runs parallel to the fibril axis [11, 12]. This special folding conformation of β-
sheets is termed as a cross-β sheet structure which all amyloids exhibit. Hydrogen bonds 
between β-strands arranged in either parallel or antiparallel configuration (Figure 1.1 (b)). 
The monomers or soluble peptide/protein self-assemble into oligomers, which in turn give 
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rise to protofilaments and ultimately protofilaments further pack to form amyloid fibrils [12, 
13].   
 
Figure 1.1: Common structural features of amyloid fibrils. (a) Electron micrograph of substance P functional 
amyloid nanofibrils spontaneously formed in 150 mM NaCl, peptide concentration 2% w/w. (b) Hydrogen 
bonds form between β-strands either in an anti-parallel or parallel arrangement. (c) The cross-β sheet structure 
and corresponding x-ray diffraction pattern. Adopted from [14]. 
 
Preliminary characterization of amyloid fibrils can be obtained by transmission electron 
microscopy, atomic force microscopy, X-ray diffraction, and X-ray crystallography. These 
techniques will provide information about morphology, size, shape, cross-β sheet architecture 
and polymorphism. All amyloids show characteristic features in electron microscopy (EM), 
X-ray fiber diffraction, and specific dye binding. According to EM observations, typical 
amyloid fibrils are straight, unbranched and exhibit a diameter of 7–12 nm (Figure 1.1 (a)) 
[12]. Amyloid fibrils show typical X-ray diffraction pattern of the cross-β structure at 4.8 Å 
(meridional reflection) corresponding to the distance between β strands and at 10-11 Å 
(equatorial reflection), which corresponds to the distance between β sheet networks (Figure 1 
(c))[15]. In optical microscopy, amyloids exhibit apple-green birefringence when stained with 
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Congo red and observed under cross polarised light [16]. Further, amyloids show an increase 
in fluorescence after binding to Thioflavin T dye [17]. 
 
The atomic resolution X-ray data revealed that interdigitated β-sheet structure known as the 
steric zipper is essential for amyloid fibril formation. Eight theoretical steric zipper classes 
have been identified depending on the structural arrangement of β sheets and however, seven 
of them were observed by X-ray crystallography [18]. Apart from finding of β-strand as 
building blocks of amyloids and cross-β steric zippers, the recent finding of amyloid 
polymorphism has greatly improved the understanding of amyloid structure at the molecular 
level. Amyloid polymorphism in which a certain peptide/protein chain adopts two or more 
structurally distinct conformations of amyloid under the same environmental conditions. This 
phenomenon can observe both at the atomic level and mesoscopic level. This structural 
heterogeneity can clearly identify in solid-state NMR spectra as differences in chemical shifts 
either peak broadening or doubling (multiplets) [19, 20]. Combination of solid-state NMR 
and cryo-SEM with complementary biophysical techniques Dobson group has shown that 11-
residue peptide adopted from transthyretin forms three polymorphs of twisted fibrils made up 
of two, three and four protofilaments [21].  By combining crystallography, NMR data and 
molecular modeling techniques, polymorphism at the atomic level were observed for amyloid 
β peptide (Aβ) derived sequences. For instance, three steric zipper cross-β-sheet motifs were 
identified for peptide fragment  KLVFAA derived from Aβ (1-42) [22]. Indeed, steric zipper-
based polymorphism represents two types of polymorphism which are packing and segmental 
polymorphism. 
 
1.1.2 Disease-associated amyloids 
More than 20 disease conditions are associated with amyloid plaques/fibril formation, 
including Alzheimer’s disease, Parkinson's disease and Type II diabetes [23, 24]. Disease 
conditions involved with protein misfolding and subsequent amyloid formation are known as 
protein misfolding diseases. Several protein misfolding diseases and protein/peptide 
responsible for the disease condition are given in Table 1.1. In each disease condition, 
different types of proteins are responsible for amyloid formation. For instance, in 
Alzheimer’s disease, amyloid β peptide (Aβ) and in Parkinson’s disease, α-synuclein 
undergoes conformational changes to form water-insoluble amyloid plaques. Most of the 
amyloid plaques are found extracellularly and thought to have a pathological effect on cells. 
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In Alzheimer’s disease, two types of amyloid plaques are formed: neuritic amyloid plaques 
(extracellular plaques) and neurofibrillary tangles (intracellular plaques). Neuritic amyloid 
plaques composed of Aβ 42 are found in the extracellular matrix around cerebral vessel walls 
and in the brain parenchyma. These plaques are the main cause of dementia, cognitive 
dysfunction and loss of personality observed in Alzheimer’s patients [25]. On the other hand, 
neurofibrillary tangles are made up of tau protein and found in the cytoplasm of degenerating 
neurons [26]. The Aβ is produced by cleavage of the amyloid precursor protein which is 
present in normal individuals and thought to have a biological function. However, in 
Alzheimer’s disease, this peptide misfolds and form toxic amyloid aggregates. 
Table 1.1. Diseases due to protein misfolding and corresponding protein/peptide [27]. 
Protein misfolding disease Protein/peptide involved 
Alzheimer’s disease Aβ 
Parkinson disease α-synuclein 
Diabetes mellitus type II Islet amyloid polyprotein (IAPP/Amylin) 
Huntington's disease Huntingtin 
Immunoglobulin light-chain amyloidosis Monoclonal immunoglobulin 
light chain 
Immunoglobulin heavy chain amyloidosis Monoclonal immunoglobulin heavy chain  
Spongiform encephalopathy Prion protein 
Chronic inflammatory diseases, 
Secondary systemic amyloidosis 
Serum amyloid A protein or fragments 
Senile systemic amyloidosis Normal plasma transthyretin 
Medullary carcinoma of the thyroid Calcitonin 
Creutzfeldt–Jakob Disease Prion protein 
Prolactinomas Prolactin 
Atherosclerosis Apolipoprotein AI 
Hereditary renal amyloidosis 
Hereditary cerebral amyloid angiopathy 
Cystatin C 
Hereditary renal amyloidosis Gelsolin 
 
1.1.3 Functional amyloids 
In recent years several peptides and proteins that are not apparently associated with amyloid 
diseases have been shown to self-assemble into amyloid-like fibrils both in vivo and in vitro. 
These non-toxic biologically beneficial amyloids are known as “functional amyloids” and are 
composed of natural peptides/proteins in their native conformation under physiological 
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conditions. Functional amyloids have been found in a wide range of organisms, including 
human however they were first found in microbes. For instance, curli protein in Escherichia 
coli is involved in surface and cell-cell interactions [28]. The chorion protein of silkworm 
protects the oocyte and the developing embryo from environmental hazards [29]. Prion 
protein in yeast increases the survival of the host in special environmental conditions [30]. 
Further, chaplins produced by Streptomyces coelicolor to support hyphae formation and spore 
spreading[31]. Spidroin protein produced by a spider to form silk fibers of the web [32]. 
Indeed, the mammalian protein Pmel17 forms functional amyloid, which assists in melanin 
production [33]. It is noteworthy that peptide and protein hormones, such as prolactin[34], 
growth hormone [35], chromogranins, insulin, β-endorphin, somatostatin-14 [36] and 
tachykinin neuropeptides [37] have been shown to self-assemble in vitro into amyloid-like 
structures. This evidence further supports the fact that amyloid formation is an intrinsic 
property of polypeptide chains under suitable conditions [1, 2]. Examples of functional 
amyloids are given in Table 1.2. Later on, Maji and co-workers have shown that the protein 
and peptide hormones are stored inside the secretory granules as an amyloid-like structure 
[38]. This finding led to an important question that is not clearly answered up to date is that 
the mechanism behind peptide/protein amyloid formation in secretory pathway and 
reconversion of these aggregates to native structure/monomer upon physiological demand to 
perform their biological roles. However, non-cytotoxicity observed for functional amyloids is 
thought to be due to their ability to reversibly self-assemble into monomers [38]. In 
accordance with Maji and co-workers, over 30 human peptide/protein hormones that are 
stored as amyloids in secretory granules have been identified. Highly concentrated 
peptide/protein hormones are stored in secretory granules found in neurosecretory cells and 
exocrine cells [39]. It has been previously shown that densely packed cores of secretory 
granules are consist of protein aggregates with different protein structure [40]. Maji et al. 
reported that 10 peptide hormones out of 42 form amyloids in vivo without the help of an 
aggregation helper. However, in the presence of an aggregation helper called “heparin,” 31 
out of 42 peptides showed amyloid-like structures in vitro. Heparin belongs to a family of 
anionic polysaccharides called glycosaminoglycans (GAGs). GAGs have been reported to 
play a significant role in the amyloid formation of a wide range of proteins/peptides either 
associated with diseases or native biological functions [41-43]. They have also been found to 
influence amyloid formation in vitro by favoring amyloid fibril formation and stabilization 
[42]. Moreover, GAGs perform an important role in the packaging of peptide/proteins into 
secretory granules [44].  
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Most of the neuropeptides found in neurosecretory cells of brain form amyloid-like structures 
both in vivo and in vitro. Tachykinin group neuropeptides; kassinin, physalaemin, and 
substance P have shown amyloid-like structure formation in vitro in the presence of heparin 
[37]. Glucagon-like peptide I and II have also demonstrated amyloid-like structure formation 
in vitro[45]. It has been reported that somatostatin-14 forms both nanofibers and amyloid 
droplets that possess structural features similar to typical amyloids [36, 46]. Moreover, 
growth hormone forms amyloid-like self-assemblies both in vivo and in vitro in the presence 
of Zn [35]. An interesting finding has been reported by Maji et al on account of co-
aggregation of adrenocorticotropic hormone (ACTH) with β-endorphin [38, 47]. Both 
peptides follow the same biosynthetic pathway and co-localized in the pituitary secretory 
granules. Even though ACTH was shown to form amyloid-like aggregates in the presence of 
β-endorphin, ACTH alone was unable to form amyloids. In addition to neuropeptides, other 
peptide/proteins also demonstrated the ability to form amyloid-like structures. For instance, 
Insulin has been shown to form amyloid-like assemblies both in vitro and in vivo [48, 49]. 
Indeed, HypF-N protein extracted from Escherichia coli also has the ability to self-assemble 
into amyloid-like structures [50]. This protein is apparently not associated with any amyloid 
forming diseases. However, prefibrillar aggregates of HypF-N protein have shown to be 
toxic.  
Table 1.2. Functional amyloids found in prokaryotes and eukaryotes. 
Protein  Organism 
Curli Escherichia coli [28, 51] 
Microcin E492 Enterobacteriaceae [52] 
Chaplins Streptomyces coelicolor [53] 
Harpins Xanthomonas species s[54] 
Sup35 Saccharomyces cerevisiae [30] 
Ure2p Saccharomyces cerevisiae [55] 
Hydrophobins Schizophyllum commune [56] 
HET-s Podospora anserine [57] 
Pmel17 Mammalians [33] 
Cytoplasmic polyadenylation element-binding 
protein 
Saccharomyces cerevisiae [58] 
Mot3 Saccharomyces cerevisiae [59] 
Neuropeptides  
Most of the peptide hormones 
Humans [38] 
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1.2 Protein aggregation and amyloid formation 
Protein aggregation kinetics and mechanisms have been extensively studied over the past 
decade. Even though several mechanisms have been proposed for amyloid aggregation, 
nucleation-dependent polymerization is the most widely accepted mechanism in this regard. 
Firstly, protein/peptide must be partially unfolded, misfolded or intrinsically disordered for 
the aggregation to be initiated. Amyloid formation is characterized by three distinct kinetic 
phases: lag phase, growth phase and final saturation phase (Figure 1.2). The lag phase is 
characterized by slow nucleation and the structural change occurs in soluble protein/peptide 
which is the transition of the helical structure into β-sheet rich structures. Since nucleation is 
a thermodynamically unfavorable process, the lag phase turns out to be the rate-limiting step 
in protein aggregation. However, multiple nucleations that occur in the lag phase lead to the 
formation of many oligomeric species which has different structural characteristics to that of 
the final amyloid fibrils.  
 
Figure 1.2: Species involved in the amyloid fibrillization process (a) and a generic kinetic scheme of 
aggregation (b). Adapted from [60]. 
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Primary nucleation produces oligomers that further extend into fibrils by the addition of 
monomers [61]. In most cases, the proliferation of nuclei formed in the early lag phase takes 
place via secondary nucleation where existing fibrils are fragmented to provide seeds that 
grow into fibrils or existing fibril surfaces catalyze the formation of new aggregates from 
monomers [61]. Fibril surface catalyzed secondary nucleation has been reported for many 
systems, including Aβ40, Aβ42, and α-synuclein [62-64]. Elongation and replication through 
primary and secondary nucleation occur during all three kinetic phases however at different 
rates [61]. The growth phase is characterized by the addition of monomers/oligomers onto 
protofilaments which finally become amyloid fibrils. Notably, in the growth phase, 
monomers and protofilaments are approximately at equimolar concentrations. From a 
thermodynamic perspective, the growth phase is a thermodynamically stable process which 
has less Gibbs free energy than native state and oligomers, therefore this phase occurs rapidly  
Due to the less Gibbs free energy associated with amyloid state, native peptide/protein will 
spontaneously transit form a state of high free energy to a state of lower free energy [65] 
(Figure 1.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Energy landscape of protein folding and aggregation. Reproduced with permission from Hartl, F.U. 
and M. Hayer-Hartl, Converging concepts of protein folding in vitro and in vivo. Nat Struct Mol Biol, 2009. 
16(6): p. 574-581 [66]. Copyright (2016), Nature publishing group. 
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Hence, the amyloid state is one of the most thermodynamically stable protein folding states. 
The final saturation phase is a steady-state where protofilaments associate to form amyloid 
fibrils. These fibrils are the predominant species in the saturation phase, while monomer 
concentration has reached the equilibrium value. Intrinsic and extrinsic factors can modulate 
the lag and growth phases by altering the concentration of the free monomer in solution 
and/or introducing preformed nuclei to the solution [61].  
 
In contrast to the nucleation-dependent polymerization mechanism, the nucleated 
conformational conversion model proposed by Serio et al for IAPP and Aβ, [67] 
demonstrates that the rapid formation of oligomers takes place at first and later on these 
oligomers convert to fibrils at a slower rate. It has been suggested in another mechanism that 
monomer influence the conversion of other native monomers to prefibrillar state which 
eventually forms amyloid fibrils [68, 69].  
1.3 Atomic to mesoscopic structures of amyloids 
Differences in aggregation pathways could lead to the formation of diverse amyloid 
nanostructures. Atomic-level structures include oligomers and 0D aggregates (nanoclusters, 
nanoparticles, nano triangles, squares, and loops), while mesoscopic structures include, 1D 
aggregates (protofibrils, nanofibrils, nanoribbons, and nanotubes), 2D aggregates (sheets, 
films, and membranes) and 3D amyloid plaques (amorphous aggregates observed in 
neurodegenerative diseases [70].  
 
The study of amyloids over the past half-century led to the belief that amyloid fibrils and 
amorphous aggregates were the agents responsible for cytotoxicity observed in 
neurodegenerative diseases [71-73]. In sharp contrast, current growing evidence suggests that 
oligomers and 0D aggregates found in the early stage of aggregation pathway are responsible 
for the cytotoxicity rather than mature fibrils [74-76]. Oligomers are small molecular 
aggregates that later form fibrils. They are formed by assembling individual monomers 
(monomers from 2- 30) [77]. Indeed, oligomers are soluble in aqueous solutions and have 
different sizes and morphologies. They are usually known as spherical species due to EM 
observations. Oligomers are formed in early stages of aggregation pathway as a metastable 
species which in turn converts to energetically more favorable species. In addition to the 
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differences seen in size and shape compared to fibrils, oligomers do not contain cross-β 
structure which is specific to amyloid fibrils [78]. In the context of the secondary structure of 
oligomers, some of the oligomeric species are rich in β-sheets, while others contain random 
coil [79]. A recent study has shown that amyloid oligomers have the ability to self-replicate 
from the monomer at physiological temperatures and thereby promote protofilament 
nucleation and further assembly into fibrils [80]. Some of the amyloid oligomers exhibit 
crystalline morphology, for instance, peptide segments derived from Aβ and tau proteins [81, 
82]. Apart from oligomers, other prefibrillar aggregates which are a nanoparticle, 
nanospheres, and annular oligomers are also believing to cause toxicity in neurodegenerative 
diseases. Prefibrillar aggregates or 0D nanostructures are aggregates or clusters without any 
prominent dimensional feature. A study conducted to identify sizes of toxic species involved 
in PrP aggregation has revealed that PrP nanoparticles with masses similar to 14-28 PrP 
molecules are the highest toxic initiator species found in PrP disease [73]. Furthermore, Guo 
et al have shown that triphenylalanine peptide self-assemble into nanospheres with significant 
β-sheet content [83]. Another study has demonstrated that lipid-induced nanosphere 
formation by Aβ(1-40) which could be a possible mechanism to occur in Alzheimer’s disease 
[84]. Some of the studies have suggested that annular oligomer formation is related to 
channel hypothesis which is one of the toxicity mechanisms found in neurodegenerative 
diseases. The Aβ protein or α-synuclein based annular oligomers insert themselves into the 
cell membrane and form ion channels which could lead to the calcium influx into cells [85].  
 
The 1D amyloid nanostructures include protofilaments, protofibrils, and nanofibrils. These 
structures have high hierarchical morphology in which individual protofilaments self-
assemble to form protofibrils which in turn packed into mature amyloid fibrils. Differences in 
packing of protofilaments give rise to a diverse range of morphologies including nanofibrils, 
nanotubes, and nanoribbons. Nanotubes are tube-like structures with well-defined 
morphology and hollow architecture. This bio-inspired group of nanostructures is widely 
implicated in material science and nanotechnology in the last decade. Nature provides a few 
examples of biological tubular assemblies based on peptides and proteins such as capsid of 
the tobacco mosaic virus, microtubules, some of the disease associated amyloid fibrils [12, 
86, 87]. Lanreotide which is a somatostatin analog has been reported to form nanotubes with 
2D hexagonal packing, the diameter of 244 Å and a wall thickness of 18 Å [88]. Further, they 
proposed that electrostatic interactions are an important factor in the formation of nanotubes 
in the hexagonal lattice. In addition, lanreotide has been used as a template for silica 
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nanotube fabrication [89]. Apart from single peptide or protein, nanotubes can also form by 
the closure of the helical ribbon [90]. Elsewhere, pH dependant nanotube formation was 
reported for triptorelin where conformational changes in the peptide lead to the formation of 
either small or large nanotubes depending on the pH [91]. Recently, Zhao et al has shown that 
nanotubes formed by symmetric amphiphilic peptide could be converted to nanofibrils by 
increasing acetonitrile concentration in their solvent system [92]. Interestingly, co-assembly 
of phenylalanine-based peptides of FF and Boc-FF (N-(tert-butoxycarbonyl)- L-Phe-L-Phe-
COOH) has formed nanotubes. Variation in the molar ratio of these two peptides could give 
rise to nanotubes with different length distribution [93]. Nanotube diameter of lanreotide has 
been finely amended by chemically modifying the building blocks of the peptide [94]. 
Twisted ribbons and helical ribbons are the other frequently reported fibril morphologies. 
Twisted ribbons are identified by Gaussian curvature (saddle-like curvature), while helical 
ribbons are identified by zero Gaussian curvature. Twisted ribbon will convert to helical 
ribbon depending on a number of protofilaments associated which in turn closure to form 
nanotubes. Amyloidogenic hexapeptide ILQINS derived from hen egg-white lysozyme form 
right-handed helical ribbons and crystals [95]. The same group has shown that conversion of 
fibrils to the crystal in single aggregates occurs via untwisting of the twisted ribbon by using 
similar type peptide sequences as above [96].  
 
Due to high mechanical properties and adherence properties, amyloids can be used in 
applications in material science and nanotechnology. Modifications to 1D structures could 
deliver a variety of 2D structures including, 2D amyloid films [97], membranes [98]and 
nanosheets [99].  
1.4 Interactions of amyloids with aggregation helpers 
1.4.1 Glycosaminoglycans (GAGs) 
The GAGs are a family of anionic polysaccharides, having molecular weights of roughly 5-
100 kDa, which contains hyaluronic acid (HA), chondroitin sulfate (CS), dermatan sulfate 
(DS), keratan sulfate (KS), heparan sulfate (HS) and heparin [100, 101]. They are composed 
of repeating disaccharide units consisting of uronic acid (either glucuronic acid (GlcA) or 
iduronic acid (IdoA)) or galactose(Gal) and an amino sugar (either N-acetylglucosamine 
(GlcNAc) or N-acetylgalactosamine (GalNAc))[102]. The structures of different GAGs are 
shown in Figure 1.4.  
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Figure 1.4: Structures of different GAGs. Galactose (Gal), glucuronic acid (GlcA), iduronic acid (IdoA), N-
acetyl-glucosamine (GlcNAc) and N-acetyl-galactosamine (GalNAc). Reproduced from [44].  
 
With the exception of HA, the only un-sulfated member, all GAGs contains a degree of O-
sulphation, while heparin and HS contain N-sulphates as well [102]. GAG chain synthesis is 
initiated in the early secretory pathway by the formation of a tetra-saccharide linker on serine 
residues, except for KS. Chain extension, deacetylation, and epimerization continue during 
the transport through the Golgi complex, while sulfation occurs in the trans-Golgi and the 
trans-Golgi network. Degradation of GAG chains takes place in the lysosomes by the help of 
endo-type hydrolases, exotic glycosidases and sulfatases [103, 104]. Most of the GAGs are 
usually found covalently linked to a protein backbone, except HA. This protein-GAG 
complex is termed as a proteoglycan (PG) [105]. GAGs are located primarily on the surface 
of cells or in the extracellular matrix (ECM) of multicellular organisms, where they can be 
found either covalently linked to the protein core of proteoglycans or as free macromolecules 
[105, 106]. The major portion of proteoglycans located at the cell surfaces in the ECM is HS 
proteoglycans (HSPG) [103]. 
1.4.1.1 Interactions of disease associated amyloids with GAGs 
Amyloids can be formed in vitro under suitable conditions. However, in vivo these conditions 
are different, and the environment is complex. Therefore, these aggregates formed and grow 
with other molecules which may or may not have an influence on the amyloid formation and 
subsequent growth. Among these amyloid associated molecules, GAGs are considered as an 
important molecule group that has an influence on amyloid formation in both vivo and vitro. 
The high concentration of GAGs have been observed in the extracellular matrix and have 
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found in amyloid plaques as well [42, 107]. GAGs have been reported to play a significant 
role in the amyloid formation of a wide range of proteins/peptides either associated with 
diseases or native biological functions [108-110]. Amyloid deposits in the tissues of patients 
affected by amyloid diseases have been frequently found associated with GAGs [41, 111-
113]. Among different GAGs, HS is the most common, being found in a variety of amyloid 
disorders including Alzheimer’s disease, type II diabetes, light chain amyloidosis and prion-
related diseases [113-116].  Besides HS/HSPG, KS/KS proteoglycan (KSPG), DS/DS 
proteoglycan (DSPG) and CS/CS proteoglycan (CSPG) have been shown to be associated 
with senile plaques (SPs) and neurofibrillary tangles (NFTs). The KSPG core protein and 
GAG chains were identified in the periphery of senile plaques by two different antibodies in 
Alzheimer’s brain [117]. In addition, Lindahl et al. reported that amounts of KS are reduced 
to less than half of the control values in the cerebral cortex of Alzheimer patients [118]. In the 
case of DS, Decorin, and Biglycan, two DSPG was weakly bound to Aβ peptide [119]. 
Moreover, Decorin was more localized towards the periphery of spherically shaped SPs and 
to the edges of amyloid fibril bundles within the plaque periphery  [120]. An 
immunocytochemical study has demonstrated three types of CS chains, including 
chondroitin-4-sulfate, chondroitin-6-sulfate and unsulfated chondroitin in Alzheimer's brain. 
The chondroitin 4-sulfate was found in both SPs and NFTs, while chondroitin 6-sulfate was 
found in NFTs and the area around SPs. Further, unsulfated Chondroitin was observed in 
intracellular NFTs and the dystrophic neurites of SPs [121]. It has been revealed that KS, DS, 
and CS are found in the periphery of SPs, whereas HS tends to be evenly distributed 
throughout SPs.  
Evidence for interactions of GAGs with amyloids originates from both in vivo and in vitro 
studies. GAGs have shown to play important roles in amyloid fibrils formation, stability, and 
resistance to proteolysis. It has been reported that heparin binds to Aβ 1–40/1–42 and rapidly 
convert soluble peptide with the α-helix structure to well-organized amyloid fibrils with β-
sheet structure. This observation has revealed that GAGs accelerate the fibril formation by 
acting on the early stage of fibril formation. The lateral aggregation has also been observed 
with GAGs when incubated with preformed Aβ fibrils [122-124]. Sulfate moieties in GAGs 
are important for their inducer activity. Notably, complete removal of sulfate moieties in 
heparin led to the complete loss of its inducer activity [125]. Sulfates enhance the anionic 
nature of GAGs which is important in their electrostatic interactions with positively charged 
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proteins. Another study has shown that the replacement of sulfate with magnesium and 
calcium ions reduce this electrostatic interaction [125, 126]. 
Besides Aβ, GAGs especially heparin and HS induce fibril formation in α-synuclein, tau 
protein, gelsolin, β2-microglobulin, and IAPP. Cohlberg et al. reported that heparin has a 
high affinity to α-synuclein and not only accelerate the fibrillation but also increase the fibril 
yield. Further, they have suggested that the intracellular protein aggregates found in 
Parkinson’s disease known as “Lewy bodies” may also contain GAGs [42]. Several studies 
conducted on Tau protein which is the protein responsible for intracellular deposits found in 
Alzheimer’s disease have revealed that both sulfated GAGs and Tau protein co-exist in 
NFTs. Moreover, they also showed that sulfated GAGs stimulate tau phosphorylation. Both 
these finding taken together propose that GAGs may be a key determinant in the formation of 
NFTs in Alzheimer’s disease [127, 128]. Suk et al. reported that heparin promotes 
aggregation at both early and late stages of amyloidogenesis of gelsolin and sulfate moieties 
play an essential role in promoting activity [129]. Heparin is also important in the amyloid 
formation of β-2microglobulin [130]. On the other hand, heparan sulfate converts IAPP 
protein into a partial helical structure which can eventually form amyloids [131]. Another 
similar study has revealed that protonation of histidine residue promotes binding of IAPP to 
heparin which in turn accelerates fibrillation. Further, the presence of soluble heparin in cell 
media reduces the toxicity of IAPP amyloids to cells. Therefore, they suggested that GAGs 
reduce the toxicity of amyloids by accelerating the conversion of toxic oligomers to non-
toxic/less toxic amyloid fibrils [132]. In the case of prion protein (PrP), HS showed paradox 
effect which is HS act as an accelerator in the conversion of PrP to scrapie PrP and 
simultaneously it also provides protective action against this conversion [133].  
Among all GAGs, heparin has the highest accelerating activity, due to its high sulfate 
content. Although there are several reports have been published on interactions of amyloids 
with GAGs, very few explain the mechanism of these interactions. Motamedi-Shad et al. 
reported that HS splits the aggregation process into two different pathways which occur in 
parallel. On one hand, HS binds to the soluble protein and accelerates the conversion of 
monomers to β-sheet rich fibrils which happens very fast. On the other hand, HS converts 
protein fraction that cannot interact with HS to fibrils which are normally slow aggregation 
[134]. However, according to a recent study, GAGs do not bind to secondary structures of 
monomeric 8 kDa gelsolin, but they bind to oligomers with β-sheet structures and in turn, 
accelerate amyloid fibril formation [135] (Figure 1.5).  
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Figure 1.5: Proposed mechanism of heparin-mediated enhancement of protein self-assembly into amyloid 
fibrils.  Some discrepancies exist from one protein system to another, depending on which protein species can 
efficiently bind to heparin/GAGs (see text). Adapted from [60]. 
The same research group has proposed a similar mechanism for interactions of heparin with 
transthyretin protein. GAGs bind to transthyretin oligomers and accelerate the formation of 
quaternary structures (amyloid fibrils and aggregates). This hypothesis led to an important 
question that if GAGs only binds to oligomers, then how monomeric transthyretin rapidly 
disappear immediately after mixing GAGs with peptide. They addressed this question using 
light scattering data and suggested that monomer–misfolded amyloidogenic monomer–
oligomer–fibril all these are linked together and follow equilibrium. Presence of sulfate 
moieties is essential for this binding since binding occurs through electrostatic interactions. 
Further, the polymeric nature of heparin is critical for binding to multiple transthyretin 
oligomers simultaneously [136]. More recently, Blancas-Mejía et al. described that the 
mechanism of amyloid and GAGs interactions depends on the amyloidogenicity of peptide 
and type of GAG. Amyloid light chain protein wild-type and mutated version with different 
amyloidogenic propensities were subjected to in vitro amyloid formation in the presence of 
HS and CS. Results proposed that HS promotes the formation of transient amyloidogenic 
structures, thus favors amyloid formation, while CS kinetically trap unfolded intermediates 
and inhibit fibril formation resulting in accumulation of oligomeric species [137].  
Interactions of amyloids with GAGs also depend on structural features of the native peptide. 
Malik et al. showed that carbohydrates prefer binding to aromatic residues especially 
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tryptophan over other amino acids [138].  Highly sulfated GAGs like heparin strongly 
interacts with peptides that have binding sites rich in a high density of positive charges. HS 
containing less and highly spaced negative charges interacts strongly with a peptide 
containing a binding site with widely spaced cationic residues [139]. The important 
determinants of binding affinity of GAGs and peptides are highly acidic sulfate groups and 
basic side chains of Arg, Lys and His [139]. Arginine has the highest relative strength of 
heparin binding by basic amino acid residues followed by lysine. This is due to strong 
hydrogen bonds and electrostatic interactions between the guanidine group in Arg and sulfate 
groups in heparin [140]. However, van der Waals forces, hydrogen bonds and hydrophobic 
interactions with the carbohydrate backbone of GAGs and peptides are also playing a role in 
GAGs peptide interactions.  
 
1.4.1.2 Interactions of functional amyloids with GAGs 
Over the last few years, many research groups working on functional amyloids have been 
extensively used GAGs in the formation of amyloid aggregates in vitro. In this case, heparin 
is the most abundantly used GAG species [38, 141, 142]. Since most of these 
proteins/peptides are neuropeptides, they synthesized in hypothalamus/pituitary and stored in 
their secretory granules [38]. Even though GAGs should be located within the secretory 
granules to promote fibrillar aggregation, the presence of GAGs in the matrix of secretory 
granules of brain tissue is still not well established. It has been reported that small quantities 
of HS, heparin, and CS were detected in prolactin granules isolated from rat pituitaries [143]. 
Brain synaptic vesicles contain HS, DS, a DS-CS hybrid, CS and HA in their matrix [144, 
145]. Moreover, the occurrence of PGs in cholinergic synaptic vesicles has been reported. 
The carbohydrate chain of this proteoglycan is either HS/heparin [146]. In sympathetic 
nerves, norepinephrine is stored in large dense-cored vesicles which contain HS in their 
matrix [147]. Further, HS was detected in LHRH and somatostatin cells and their neurites 
located in the olfactory nerve bundles in chick embryos [148]. To best of our knowledge, the 
latter report is the only evidence which suggests the presence of intracellular GAGs in the 
hypothalamus. Even though available evidence for the occurrence of GAGs in brain tissue are 
very limited, there are many published reports on the presence of GAGs in secretory granules 
of other cell types. The presence of HS and CS in the matrix of chromaffin granules was 
reported [149]. The zymogen granules of the guinea pig pancreas also contain GAGs [150]. 
The mast cells have been shown to contain strongly acidic heparin in its granules [151]. 
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Although HS is the most commonly reported GAG species in tissues, most researchers used 
heparin in their studies to promote fibrillar aggregation. The difference between HS and 
heparin is that heparin has a high degree of O-sulphations than HS which explains its high 
affinity to binds to positively charged peptide and promotes fibrillar aggregation than HS.  
Most of the amyloid-like structure formation of neuropeptides has been reported in the 
presence of heparin. Maji and co-workers reported that tachykinin neuropeptides; Kassisin 
and substance P formed amyloid fibrils in the presence of heparin. Kassisin has also formed 
fibrils in the absence of heparin, while substance P did not show any amyloid-like structures 
in the absence of heparin [37]. LHRH analogs have been shown to form amyloid-like 
structures in the presence of heparin, whereas wild-type LHRH did not form amyloid-like 
structures even in the presence of heparin [141]. It has been reported that glucagon-like 
peptide I (GLP I) showed fast aggregation kinetics in the presence of heparin than alone. 
However, no change in the rate of aggregation kinetics was observed for glucagon-like 
peptide II with heparin and without heparin. This study has reported important facts about 
heparin peptide interaction in amyloid formation. On one hand, heparin interacts with GLP I, 
in turn, accelerates the amyloid formation and integrated within amyloid fibrils. On the other 
hand, heparin neither influences the amyloid formation of GLP II nor incorporate with their 
fibrils. Furthermore, heparin stabilizes GLP I fibrils over GLP II fibrils. GLP I has basic-non 
basic-basic amino acid sequence which may be the reason for the strong interactions with 
highly acidic heparin. However, the absence of such sequence in GLP II could be the cause 
for few interactions between GLP II and heparin [45]. Anoop et al. reported that 
somatostatin-14 form amyloid-like fibrils in the presence of heparin [142], while Grondelle et 
al. showed that somatostatin has ability to form amyloid-like structures even in the absence 
of heparin [36]. Maji et al. found that 31 out of 42 hormones formed amyloid-like structures 
in the presence of heparin, while only 10 out of 42 peptide hormones showed amyloid-like 
structures without heparin [38]. 
HypF-N protein extracted from Escherichia coli exhibited amyloid-like structure formation in 
vitro in the absence of GAGs. In contrast to other amyloids, heparin was not able to bind to 
HypF-N oligomers and convert them to less toxic amyloid fibrils. However, GAGs reduce the 
toxicity of prefibrillar aggregates of HypF-N protein by binding to the cell surface and 
preventing oligomer-cell interactions. This finding indicates that GAGs can reduce amyloid 
toxicity by two different mechanisms. They can either bind to oligomers and convert them to 
less toxic higher order aggregates or bind to the cell surface and prevent interactions of 
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oligomers with cells [152]. Singh et al. reported that melittin and pancreatic polypeptide form 
toxic oligomers in the presence of heparin. Melittin exhibited conversion of their random coil 
to oligomeric helical structure, whereas pancreatic polypeptide continued as helix after 
oligomerization. These toxic oligomers showed similar toxicity characteristics as α-synuclein 
[153]. Apomyoglobin is a protein does not exhibit any ability to form amyloids in vivo. 
However, in the presence of heparin apomyoglobin showed amyloid fibril formation in vitro. 
Heparin played an active role by accelerating amyloid fibril formation without a lag phase 
and it also increased fibril yield. Authors suggest that the presence of a turn in an amino acid 
sequence of apomyoglobin may be the reason for strong interactions between peptide and 
GAGs. Heparin has also induced amyloid fibril formation of partially folded intermediate of 
apomyoglobin mutant species. These findings taken together proposed that GAGs perform a 
dual role in an amyloid formation by accelerating the conversion of oligomers/intermediates 
to amyloid fibrils and also play a pathological chaperone role by inducing amyloid formation 
[154]. A similar result has been observed with the 23-residue peptide PLB, which 
corresponds to the acetylated cytoplasmic domain of the phospholamban transmembrane 
protein. This protein apparently not associated with amyloid forming diseases and predicted 
to have low amyloidogenicity. This peptide did not show amyloid formation on its own. 
However, in the presence of heparin this peptide exhibited the rapid formation of amyloid 
fibrils. Influence of heparin is prominent in low pH and showed β sheet structures [155]. 
Although several reports have been published on interactions of GAGs with IAPP (amylin), 
literature available on interactions of GAGs with IAPP non-amyloidogenic variants is 
limited. Wang et al. reported that IAPP non-amyloidogenic variant spontaneously forms 
fibrils in the presence of heparin. This effect is higher than the effect showed by model 
membranes containing anionic lipids. Well-established inhibitors of IAPP amyloid formation 
were also less effective in this case [156]. 
 
1.4.2 Granins 
Granins are a family of acidic glycoproteins that are found abundantly in secretory granules 
of the nervous, endocrine and immune system[157, 158]. Chromogranin and Secretogranin 
are the major subclasses of granins. Chromogranin are composed of a well-known compound 
Chromogranin A (CgA) and chromogranin B (CgB). Secretogranins includes Secretogranins 
II (SgII), III, IV, V (or neuroendocrine secretory protein 7B2), VI (or NESP55) and VII (or 
nerve growth factor-inducible protein VGF). CgA, CgB, and SgII are the well-characterized 
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members of granin family. CgA was first isolated from bovine chromaffin cells as a high 
molecular weight acidic protein that secreted with catecholamine [159]. It possesses N-
terminal disulfide bridge, the middle portion of acidic amino acids and several dibasic 
cleavage positions which indicates their ability to generate small bioactive peptides by 
proteolysis. Catestatin and vasostatin are CgA derived peptides. SgII was first discovered in 
the anterior pituitary [160]. This protein also exhibits dibasic cleavage positions in their 
amino acid sequence which also suggest their capacity to generate peptide sequences. 
Secretoneurin is a neuropeptide derived from SgII [161].  
CgA has been reported as a critical factor in the secretory granule biogenesis and subsequent 
hormone storage. Kim and co-workers have shown that down-regulation of CgA expression 
in PC12 cells resulted in a significant reduction of dense-core secretory granules and 
secretory granule proteins. This was reversed when CgA was transfected into CgA deficient 
PC12 cells [162]. Several studies conducted on secretory granules of adrenal chromaffin cells 
have also indicated that the down-regulation of CgA expression led to decrease the number of 
secretory granules formed and also caused mutations in catecholamine storage [163, 164]. 
Moreover, Montesinos et al. demonstrated 30% decrease in catecholamine production and 
content in CgA knock-out mice than the wild type which also confirms the importance of 
CgA in hormone storage in secretory granules of neuroendocrine cells [165, 166]. All these 
evidences taken together suggest that CgA may influence the storage of hormones as 
amyloids in secretory granules. 
CgA was found mainly in senile plaques of Alzheimer’s disease and Parkinson’s disease 
[167, 168]. Increased levels of IgA were demonstrated in the temporal cortex of the brain of 
patients with Alzheimer’s disease. CgB was also observed in Aβ plaques, but mainly in 
entorhinal cortex and subiculum [168, 169]. Further, SgII was also found mainly in Aβ 
plaques in the entorhinal cortex [170]. Co-localization of SgII with CgA and CgB has also 
been reported [168]. However, there are no clear evidence to prove the influence of grains in 
toxic amyloid formation, even though they have been found in amyloid plaques.  
 
1.4.3 Metal Ions 
The D block metal ions, predominantly CuII, ZnII and FeII/III were found associated with 
protein misfolding diseases, including AD, Parkinson disease, prion diseases, and 
amyotrophic lateral sclerosis (ALS). Metal homeostasis is an important factor for neuronal 
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function. Homeostatic dysfunction of metals in several amyloid diseases has been identified 
[171, 172]. Significantly, high concentrations of CuII, ZnII, and FeIII have been demonstrated 
in the core and rim of senile plaques in AD patients [173, 174]. Interestingly, CuII  and ZnII 
were found as bound to Aβ in amyloid plaques [175]. A subclass of glutameric neurons found 
in the hippocampus upon excitation release micromolar concentration of ZnII into the 
synaptic cleft [176]. Hippocampus is responsible for memory and is one of the sites affected 
by AD in early stages [177]. Growing evidence have shown the similar situation for CuII 
which also release high concentrations into the synaptic cleft [178]. The high concentration of 
Aβ has also been found in the synaptic cleft. In this case, since both Zn and Cu are not tightly 
bound to biological ligands which in turn create a labile pool. It has been proposed that in the 
presence of Zn/Cu labile pool Aβ form aggregates and this aggregation is induced by Zn/Cu 
binding. Amylin/IAPP also forms aggregates in the presence of Zn in pancreatic β-cells 
[179]. Iron deposits have been found in Lewy bodies formed in Parkinson’s disease [180].  
In most cases, transition metal ions bind to peptides through side chains of amino acid 
residues, but in some cases, binding can occur via backbones such as carbonyl group or N-
terminal amine [181]. Cu and Zn mainly bind to peptides via side chains of histidine, cysteine 
and N terminal amine. Histidine carries imidazole group which has a nitrogen lone pair that 
can coordinate with a metal ion. Cysteine bears thiol side chain which can coordinate with 
metal ions. Metal binding can also occur through carboxylate ions of aspartate or glutamate 
and the side chain of methionine to a lesser extent. Metal binding sites for Aβ has been 
extensively studied. Major binding sites for Aβ are histidine (His 13, 14 and 6), tyrosine (Try 
10), aspartate (Asp1, 7 and 23) or glutamate (Glu 3, 11 and 22), methionine (Met 35), 
deprotonated amide and carbonyl groups in peptide backbone [182-185].  
Several in vitro studies have shown that transition metal ions mainly CuII and ZnII modulate 
peptide/protein aggregation. Both these ions have been shown to accelerate Aβ aggregation 
by reducing the lag phase. Metal to peptide ratio (stoichiometry) plays an important role in 
metal induces aggregation kinetics. In other words, this ratio will determine the ultimate 
aggregation product. When superstoichiometric levels of CuII and ZnII are present in a 
solution Aβ form amorphous insoluble aggregates and inhibit fibrillization [186-188]. At 
equimolar levels of CuII and ZnII give rise to amorphous aggregates of Aβ that in turn slowly 
release amyloid fibrils [189]. Subequimolar levels of CuII accelerate the amyloid fibril 
formation kinetics of Aβ by rapidly forming nuclei [190, 191]. The excess amount of iron 
gives rise to the formation of Aβ annular protofibrils [192]. It has been recently reported that 
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MnII possesses a weak binding affinity to N terminal part of Aβ (1-40) [193].  Since the 
affinity is very low, Mn binding may not contribute to AD pathology. Both ZnII and FeIII bind 
to hyperphosphorylated tau protein and trigger the aggregation. High level of ZnII induces 
granular aggregate formation, while low levels induce fibril formation [194]. FeIII induces tau 
aggregation mainly into the formation of paired helical filaments [195]. In the case of α-
synuclein, the equimolar concentration of CuII has significantly reduced the lag phase of fibril 
formation [196]. A recent study conducted on amylin has shown that Cu suppresses the 
formation of fibrils and induces the formation of toxic oligomers [197]. Further, Cu has 
driven the IAPP aggregation into a different pathway which ends up forming toxic globular 
oligomeric species. After binding to one site of a peptide-metal can rapidly exchange between 
another site of the same peptide or in between another peptide [198]. Peptides have shown 
fast exchange rates as well. Based on both facts, Faller et al. proposed that even at high 
concentration of peptide, metal can bind to all the possible sites by transient binding and fast 
exchange. They have tested this hypothesis with Aβ 11-28 and ZnII (Figure 1.6). 
Figure 1.6. Mechanisms of metal-induced fibrillization, without transient binding (top) or with transient binding 
(bottom). Reproduced with permission from Faller, P., C. Hureau, and G. La Penna, Metal ions and intrinsically 
disordered proteins and peptides: from Cu/Zn amyloid-beta to general principles. Acc Chem Res, 2014. 47(8): 
p. 2252-9 [199]. Copyright (2016) American Chemical Society. 
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In this case, they believe that Zn acts as an aggregation catalyst. Further, Zn was capable to 
induce the aggregation of Aβ 11-28 monomers by binding to aggregates and rapid 
exchanging [200]. 
1.5 Interactions of amyloids with cell membranes 
According to the World Health Organization, 47.5 million people have dementia worldwide, 
of which Alzheimer’s disease accounts for 60-80% of cases. Alzheimer’s disease is a 
neurodegenerative disease, an umbrella term that encompasses over 20 pathologies with 
different clinical features, but similar cellular processes of brain cell damage by toxic protein 
species. It is currently thought that an important role is played by small protein oligomers 
rather than mature fibers. However, in several studies, mature fibrils have also been found to 
harm cell viability. The interaction of disease associated amyloid aggregates with the cell 
plasma membrane is widely being explored. However, the knowledge available on the 
interactions of functional amyloids with cells is very limited. 
It has been frequently reported that Aβ fibrils and other disease-associated amyloid fibrils are 
toxic to several types of brain cells. Annular protofibrils of α-synuclein showed to alter 
membrane permeability which led to an increased influx of calcium from the extracellular to 
intracellular space that causes cell death [201]. It has been reported that Aβ cause toxicity to 
neuronal cells by apoptosis [202]. Mirzabekov et al. proposed that membrane pore formation 
may be the cause for the toxicity of human amylin towards β cells [203]. In another study, 
both fibrils and soluble oligomers of Mammalian prion protein showed toxicity towards 
cultured cells and primary neurons [204]. Bucciantini et al. reported Sup35p fibrils to induce 
abnormal accumulation and over stabilization of lipid raft domains in the cell membrane 
which in turn cause membrane disruption [205]. In the case of functional amyloid 
cytotoxicity, Maji et al showed that tachykinin neuropeptides are non-toxic to neuroblastoma 
cells [37]. A recent study conducted on the cytotoxicity of HypF-N protein oligomers 
proposed a correlation between oligomer hydrophobicity and size to predict oligomer toxicity 
[206]. In accordance with this study, toxic oligomers have high hydrophobicity and small 
size. 
Lipid components of cell membrane play a crucial role in cell membrane-amyloid 
interactions. Lipids such as cholesterol, sphingomyelin, and phospholipids are important in 
this regard [207]. Aβ induced membrane toxicity through several mechanisms. Aβ may 
influence the fluidity of lipid bilayer via strong physicochemical interactions. Aβ could be 
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inserted into the membrane, in turn, disturb the structure of the plasma membrane. Further, 
Aβ oligomers promote the release of lipid such as cholesterol and phospholipids which leads 
to the disruption of neuronal lipid homeostasis. Aβ can also form ion channels in lipid 
bilayers [208, 209]. Some of the studies have reported that binding of Aβ to membrane lipids 
induces Aβ fibrillation, thereby disturbs the structure and function of the membrane, for 
instance, membrane fluidity or pore formation [210]. 
1.6 Amyloids as biomaterials 
Amyloids are excellent candidates for the fabrication of biomaterials for a variety of 
technological and biological applications. Several unique properties of amyloids make it 
suitable for nanomaterial, including spontaneous fibrillization under suitable conditions, 
stability and high mechanical stiffness, highly ordered structures, nucleation-dependent 
polymerization, and ability to change physicochemical properties by either modulating amino 
acid sequence or experimental conditions and nanoscale dimensions [211, 212]. The most 
important characteristic of amyloid fibrils is size, shape, morphology and secondary structure 
could be modulated by varying experimental conditions. There is a range of potential 
applications of amyloid fibres in material science, including nanotubes, 
nanowires/nanocables, biosensors, scaffolds, hydrogels, and drug delivery vehicles. 
Several studies have demonstrated the used of amyloid self-assemblies as templates for 
nanotubes and nanowires/cables. Nanotubes formed by the central region (Phe-Phe dipeptide) 
of Aβ amino acid sequence was utilized in the fabrication of metal nanowires [213, 214]. 
Silver ions were diffused to the lumen of these nanotubes led to the fabrication of silver 
nanowires [214]. In another study, platinum nanoparticles were incorporated into the 
nanotubes to form peptide–nanotube platinum–nanoparticle composites [215]. Carny et al. 
reported the fabrication of coaxial trilayer metal–peptide-metal nanocables with gold-coated 
silver filled nanotubes [216].  Moreover, diphenylalanine nanotubes were decorated with 
generic avidin–biotin adaptor for the use of enzyme immobilization [217]. Indeed, 
Genetically modified protein NMSup35 was used to develop gold coated nanowires that 
conduct electricity [218]. Hen egg white lysozyme was utilized in the fabrication of 
conducting polyalanine nanowires [219]. Yemini et al. reported the fabrication of biosensors 
by attaching diphenylalanine nanotubes to gold electrodes [220]. Fabrication of glass 
nanotubes from lanreotide peptide has also been reported [221].  
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Self-assembling properties of peptides are used in the fabrication of hydrogels, scaffolds, and 
drug delivery vehicles as well. Zhang and co-workers developed a hydrogel that can be used 
as a scaffold to support neuronal cell attachment, differentiation and neurite outgrowth [222]. 
Kisiday et al. reported that hydrogel formed by KLD-12 peptide provides an outstanding 3D 
tissue culture material for the production of a cartilage-like extracellular matrix [223]. 
Amyloidogenic 9-fluorenylmethoxycarbonyl (Fmoc) dipeptides and naphthalene(Nap)-Phe-
Phe conjugates were used in the fabrication of hydrogel, which is suitable for controlled drug 
release and scaffold for cell growth [224]. Another study has shown that Fmoc peptide 
hydrogel can be used as scaffolds that can determine the differentiation of mesenchymal stem 
cells [225]. Insulin fibrils have been used in designing of amyloid-based drug delivery 
vehicle [226]. Maji et al. showed the development of long-acting drug depot using LHRH 
analogs [141]. Self-assembly of L-diphenylalanine was used as a vehicle for model drug 
Rhodamine delivery. Further, they have observed that the depot was distributed as small 
aggregates or homogeneously inserted in the structure [227]. 
1.7 Scope of this thesis 
Although functional amyloids have been discovered decades ago, still limited literature is 
available on the characterization of this type of amyloid. Due to the lack of characterization, 
functional amyloids have not frequently been used to develop biomaterials although they 
retain the advantages of typical amyloid-based materials, while they are more likely to ensure 
biocompatibility. I hypothesise that functional amyloids can give rise to various 
morphologies that can be directly used as biomaterials or as templates for nanomaterials is 
explored. In this context, the results presented in this thesis contribute to advance the current 
understanding of the functional amyloid formation and paved the way to translating these 
peptide nanostructures into nanomaterials for drug delivery [228-230], inorganic biomedical 
diagnostic tools or nanoelectronics [231]. 
This thesis is focused on the structure, properties, biological relevance and applications of 
functional amyloids by three natural neuropeptides: somatostatin-14, substance P and 
luteinizing hormone-releasing hormone (LHRH).  
Chapter 2: The materials utilized, and experimental procedures performed throughout the 
research work. 
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Chapter 3: Substance P was discovered to self-assemble into nanotubes and LHRH was found 
to form liquid crystalline nanostructures. To get insight into the structure of SP and LHRH at 
both supramolecular and molecular scales, a combination of complementary biophysical 
techniques, including microscopic, spectroscopic and scattering techniques were used. 
Chapter 4: Influence of aggregation helpers like glycosaminoglycans on structure and 
kinetics of functional amyloid self-assemblies were investigated using a combination of 
biophysical techniques.   
Chapter 5: Interactions of neuropeptide nanostructures with different types of brain cells such 
as microglia and neuroblastoma were determined by classical cell culture assays and 
microscopic techniques. 
Chapter 6: Downstream applications of nanostructures formed by neuropeptide in the 
fabrication of biomaterials were studied using biophysical techniques. 
1.8 The aims of the research for this thesis were: 
1. To investigate the biophysics and biological relevance of nanostructure formation by 
model neuropeptides 
1.1. To determine the influence of pH, ionic strength and concentration on peptide 
nanostructure formation. 
1.2. To determine the influence of aggregation helpers on peptide nanostructure formation. 
2. To investigate the interactions of functional amyloid nanostructures and disease-associated 
amyloid fibrils with different brain cells. 
3. To design biomaterials from model neuropeptides using their self-assembling properties. 
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Chapter 2 
Materials and methods 
2.1 Materials 
2.1.1 Chemicals and reagents 
Thioflavin T (ThT), sodium azide, phosphate buffered saline (PBS) tablets, heparin sodium 
salt from porcine intestinal mucosa (Molecular weight, 17000 - 18000 Da.) and chondroitin 
sulfate sodium salt from shark cartilage were purchased from Sigma-Aldrich (Australia). 
Sodium chloride ACS was obtained from Alfa Aesar (United Kingdom). Uranyl acetate and 
200 mesh Cu grids with formvar and carbon coating were obtained from ProSciTech Pty Ltd 
(Australia). A Millipore filtration system was used to obtain fresh purified water for sample 
preparation. Quartz glass capillaries of 0.01 mm wall thickness and 1.5 mm outer diameter 
were purchased from Hilgenberg GmbH (Germany).  
 
2.1.2 Peptides 
Tables 2.1 gives the details of the peptide sequences studied in this research. 
 
Table 2.1: Neuropeptide sequences used in this study 
 
 
 
Peptide Composition Net charge at pH 7 Molecular 
weight (Da) 
SST-14 AGCKNFFYKTFTSC +2 1638 
Substance P RPKPQQFFGLM-NH2 +3 1348 
LHRH XHYSYGLRPG-NH2 +2/+1 1182 
Oxytocin CYIQNCPLG-NH2 +1 1007 
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Neuropeptides were obtained as acetate salts with a purity of > 95% as tested by matrix-
assisted laser desorption ionization (MALDI) mass spectrometry by the provider. 
Somatostatin-14 (SST-14) and oxytocin were purchased from Polypeptide (India). Substance 
P and luteinizing hormone-releasing hormone (LHRH) were obtained from ChemPep (USA). 
All peptides were obtained as powders and stored at -30°C except oxytocin acetate, which 
was stored at 2-8°C.  
 
2.1.3 Preparation of buffers and staining solutions 
NaCl 150 mM solution. - The weighed fraction of NaCl was dissolved in water to obtain a 
150 mM NaCl solution. 
PBS solution. - One tablet of PBS was dissolved in 200 mL of water to obtain a 137 mM 
NaCl, 2.7 mM KCl and 10 mM phosphate buffer solution (pH 7.4 at 25 °C). 
Phosphate buffer pH 8. – Potassium dihydrogen phosphate 0.523 g and 16.73 g of 
dipotassium hydrogen phosphate were dissolved in water and topped up until 1000 mL with 
the same solvent to obtain 0.1 M phosphate buffer solution at pH 8.  
ThT 25 µM in NaCl. - A stock solution of 250 μM ThT NaCl was used for ThT binding 
assays. To prepare the stock solution, 8.0 mg of ThT was weighed and dissolved in 50 mL of 
150 mM NaCl. The stock solution was diluted to a working concentration of 25 μM with the 
same solvent.  
Sodium azide 0.01% (w/v) was added all buffers and solutions to prevent microbial growth.  
 
2.1.4 Preparation of peptide solutions 
Solvent (150 mM NaCl, PBS or phosphate buffer pH 8) containing 0.01% sodium azide was 
added to a weighted fraction of acetate salt of the peptide powder. The solution was then 
vortexed for a few seconds to mix and stored at 4°C.  
Self-assembly of peptides with heparin or chondroitin sulphate – A weighed fraction of 
heparin was dissolved in 150 mM NaCl containing 0.01% sodium azide. This solution was 
then used to dissolve the peptide acetate powder. In all samples, the molar ratio of heparin to 
peptide was used as1:1 unless otherwise stated. Peptide solutions prepared in the presence of 
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heparin showed a precipitate immediately after the addition of heparin to the peptides except 
for oxytocin. Mixing was realized with vortex and all the samples were then stored at 4°C. 
The same protocol was used for peptide samples with chondroitin sulphate. 
 
2.2 Methods 
2.2.1 Thioflavin T (ThT) fluorescence assay 
ThT is a benzothiazole dye (Figure 2.1) which is widely used as an amyloid identification 
method. ThT binds to the cross-β structure of the amyloid fibrils. Upon binding of the fibrils, 
ThT displays a dramatic increase in fluorescence intensity by shifting excitation maximum 
(from385 nm to 450 nm) and the emission maximum (from 445 nm to 482 nm) [1, 2]. ThT 
fluorescence assay demonstrates advantages over conventional staining methods used in 
amyloid identification. Most importantly, ThT assay enables real-time in-solution observation 
of fibrillization [3]. In addition, it’s high solubility in water and moderate affinity to fibrils 
make this method easy to controlled according to the experimental system [4]. Moreover, it 
has been demonstrated that ThT molecule binds to both fibrils composed of synthetic and 
biological sources effectively [1, 2].  
 
Figure 2.1: Chemical structure of thioflavin T molecule 
According to the literature, few models have been proposed to explain ThT-fibril interactions. 
Among these models, the channel model is the most accepted model (Figure 2.2). ThT 
recognizes a common structural feature in amyloid fibrils which is the cross-β structure. The 
surfaces of the cross-β structures make the ThT-binding sites (Fig 2.2a). The side-chains in 
cross-β structures of fibrils arranged in a specific way to form a structure named “cross-strand 
ladders” [5]. Cross strand ladders are composed of repeating side-chain interactions, which 
are running parallel to the long axis of the fibril. These side chains form grooves along 
solvent-exposed surfaces of fibrils into which linear ThT molecule inserts itself (Fig 2.2b). 
Further, ThT binds parallel to the long axis of the fibril surface in grooves [6-9]. MD 
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simulations have been conducted to study ThT-fibril interactions at the atomic level. The 
results of these studies strongly support the channel model [10, 11]. 
 
Figure 2.2: The cross β sheet structure of amyloid fibrils and channel model of ThT-fibril interactions. (a) The 
common structure of amyloid fibrils. (b) Channel model of ThT binding to fibrils. Linear ThT molecule binds to 
fibril through grooves generated by side chain interactions. Adapted from [12].  
For ThT assay, two protocols were used based on the aggregation rate (fast kinetics and slow 
kinetics). Peptides in the presence of heparin/chondroitin showed rapid aggregation kinetics 
(in a few seconds) forming precipitates or gels immediately after mixing. Therefore, it was 
impossible to detect the starting point by manual mixing of peptide and heparin/chondroitin. 
Hence, we used Flexstation microplate reader, which has an option to add heparin into 
peptide inside the instrument that allowed to detect the starting point. Pure peptides need at 
least a few hours to aggregate which allowed us to capture the starting point by a 
conventional microplate reader (Clariostar). 
Slow kinetics – The fibril formation was monitored by β-sheet-sensitive dye ThT. A weighed 
fraction of the peptide acetate powder was dissolved in 25 µM ThT NaCl solution. The first 
measurement (t=0) was recorded immediately after the sample preparation. All the samples 
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were then stored at 4°C to equilibrate during the experiment and fluorescence intensities were 
recorded at different time points. Fluorescence intensity was performed in triplicates using 
ClarioStar a fluorometer equipped with a plate reader (excitation wavelength: 440 nm, 
emission wavelength: 482 nm). The fluorescence intensity was measured from 80 μL samples 
in 96 well plates. The data are corrected for blank intensity (25 µM ThT in NaCl) and 
expressed as mean ± S.D. Three independent experiments were performed for each 
concentration. ThT fluorescence was plotted against experiment time using Graph Pad 
software.  
Fast kinetics – A weighed fraction of the peptide acetate salt was dissolved in a solution of 25 
µM ThT NaCl containing 0.01% sodium azide. Heparin powder was also dissolved in the 
same solvent to obtain the same final molar concentration as the peptide. A 50 μl aliquot of 
heparin solution was added to a 50 µl of the peptide acetate solution in Flexstation 3 
microplate reader. Fluorescence was measured before the addition and immediately after the 
addition of heparin solution. Fluorescence intensity was then recorded in every 30 seconds 
until 20 minutes. Samples were excited at 440 nm, and fluorescence intensity was recorded at 
482 nm, using a 25 μM ThT NaCl solution as a blank. Three replicates were performed. The 
same procedure was used for chondroitin sulphate. Three independent experiments were 
conducted and results were expressed as mean ± S.D. ThT fluorescence was plotted against 
experiment time using Graph Pad. ThT fluorescence emission intensity, F(t), is reported as a 
function of time, t, and fitted to either of the following single exponential functions: one 
phase association (1) or plateau followed by one phase association (2). 
𝑓𝑓(𝑡𝑡) = 𝑌𝑌0 + (𝑃𝑃𝑃𝑃𝑃𝑃𝑡𝑡𝑃𝑃𝑃𝑃𝑃𝑃 − 𝑌𝑌0) ∗ (1 − 𝑃𝑃−𝑘𝑘𝑘𝑘)                       (1) 
Y0 is the Y value when time (t) is zero and K is the aggregation rate constant, expressed in 
reciprocal of the X-axis time units. 
𝑓𝑓(𝑡𝑡) = 𝐼𝐼𝐼𝐼 (𝑋𝑋 < 𝑋𝑋0,𝑌𝑌0,𝑌𝑌0 + (𝑃𝑃𝑃𝑃𝑃𝑃𝑡𝑡𝑃𝑃𝑃𝑃𝑃𝑃 − 𝑌𝑌0) ∗ �1 − 𝑃𝑃�−𝐾𝐾 ∗ (𝑋𝑋 − 𝑋𝑋0)��               (2) 
X0 is the time at which the association begins. Y0 is the average Y value up to time X0. It is 
expressed in the same units as Y. Plateau is the Y value at infinite times, expressed in the 
same units as Y. K is the rate constant, expressed in reciprocal of the X-axis time units. 
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2.2.2 Attenuated total reflectance Fourier-transform infrared spectroscopy 
(ATR-FTIR). 
IR spectroscopy is the measurement of the wavelength and intensity of the absorption of 
infrared light by a sample. The ATR technique is based on a property of total internal 
reflection resulting in an evanescent wave [13]. The ATR technique is illustrated in Figure 
2.3.  
 
Figure 2.3: Schematic representation of ATR-FTIR  [14] 
The ATR crystal generally has a higher refraction index than the sample being studied 
(typically larger than 2). The sample is deposited as a thin film on the ATR crystal. The 
infrared beam is coupled into the crystal and directed towards the sample interface at such an 
angle of incidence that it is totally reflected at the interface between sample and crystal. This 
reflection creates evanescent waves which penetrate into the sample. This penetration depth 
depends on the optical thickness of the sample, the angle of incidence (θ) and the ratio of the 
indices of refraction of crystal and sample. After one or several reflections, the beam exits the 
crystal and is concentrated on the detector. If the sample absorbs evanescent wave the light 
reaching the detector has the data about the IR spectrum of the sample [13, 15, 16]. 
IR spectroscopy provides information about the secondary structure content of proteins and 
peptides. The IR spectrum of a protein or peptide contains nine characteristic IR absorption 
bands, that is, amide A, B, and I−VII (Table 2.2)  [13, 17]. However, among all these nine 
bands Amide I and II are the most prominent vibrational bands of the protein backbone 
(Figure 2.4). These arise from the amide bonds that link the amino acids. The most sensitive 
spectral region of the protein secondary structural components is the amide I band 
Chapter 2 
 
46 
 
(1700−1600 cm−1), which is due almost entirely to the C=O stretch vibrations of the peptide 
linkages (approximately 80%) [13]. The amide II band, in contrast, derives mainly from in-
plane NH bending (40−60% of the potential energy) and from the CN stretching vibration 
(18−40%). This region shows much less protein conformational sensitivity than its amide I 
counterpart [13].  
 
Figure 2.4: Characteristic amide I and II bands in the IR spectrum of a peptide. 
 
Table 2.2: Characteristic IR bands of proteins/peptides [17] 
Amide band Wavenumber 
(cm-1) 
Description 
Amide A 3300 NH stretching 
Amide B 3100 NH stretching 
Amide I 1600-1700 C=O stretching 
Amide II 1480-1575 CN stretching, 
NH bending 
Amide III 1229-1301 CN stretching, 
NH bending 
Amide IV 625-767 OCN bending 
Amide V 640-800 Out-of-plane 
NH bending 
Amide VI 537-606 Out-of-plane 
C=O bending 
Amide VII 200 Skeletal torsion 
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The amide I vibrations (1600–1700 cm−1) are commonly used as conformational markers for 
peptides and proteins. They can be assigned to specific secondary structures. According to 
the literature, two peaks for antiparallel β sheets can be observed at one strong peak near 
1620 and a weaker peak 1680-1690 cm-1. Some peptides also exhibit a peak for parallel β 
sheet near 1630 cm-1. Peaks for random coil and turn can be demonstrated at around 1650 and 
1660-1670 cm-1 respectively [13].  
Second derivative spectroscopy is widely used as a spectral analysis technique for IR 
spectroscopy. It allows more specific identification of small and nearby lying absorption 
peaks which are not well resolved in the original spectrum [18, 19]. Figure 2.5 shows the 
original spectrum and its second derivative which exhibits enhance the resolution of peaks. 
According to Beer-Lambert law, beam absorbance of the sample can be stated as follows (3) 
[20]: 
𝐴𝐴(ѵ) = ∝ (ѵ)𝑃𝑃𝑙𝑙            (3) 
Where A is the wavenumber, ѵ = dependent absorbance, α = the wavenumber-dependent 
absorption coefficient, l is the optical path length (mainly determined by the section 
thickness) and c is the concentration. When equation (3) is differentiated twice, the result is 
given in (4) [20]. 
𝑑𝑑2𝐴𝐴(ѵ)
𝑑𝑑ѵ2
 = 𝑑𝑑2𝛼𝛼(ѵ)
𝑑𝑑ѵ2  𝑃𝑃𝑙𝑙              (4) 
 
ATR-FTIR spectra were measured using a Tensor II Bruker Spectrometer equipped with an 
ATR attachment. The spectra are shown to result from an average of 32 scans. Each spectrum 
was scanned over the range of 4000-1000 cm-1, using a 4 cm-1 resolution. All spectra were 
baseline corrected and the water signal was removed by subtraction of respective solvent 
(blank) spectrum recorded the day of the experiment. Blank subtracted data corresponding to 
an amide-I region (1700-1600 cm-1) were deconvoluted using curve fitting option available in 
OPUS 7.5 software. The same software was used to obtain the second derivative of the 
spectrum using 13 to 17 points.  
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Figure 2.5: Bands responsible for protein secondary structure found in amide I region. A//β = antiparallel β 
sheet, //β = parallel β sheet, R = random coil, T = turn. 
 
2.2.3 Polarized optical microscopy  
Polarized optical microscopy is a commonly used technique to detect the existence of liquid 
crystal phases in a solution. This technique is based on the polarization of the light beam. 
There are two polarizers in a polarizing optical microscope. First polarizer situated in the 
beam path somewhere before the specimen and second polarizer (analyser) in the optical 
pathway between the objective aperture and the observation lens. They are situated at a right 
angle (90°) to each other, which is named as cross polar. Polarizers specifically transmit one 
polarization angle of light. Therefore, cross polarizers transmit no light. The first polarizer is 
oriented vertically to the beam so that the incident light waves only in the vertical direction 
can pass through it. The second polarizer is oriented horizontally to the incident light, hence 
the vertical light waves transmitted through the first polarizer are blocked by the second 
polarizer (Figure 2.6). When polarizers are crossed at a 90° angle to each other, the 
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background of the sample will turn black. Any bright spot that appears is a result of the 
interaction of plane-polarized light with a birefringent (or doubly-refracting) sample. The 
birefringent sample has two refractive indices, thus the sample will split the initial light into 
two wave components when it passes through the sample. One of the wave components will 
follow Snell’s law of refraction, which is called the ordinary ray, and one that does not follow 
Snell’s low named as the extraordinary ray. These two rays exit the sample at two different 
velocities due to the difference in their refractive indices. This leads to a phase difference, but 
are recombined with constructive and destructive interference when they pass through the 
analyzer [21]. Then the combined wave will have elliptically or a circularly polarized light 
wave. The most common case is that the incident linearly polarized light is converted to 
elliptically polarized light with one component of light that can pass through the analyzer and 
give a bright spot on the specimen. Liquid crystals will exhibit a variety of textures and 
birefringence when observed under cross-polarized light. These textures will reveal 
information about their macroscopic structure and their symmetry [21].   
 
Figure 2.6: Schematic representation of the optical microscope with cross polarizers. Adapted from [22]. 
Optical microscopy observations were performed using a Zeiss Axioskop microscope 
(Germany), at magnifications up to x20. An aliquot (10 µL) of the sample was conditioned in 
thin layers between a glass slide and coverslip. The polarizer and analyser were placed in a 
fixed crossed position. Experiments were performed at room temperature (25°C). Digital 
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images were obtained with an Axiocam 105 colour camera connected to a computer and 
recorded using the Zen software. 
 
2.2.4 Small-angle X-ray scattering 
Small-angle X-rays scattering (SAXS) is a powerful method used for the analysis of 
biological macromolecules in solution. It provides information about the sizes and shapes of 
proteins and complexes. Structural information can be obtained for nanostructures to micron 
level structures. SAXS covers a broad range of molecular sizes ranging from a few kDa to 
GDa and under different experimental conditions [23-25]. High-intensity synchrotron sources 
provide high-quality data. In addition, synchrotron SAXS is a rapid technique and time-
resolved studies yield unique information about the kinetics of processes and interactions 
[26]. In a typical SAXS experiment, dissolved macromolecules are exposed to a collimated 
and focussed X-ray beam and the scattered intensity (I) is recorded by an X-ray detector as a 
function of the scattering angle (Figure 2.7). Due to the random orientations of the particles 
in solution, the scattering pattern is isotropic. The scattering intensity (I) depends on the 
modulus of the momentum transfer “s” (5). The scattering pattern of the pure solvent is also 
collected and subtracted from the sample solution scattering, leaving only the signal from the 
macromolecule of interest.  
 
Figure 2.7: Schematic representation of a SAS experiment. 2θ is the angle between the incident and scattered 
beam [27] 
 
𝑠𝑠 = 4𝜋𝜋 sin(𝜃𝜃)
𝜆𝜆
                       (5) 
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𝐼𝐼(𝑠𝑠) =  〈𝑰𝑰(𝒔𝒔)〉𝛺𝛺 = 〈𝑨𝑨(𝒔𝒔)𝑨𝑨∗(𝒔𝒔)〉𝜴𝜴       (6) 
In equation 6, scattering amplitude A(s) is a Fourier transformation of the excess scattering 
length density, and the scattering intensity is averaged overall orientations (Ω). After solvent 
subtraction, the background corrected intensity I(s) is proportional to the scattering of a single 
particle averaged over all orientations. The scattering patterns generated from a dilute 
solution of proteins or other macromolecules are typically presented as radially averaged one-
dimensional curves (Figure 7b).  
Amyloid fibrils show typical X-ray diffraction pattern of the cross-β structure at 4.8 Å 
(meridional reflection) corresponding to the distance between β strands and at 10-11 Å 
(equatorial reflection), which corresponds to the distance between β sheet networks (Figure 
2.8). 
 
Figure 2.8: The cross β-sheet motif and the corresponding X-ray diffraction pattern [28]. 
Samples were prepared within wax-sealed 1 mm quartz capillaries (Charles Supper, US) and 
kept under 4°C at least 4 days to form oligomers/fibrils before recording the x-ray pattern. 
Highly viscous samples were centrifuged to get the sample to the bottom of the capillary 
tube. SAXS and WAXS experiments were performed on the SAXS/WAXS beamline 
operated at 12 KeV at the Australian Synchrotron (Melbourne, Australia). The sample 
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capillaries were introduced into a capillary holder accommodating 20 capillaries. The 
SAXS/WAXS patterns were recorded for a sample-detector distance of 1.6 m and 1 m with 
an exposure time of 1 second, providing a q range of 0.01-1 Å-1. For WAXS, 1 m sample-
detector distance and same exposure time as SAXS were used. However, a higher q range 
was applied (1-3 Å-1) in WAXS. Scattering pattern was recorded using 1M Pilatus detector 
for SAXS and a 200k Pilatus detector for WAXS. Each pattern shown resulted from radial 
integration (Scatterbrain, Australian Synchrotron) and subtraction of the corresponding buffer 
scattering.  
 
2.2.5 Transmission electron microscopy (TEM) 
TEM is a biophysical technique which is used to visualize and analyze specimens in the size 
of the submicron level. It reveals levels of detail and complexity which cannot obtain light 
microscopy since it uses a focused beam of high energy electrons. TEM is used to produce 
images from a sample by illuminating the sample with electrons within a high vacuum and 
detecting the electrons that are transmitted through the sample. One of the most common 
detectors equipped with a transmission electron microscope is the x-ray energy dispersive 
spectroscopy (EDS or EDX) system [29]. Liquid nitrogen is used to keep the detector cold. 
The most common image generated using a TEM is a bright field image. Some areas of the 
sample scatter or absorb electrons and therefore appear darker. Other areas transmit electrons 
and appear brighter. TEM image formation involves two stages (Figure 2.9) [29]. In stage 
one (stage A), the incident electron beam is scattered by the sample. This scattered electron 
beam passes via an objective lens, which focuses it to form the primary image. In stage two 
(stage B), the primary image is magnified using additional lenses. TEM permits high-
resolution (below 1 nm) and high magnification (up to 1,000,000 x) imaging [29]. It provides 
details about sample morphology and can use to construct a 3-dimensional image. In 
addition, TEM can measure the mechanical properties of the sample when it has necessary 
settings for this technique. It also can use to view frozen material when it has a cryo-stage. 
However, TEM cannot use to obtain colored images. Since electrons cannot readily penetrate 
sections much thicker than 200nm, TEM cannot use to observe thick samples [29].  
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Figure 2.9: Schematic representation of TEM image formation. Adapted from [29]. 
In TEM, negative staining is generally used for the sample preparation. Negative staining is a 
technique where the background is stained, leaving the actual specimen untouched, and thus 
visible. Heavy metals derived salts are usually used as staining agents such as molybdenum, 
uranium, or tungsten acetates. Heavy ions are readily interacting with the electron beam and 
produce phase contrast. When the sample (mounted on the copper grid) is added to the stain, 
the stain surrounds the sample but is excluded from the volume occupied by the sample. 
Thus, it termed as negative staining. 
Negative staining of samples was done on carbon-coated Formvar 200-mesh copper grids. 
The grids were deposited one minute each, on 15µL drops of (i) Peptide solution (ii) water 
(separated into 3 drops, 20 seconds for each) and (iii) 1% (w/w) aqueous uranyl acetate. The 
filter paper was used to remove excess liquid from the grids, which were then placed back 
into the grid holder to dry for a minimum of one hour before use in TEM. Samples with 
heparin or chondroitin sulphate were centrifuged and resulting residue which was redissolved 
in NaCl was used for negative staining. The grids were examined with a JEOL 1010 
transmission electron microscope operating at 100 kV, with magnifications up to x 12k. 
Micrographs were captured using a Gitan digital camera. 
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2.2.6 Atomic force microscopy (AFM) 
AFM is one of the most widely used biophysical characterization techniques. The main 
difference between electron microscope/light microscope and AFM is that this technique 
does not need lenses, light or electron sources to create an image [30]. The physical basis of 
AFM is based on the tunneling effect [30]. It is a quantum mechanical property which can be 
generated by only applying a voltage between a sharp metallic tip and the investigated 
surface, both separated by a vacuum barrier. Electrons tunneling ability via this vacuum 
barrier depends on its thickness. If the thickness is a few atomic diameters, then the electrons 
would be able to tunnel via it which gives rises to current flow. Hence, tunneling current 
exponentially depends on vacuum barrier distance or height [30]. Figure 2.10 shows a 
schematic diagram of AFM [31]. To obtain the surface topography of the sample, it is 
essential to scan the tip over the surface at a constant current or height [31]. Then the 
interaction between the top of the tip and surface is measured and converted into an electrical 
signal which is developable into a three-dimensional image of the sample topography. AFM 
has an extremely high spatial resolution of the order of 0.01 nm [30]. AFM has the potency to 
image the sample via several different mechanisms in addition to topographic imaging. Those 
mechanisms are a frictional force, phase contrast, amplitude, adhesion, and elasticity [31]. 
Further, electronic, magnetic and thermal interactions are also able to record if the tip is 
capable to identify these forces [31]. 
 
 
Figure 2.10: A schematic diagram of AFM. Adapted from [31]. 
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A 20 µl aliquot of the sample solution was deposited onto freshly cleaved mica, rinsed with 
Milli-Q water and dried by air for 15 to 20 minutes at room temperature before the imaging. 
Quantitative Nanomechanical AFM (QNM-AFM) was used to analyse fibrils on mica 
substrates using a Bruker Multimode 8 AFM, a Nanoscope V controller and antimony (n) 
doped silicon cantilevers with 525 kHz resonant frequency and a 200 N/m spring constant 
(RTESPA-525, Bruker). Before use each cantilever was individually calibrated, cantilever 
deflection sensitivity was determined from indenting a hard sapphire surface and the precise 
spring constant was determined using the thermal method, finally, tip radius was determined 
from analysis of a roughened Ti calibration grid (RS-12 M) using the NanoScope Analysis 
software (Bruker). Absolute Calibration of the cantilever was confirmed by measuring the 
stiffness of a polystyrene film with well-defined stiffness in the same order of magnitude as 
the fibrils (2.7 GPa) (PSFILM-12M, Bruker). If required the recorded tip radius was slightly 
adjusted so that the measured stiffness was within 5 % of the known stiffness. Topographic 
and Nanoscale force maps were simultaneously generated with a resolution of 512 x 512 
pixels, the Derjaguin–Muller–Toporov (DMT) model was used to quantify stiffness’s from 
the recorded force curves. Topographic images were flattened (1st Order) using the 
Nanoscope Analysis Software and no further processing was performed.  
 
2.2.7 Cryo-scanning electron microscopy (CryoSEM) 
Scanning electron microscopy is a technique used to observe micron and nanostructures. It 
uses a focussed beam of electrons which is guided by electromagnets. A schematic diagram 
of the SEM is given in figure 2.11 [32].  The electron beam is created by an electron gun 
which is situated on the top of the instrument. This electron beam is then focused by an 
electron column and illuminates the specimen. The specimen is scanned in X- and Y- 
directions by the beam. When the electron beam illuminates sample it interacts with the 
atoms in the sample. This can lead to several possible outcomes which are electrons can be 
bounced back out of the sample (backstage electrons) and some can be knocked into atoms 
and displace electrons, as results that can come out of the sample (secondary electrons) [33]. 
These electrons are then captured by either backscattered electron detector or secondary 
electron detector depending on the type of the scattered electron. An image is produced by 
amplifying and modulating the brightness of the detected electron signals. SEM images are 
displays as monochromic grey scale images which is because electrons do not show any 
colors even though they have different wavelengths. A number of the electrons originally 
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captured is directly proportional to the intensity of the brightness that displays on the screen. 
SEM images carry information in the shade of gray changing from white at the strongest and 
black at the weakest.  
 
 
Figure 2.11: A schematic diagram of SEM. Adapted from [32] 
 
There are a few types of SEMs are available including cryoSEM, environmental SEM, and 
focused ion beam SEM [33]. CryoSEM has specific equipment that permits samples to be 
viewed in the frozen state. This technique is useful for direct observing of wet samples, 
delicate biological samples, hydrogels, food, biofilms, foams, fats, and waxes, suspensions, 
pharmaceuticals, and nanoparticles. There are two protocols are available to freeze sample 
which is either freeze the sample outside the machine and then inserted in its frozen state or 
insert the sample in its unfrozen state and then freeze the sample slowly while it's in the 
machine. This frozen sample can be fractured or cut during sample preparation to explore 
internal structures [33]. 
 
Cryo-SEM was performed on FEI Quanta microscopy equipped with a cold stage and Gatan 
sample preparation chamber. An aliquot of the sample was placed in the sample holder and 
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rapidly frozen by plunging into liquid nitrogen (–196°C) under vacuum conditions. The 
frozen sample was transferred under the vacuum conditions into the preparation chamber and 
surface fractured with a cold knife. The fractured sample was sputter coated with gold to 
increase its surface conductivity for 2 minutes. The sample was then imaged at 30 kV 
accelerating voltage.  
 
2.2.8 Cell studies 
The methods used for cell studies are detailed in Chapter 5. 
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Chapter 3 
 
Self-assembly of native neuropeptides into 
nanostructures: Substance P and Luteinizing-
hormone releasing hormone (GnRH) 
3.1 General introduction 
Although protein misfolding and subsequent amyloid formation is typically associated with 
protein neurodegenerative diseases, lately a number of peptides/proteins that are not apparently 
associated with protein misfolding diseases have also been shown to form amyloid-like 
structures both in vivo and in vitro [1-4]. Amyloids that grant advantages to the host organism 
are known as functional amyloids [2, 5]. It has been recently proposed that the majority of 
peptide and protein hormones are stored in secretory granules in the human brain as amyloid-
like cross-β-sheet-rich structures, including neuropeptides such as somatostatin and endorphins 
[2]. Indeed, somatostatin and endorphins are reported to form well-defined nano-fibrillar 
structures in vitro [1, 6]. In this context, we studied the self-assembly of two neuropeptides, 
substance P and luteinizing hormone releasing hormone (LHRH) using a range of biophysical 
techniques. 
3.2 Prior knowledge on the self-assembly of neuropeptide Substance P and 
GnRH 
Substance P (SP) is a tachykinin neuropeptide with 11 amino acids (Arg-Pro-Lys-Pro-Gln-Gln-
Phe-Phe-Gly-Leu-MetNH2) and has a +3 net charge over the physiological range of pH [5.0-
7.4] [7]. The peptide is widely distributed in the central, peripheral and enteric nervous systems 
of many species [8, 9]. In the central nervous system, it functions as a neurotransmitter [8]. It 
has also been implicated in inflammation, pain, and depression in other tissues [9]. Due to the 
presence of the Phe-Phe amino acid motif (FF) in their structure [10, 11] and structural 
similarity of tachykinin neuropeptides to amyloid β (25-35) fragment, SP has a great potential 
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to form self-assemblies [12, 13]. However, Maji and co-workers have shown that substance P 
self-assembles only in the presence of an aggregation helper, heparin.  
 
Natural luteinizing hormone releasing hormone (LHRH) is a neuropeptide with 10 amino acids 
(p-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) and has a +2/1 net charge over the 
physiological range of pH [5.0-7.4]. This decapeptide is produced in the hypothalamus, 
stimulates the secretion of gonadotrophins, and thus plays a pivotal role in the development 
and normal functioning of the reproductive system [14]. According to recent findings, native 
LHRH does not self-assemble into amyloid-like structures although LHRH analogs, with only 
one amino acid variation, have been shown to form amyloid-like structures [15] and nanotubes 
[16].  
 
Peptide self-assembly is highly sensitive to extrinsic factors such as pH, ionic strength, 
concentration and temperature [17]. Since LHRH has a histidine residue in its structure, the 
self-assembly of LHRH can be influenced by the pH of its solvent. Due to the pKa (pKa=6.1) 
of histidine, it can either be protonated at low pHs (pH<6) and unprotonated at higher pHs 
(pH>6) leading to net charge of LHRH as +2 or +1 depending on the pH of the solvent. Valery 
et al have reported pH dependant nanotube formation by the LHRH analogue triptorelin [16]. 
pH-dependent nanostructures are excellent candidates for bionanomaterials with applications 
in targeted drug delivery [18, 19]. Therefore, a proper understanding of self-assembling 
mechanisms and properties of such peptide nanostructures are vital in designing of versatile 
bionanomaterials. In this framework, functional amyloids provide an extra set of advantages, 
for instance, non-toxicity and reversibility over disease-associated amyloids while retaining 
their amyloid-based properties. However, characterization of functional amyloids is poorly 
documented in literature which might be the reason behind their limited use in biomaterial 
design.  
 
Inspired by these findings and we studied SP and LHRH self-assembly in 150 mM NaCl under 
conditions relevant to secretory granules, including mildly acidic pH, high peptide 
concentrations, high ionic strength, and without aggregation helpers. The influence of 
aggregation helpers is investigated in chapter 4. A variety of biophysical techniques were 
applied, including ThT binding assay, transmission electron microscopy (TEM), atomic force 
microscopy (AFM), optical microscopy, small angle x-ray scattering (SAXS) and vibrational 
spectroscopy (ATR-FTIR).  
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3.3 Materials and methods 
3.3.1 Materials 
All the chemicals and reagents used for this study are described in section 2.1. 
3.3.2 Methods 
3.3.2.1 TANGO analysis 
Substance P sequence was subjected to TANGO analysis [20] which is a computer-based 
algorithm that predicts the amyloidogenic propensity of peptides and proteins. This algorithm 
is based on physicochemical principles of peptide/protein secondary structure formation 
assuming that the core region of an aggregate is fully hidden. All the predictions were 
conducted at pH 7, 25°C and ionic strength of 0.15 M which aligns with conditions used for 
this study. 
3.3.2.2 Thioflavin T (ThT) binding assay 
ThT is an amyloid-specific dye which binds to cross-β-sheet structures, however, not to the 
monomeric peptide [21, 22]. Upon binding to amyloids, ThT exhibits a significant increase in 
the fluorescence intensity. Rate constants of aggregation for both substance P and LHRH were 
calculated by GraphPad Prism 7 software from the best fit kinetic (details in section 2.2.1). 
3.3.2.3 Optical microscopy 
Polarized optical microscopy was used to observe the liquid crystalline textures formed by 
substance P and LHRH (Technique and protocol described in section 2.2.3). 
3.3.2.4 Transmission electron microscopy (TEM) and atomic force microscopy 
(AFM) 
To gain insights into the supramolecular structure of formed by substance P and LHRH, 
transmission electron microscopy (TEM) (section 2.2.5) and atomic force microscopy (AFM) 
(section 2.2.6) were performed at similar concentrations as the ThT assays. 
3.3.2.5 Attenuated total reflectance Fourier-transform infrared spectroscopy 
(ATR-FTIR) 
To identify the secondary structures formed by self-assembling of substance P and LHRH, 
FTIR spectroscopy was carried out at high concentrations (20%w/w) of the peptide (section 
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2.2.2). In the case of LHRH assembly, FTIR was also used to identify histidine protonation as 
a function of the pH. 
3.3.2.6 Synchrotron small and wide-angle x-ray scattering (SAXS and WAXS) 
Both SAXS and WAXS experiments were conducted at Australian synchrotron to identify 
inner symmetries of peptide assemblies (Protocols are described in section 2.2.4). 
3.3.2.7 Nuclear magnetic resonance (NMR) 
To identify the structural difference between substance P soluble state and aggregated state, 
NMR spectroscopy was performed. A weighed fraction of substance P acetate powder was 
dissolved in D2O to obtain 0.1%w/w and 1%w/w as the final concentration, which corresponds 
to soluble-state of peptide and aggregated state respectively. The aggregated peptide sample 
was left for a few days at room temperature before NMR experiments, to allow for nanotube 
formation, while soluble-state peptide sample was subjected to NMR experiments immediately 
after preparation. All NMR experiments were performed on Agilent DD2 500 MHz NMR 
spectrometer equipped with a 5 mm probe. NMR experiments carried out included proton 
nuclear magnetic resonance (1H NMR), carbon nuclear magnetic resonance (13C NMR), 
correlation spectroscopy (COSY NMR), total correlated spectroscopy (TOCSY NMR), 
heteronuclear single-quantum correlation spectroscopy (HSQC NMR), and heteronuclear 
multiple-bond correlation spectroscopy (HMBC NMR). These NMR experiments were 
conducted both on the soluble state and aggregated state of substance P. Along with these 
experiments, NMR relaxation experiments (T2-CPMG) were carried out on both substance P 
samples. All NMR data were processed and analysed using the VnmrJ program. The NMR data 
were compared to previously published reports [23-26].  
3.3.2.8 Reversibility of GnRH assemblies by ThT binding assay 
LHRH samples were prepared at concentration of 5% in 25 µM ThT in 150mM 
NaCl/PBS/phosphate buffer at pH 8 containing 0.01% sodium azide. Samples were 
equilibrated at 4°C for one week prior to the experiment to allow fibril formation. On the 
experiment day, fluorescence intensities were recorded for one-week old samples and then 
diluted to obtain other concentrations. Fluorescence intensities of diluted samples were 
recorded immediately after dilution and 24 hours after dilution equilibrate at 4°C. The 
fluorescence intensities were measurements from 80 µL triplicate samples in 96 well plates and 
were recorded using a ClarioStar fluorimeter equipped with a plate reader (excitation 
wavelength: 440 nm, emission wavelength: 482 nm). The data are corrected for blank intensity 
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(25 μM ThT in 150 mM NaCl/PBS/phosphate buffer pH 8) and expressed as mean ± S.D. Three 
independent experiments were performed.  
3.4 Results  
3.4.1 Self-assembly of neuropeptide Substance P into nanotubes 
3.4.1.1 Substance P forms β-sheet rich liquid crystalline self-assemblies 
We used a computer-based algorithm known as TANGO to predict the amyloidogenic 
propensity of substance P. All the predictions were conducted at pH 7, 25°C and ionic strength 
of 0.15M which aligns with conditions used for in vitro studies. Figure 3.1(A) shows the 
percentage of amyloidogenic propensity against the amino acid residues of substance P. 
 
Figure 3.1: Substance P self-assembly. (A) TANGO analysis: amyloidogenic propensity and aggregation-prone 
regions. (B) ThT binding assay of 1% w/w substance P in 150 mM NaCl. 
A high percentage of amyloidogenic propensity was shown by the amino acid residues FFGLM 
in substance P sequence. This result indicates that these residues are more prone to aggregate 
at the conditions studied. In contrast, Singh et al reported that substance P has zero potential to 
form amyloid-like structures using the same analysis [27]. However, this study has used a lower 
peptide concentration compared to the present study. Since peptide self-assembly de highly 
depends on peptide concentration that might be the reason for this discrepancy. 
Thioflavin T (ThT) binding fluorescence assays were used to study the self-assembling kinetics 
of SP in 150 mM NaCl following the protocol described in Chapter 2, section 2.2.1. Amyloid 
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specific dye ThT binds to the cross β-sheet structure of amyloids [21, 22]. ThT exhibits a 
significant increase in fluorescence intensity after binding to the cross β-sheet structure. The 
self-assembling process of 1% (w/w) SP in 150 mM NaCl was monitored at different time 
intervals and fitted to a single exponential curve (Figure 3.1B). The experiment was carried out 
in triplicates. Even though, at the beginning of the experiment (t0), low ThT binding was 
observed, after 1 hour an increase in ThT fluorescence was observed, which reached the 
maximum at approximately 4 hours and then remained constant. The rate constant of 
aggregation was calculated from the best fit of the kinetic traces by single exponential curves 
(first-order kinetics), as previously reported [28] and detailed in section 2.2.1. Table 3.1 shows 
the comparison of lag phase and rate constants of aggregation (Kagg) calculated in 150 mM 
NaCl for substance P with that of LHRH (section 3.4.1) and somatostatin-14 (section 4.3).  
 
Table 3.1: Kinetic parameters calculated for substance P, somatostatin and LHRH in 150 mM 
NaCl. 
 
Peptide Lag phase Kagg (s-1) 
1% w/w Substance P 0 2.33×10-4±0.28×10-4 
1% w/w Somatostatin 8 hours 0.09×10-4±0.02×10-4 
3% w/w LHRH 5 days 0.05×10-4±0.01×10-4 
 
According to table 3.1 data, among the three neuropeptides studied substance P has the highest 
rate constant of aggregation. Importantly, substance P does not show a lag phase prior to 
aggregation, whereas both somatostatin and LHRH show a lag phase prior to the aggregation. 
Apart from somatostatin and LHRH, functional amyloids such as β-endorphin and glucagon-
like peptide-1 have also been shown to exhibit a lag phase prior to the aggregation [3, 6, 29]. 
The increase in ThT fluorescence indicates the presence of β-sheet rich structures in solution. 
Similar results were reported by Maji and co-workers previously for SP self-aggregation 
kinetics accessed by ThT assay, however in the presence of heparin [27]. The absence of a lag 
phase, the higher rate constant of aggregation and increase ThT fluorescence over the time 
indicate that substance P rapidly forms β-sheet based oligomers under the conditions studied. 
Notably, ThT results reveal that substance P can also self-assemble in the absence of an 
aggregation helper. 
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All SP acetate samples in 150 mM NaCl were observed to form gels from 5% w/w onwards. 
Optical microscopy under cross polarizers was performed to reveal whether these gels possess 
liquid crystalline structures following the protocol described in Chapter 2, section 2.2.3. All SP 
gels exhibit birefringence under crossed polarizers, showing that anisotropic structures are 
formed. Figure 3.2 shows different liquid crystalline textures observed for substance P in 150 
mM NaCl. 
 
 
 
Figure 3.2: Liquid crystalline optical textures formed by substance P (magnification ×10). (A) Threaded-
like textures. (B) cholesteric focal conic defects. Note: sample concentration - 10% w/w SP in 150 mM NaCl, 
sample age- two weeks old. 
 
Two types of liquid crystalline optical textures were observed under cross polarizer for pure 
SP self-assemblies without any specificity to peptide concentration (Figure 3.2). Figure 3.2A 
shows threaded like textures which result from local and periodic variations in molecular 
orientation, and generally arise from nematic phases [30]. This type of textures have previously 
been observed for somatostatin-14 assemblies formed in both water and 150 mM NaCl [1]. 
Figure 3.2B exhibits cholesteric focal conic defects which were also previously reported for 
amyloid systems [31, 32]. These textures are compatible with columnar hexagonal liquid-
crystal phases where molecules assemble into rod-like structures [33, 34]. These observations 
demonstrate the liquid crystalline nature of the SP self-assemblies. SP hence spontaneously 
self-assembles at room temperature into liquid crystalline phases with nematic properties, in 
150 mM NaCl. 
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Using Fourier-transform infrared spectroscopy (FTIR), amide I vibrations (1600-1700 cm-1) 
can be used to identify the secondary structure of the peptide backbone. Amide I vibrations 
mainly arise from vibrational stretching modes of the backbone carbonyl groups. They can 
hence reveal information about the intermolecular and intramolecular H-bonds in which the 
backbone carbonyl groups are involved [35, 36]. The attenuated total reflectance (ATR) FTIR 
spectra were recorded at room temperature for SP self-assemblies in 150 mM NaCl, following 
the protocol described in section 2.2.2. Self-assembly of SP at three different concentrations 
(5%, 10%, and 20%) was followed by IR spectroscopy until 1 week. Figure 3.3 shows amide I 
region of all three concentration of SP studied at the end of one week. 
  
Figure 3.3: ATR-FTIR spectra of mesophases of SP acetate in 150 mM NaCl as a function of peptide acetate 
concentration: from bottom to top, respectively 5%, 10%  and 20%w/w. Note: Samples are one week old 
 
The spectra showed unstructured amide I vibrations at low concentrations (5%, 10%) which 
evolved towards well-structured amide I vibrations at higher peptide concentrations (20%w/w). 
The structured amide I of 20%w/w SP could be assigned into four well-defined vibrations at 
1622 cm-1 and 1673 cm-1 for antiparallel β sheet hydrogen-bonds, 1633 cm-1 for parallel β sheet 
hydrogen-bonds and 1652 cm-1 for random coil conformations as previously reported [1]. 
Similar vibrations were observed for 10%w/w SP assemblies as well. However, 5%w/w SP 
assemblies only exhibit vibrations at 1622 cm-1 and 1652 cm-1 that corresponds to major peak 
for antiparallel β-sheet and random coil, respectively. In other words, 5% w/w SP assemblies 
comprise of the random coil to a greater extent. This observation strongly suggests that the 
structuration of amide I vibrations is directly correlated to the peptide concentration, supporting 
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that more secondary structures are formed at higher concentrations. In accordance with the 
literature, antiparallel β sheets (1622 and 1672 cm-1) network is due to the presence of 
nanofibrils in solution [1]. On the other hand, vibration at wavenumbers of around 1630 cm-1 
is generally assigned to a parallel β sheet network. According to the previously published 
reports, 1630 cm-1 is not related to the nanofibrils formation but correlated to the lateral 
association of nanofibrils into nanofibers [37]. A similar vibration was previously reported for 
Somatostatin-14 in the water at 1627 cm-1 which has been assigned for parallel β sheet network 
[1]. To determine the number of backbone carbonyls involved in each of these vibrations, we 
decomposed the FTIR spectra obtained for 20%w/w into individual components (Table 3.2). 
 
Table 3.2: Percentages of amyloid vibrations within amide I region after deconvolution of SP 
20%w/w in NaCl FTIR spectra using the Opus software (Bruker). 
 
 
Given the presence of 11 backbone carbonyls in the SP sequence, 7 backbone carbonyl groups 
are involved in the antiparallel β sheet networks, 2 carbonyls in parallel β sheet networks and 
2 carbonyls in random conformation, on average. This type of calculation is only valid if all 
the peptide molecules are involved in the same structure. In other words, all molecules should 
contribute to fibril architecture and should not be any oligomers present in the solution. To 
minimize the effect of oligomers, present in the solution, we calculated these values for highest 
peptide concentration (20% w/w) studied. 
 
3.3.1.2. Morphology of substance P nanostructures 
The morphology of the SP self-assemblies in 150 mM NaCl was investigated by transmission 
electron microscopy (TEM) on negatively stained samples, and by atomic force microscopy 
(AFM) on air-dried samples. The corresponding protocols are detailed in section 2.2.5 and 
 
Antiparallel β sheet   Parallel β sheet  Random coil  
% area No of 
carbonyl 
groups 
% area No of 
carbonyl 
groups 
% area No of 
carbonyl 
groups 
SP (t=0) 63.6±2.8 7 13.8±3.7 2 22.6±5.6 2 
SP (t=11) 64.1±2.8 7 17.9±1.8 2 18.0±3.4 2 
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2.2.6 respectively. The electron micrographs obtained for 2% and 5%w/w/ of SP in 150 mM 
NaCl are shown in figure 3.4. 
 
Figure 3.4: Transmission electron micrographs of SP self-assembly in 150 mM NaCl. (A) 2% w/w SP in 
NaCl (5 days old), (B) 5% w/w SP NaCl (5 days old) and (C) 2% w/w SP in NaCl fibril diameter distribution. 
Note: The open source software Image J was used to measure the fibril diameter and then the measurements were 
plotted and statistically analyzed by GraphPad Prism 7 software. 
 
These electron micrographs provide evidence for the fibrillar morphology of SP self-
assemblies. The fibrils are observed to closely laterally align to form bundles. The histogram 
of fibril diameters shows the heterogeneous nature of SP nanofibrils by a spread of fibril 
diameter from 10-90 nm. The mean diameter was determined as 20 nm. However, 75% of the 
measurements fall in between 10-23 nm. Since almost all nanofibrils observed in TEM images 
display a high tendency to laterally align, it was impossible to measure the diameter of 
individual nanofibrils. The mean diameter hence represents the width of nanofibers resulting 
from the close lateral association of a few nanofibrils. Presence of the parallel β sheet network 
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as detected by IR spectroscopy taken together with closely laterally aligned nanofibrils 
observed in electron micrographs strongly suggests that SP nanofibrils laterally associate to 
form nanofibers without any specificity to peptide concentration. 
 
Inspection of air-dried samples by AFM confirmed that these nanostructures are not single 
nanofibrils despite that higher order nanostructures/nanofibers formed as a result of the close 
lateral association of nanofibrils (Figure 3.5).  
Figure 3.5: AFM images of 2% (w/w) SP self-assembly in 150 mM NaCl. (A), (B) and (C) show the 
morphology of SP self-assemblies in NaCl. (D Histograms showing the spread of fibril diameters (width) 
measured from the AFM height data for 2% SP in NaCl. (E) Histogram of counter length distribution for 2% SP 
in NaCl and (F) Height profile acquired along the portion of the contour length of the fibril shown as an insert. 
AFM images exhibit assembling points where few nanofibrils come together and associate to 
form larger assemblies/bundles. Depending on the number of nanofibrils associate to form 
fibril bundles, different diameters were obtained for fibril bundles. The open source analysis 
software fiberApp was used for the quantitative statistical analysis of AFM images [38]. 
According to the statistical analysis of the AFM data, fibril diameter of figure 3.5A is 30 nm, 
3.5B is 80 nm and 3.5C is 180 nm. Based on histogram 3.5D, the mean fibril diameter is 7.76 
nm, while most of the fibril bundles are between 4-7 nm. According to counter length 
distribution (Figure 3.5E), SP nanofibrils are a few microns long. The mean counter length is 
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2.8 µm and the majority of fibril were observed in 1-4 µm range. Interestingly, the height 
profile obtained for the nanofibrils (figure 3.5F) display a constant plateau without any periodic 
features, suggesting that these objects could be nanotubes [39]. 
 
3.3.1.3 Substance P self-assembles into nanotubes 
The inner symmetries of substance P self-assemblies were investigated by SAXS/WAXS 
beamline at Australian synchrotron. SAXS intensity profiles were recorded for substance P in 
range of concentrations (5%, 10% and 20% w/w) using 150 mM NaCl and water (section 
2.2.4). The main purpose behind the use of three different concentrations is to examine the 
effect of peptide concentration on nanostructure formation. Further, we used both 150 mM 
NaCl and water to study the effect of ionic strength on peptide nanostructure formation. 
 
Substance P nanotubes formed in 150 mM NaCl was modelled using the Irene software into a 
core-shell cylinder with an internal diameter (di), a wall thickness (twall) and a tube length (l). 
Figure 3.6 shows original x-ray scattering patterns of substance P nanotubes (blue colour dash 
line) and the fits (red colour dotted lines) for 5%w/w, 10%w/w and 20%w/w of substance P. 
Internal diameter, wall thickness and tube length obtained from core-shell cylinder model for 
each substance P concentration are tabulated in table 3.3. According to the diameter 
measurements tubes are monodisperse and the diameter centred around 6 nm for all the 
concentrations studied. This value is well aligned with AFM data that displays internal 
diameter centred around 5nm.  Tube length was determined as 100.14 nm for all the 
concentrations studied. Wall thickness remains approximately the same irrespective of the 
substance P concentration. Nanotube formation by synthetic peptides has been previously 
reported [40-43]. However, to best of our knowledge nanotube formation by a natural peptide 
has not been reported up to date. Hence, this finding is important since substance P is the first 
natural peptide which has been shown to self-assemble into nanotubes.  
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Figure 3.6: Synchrotron SAXS intensity profiles recorded for different concentrations of SP in 150 mM 
NaCl. (A) 5%w/w SP, (B) 10%w/w SP and (C) 20%w/w SP. Note: all samples are 10 days old. 
 
Table 3.3: Modelled parameters of substance P SAXS data 
 
SP concentration 
(w/w) 
Diameter/di (nm) 
Wall thickness/wallt 
(nm) 
Length/l (nm) 
5 6.54 0.90 100.14 
10 6.20 1.21 100.14 
20 6.13 1.24 100.14 
Chapter 3 
 
74 
 
Figure 3.7 shows the SAXS patterns obtained for substance P self-assemblies formed in water. 
Interestingly, these data show correlation peaks, however, oscillations for nanotubes were not 
observed. Correlation peaks arise due to the inner symmetries within the assembly [29]. First 
reflection was observed at 0.054 Å-1 for 20%w/w substance P concentration corresponding to 
d-spacing of 116.29 Å with another two poorly resolved oscillations. Substance P concentration 
at 10% w/w  also showed peaks approximately at the same positions. However, 5%w/w 
substance P showed SAXS intensity profile with a slope that tends to q−x (with x > 0), for q 
values in the range 0.01–0.6 Å−1 (Figure 3.7A). Such profiles typically arise from scattering by 
nanoscale colloids and can provide information on their morphology; typically, q−1 slopes 
suggest rod-like (e.g. fibrillar) structures, q−2 suggests flattened 2D structures such as Ribbons 
or crystals and q−4 suggests the presence of spherical or unstructured aggregates [44]. The 
SASview open source software analysis reveals that 5% SP self-assemblies formed in water 
exhibit -1.66 slope, which could be interpreted as the presence of flat 2D structures 
(nanofibrils) in solution according to previously published reports [45]. These results suggest 
that assemblies become more organized as concentration increases, which are consistent with 
results obtained for substance P assemblies formed in 150 mM NaCl. Due to the high ionic 
strength in 150 mM NaCl compared to water, more assemblies are formed in 150 mM NaCl. 
The higher ionic strength of NaCl facilitates peptide-peptide interactions between charged 
peptides. This might be the reason for the lack of oscillations for nanotubes observed in 
assemblies formed in water, as not enough nanotubes may be formed to record a clear form 
factor. 
 
The symmetries of the nanotubes were further studied by synchrotron wide-angle X-ray 
scattering (Figure 3.8). The reflections at 1.28 (4.9 Å) and 1.29 (4.8 Å) Å-1 were assigned to 
the intramolecular β sheet networks present in substance P self-assemblies formed in 150 mM 
NaCl and water, respectively.  
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Figure 3.7: Synchrotron SAXS intensity profiles recorded for different concentrations of SP in water. (A) 
5%w/w SP, (B) 10%w/w SP and (C) 20%w/w SP. Note: all samples are 10 days old. 
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Figure 3.8: WAXS pattern recorded for 10% w/w SP in (A) 150 mM NaCl and (B) water. Note: all samples 
are 10 days old. 
 
The reflection around 4.8 Å aligned on the meridional axis is due to the spacing along the 
nanofibril axis between adjacent hydrogen-bonded β-strands [46, 47]. WAXS data confirm that 
substance P self-assemblies formed in both solvents are comprised of β-sheet networks which 
are also supported by IR spectroscopic results. 
 
3.3.1.4 Amino acids directly involved in substance P self-assembly 
In order to investigate the structural differences between the monomeric state and self-assemble 
state (nanotubes) of SP, NMR spectroscopic experiments were carried out (section 2.2.9). 
1HNMR, 13CNMR, TOCSY, COSY, HSQC and HMBC experiments on SP monomer (0.1% 
w/w = 0.75 mM) and SP self-assemblies (1% w/w = 7.5 mM) in deuterium oxide (D2O) at 
room temperature were performed. According to the literature, approximately 1 mM 
concentration is used for proteins/peptides NMR experiments [48, 49]. However, present study 
used 0.75 mM and 7.5 mM concentrations depending on the requirement of monomeric state 
and aggregated state, respectively. To ensure that we are dealing with the monomeric state at 
0.1% w/w concentration, 0.1% w/w sample was diluted by ×10 and subjected to proton NMR 
experiment. In both cases (0.1% and 0.01% w/w) we observed similar chemical shifts in 
1HNMR spectra which shows that 0.1% w/w SP is in a monomeric state. In addition, we 
recorded a CD spectrum for 0.01% w/w which shows the random coil conformation confirming 
the presence of a native form of SP at 0.01% w/w concentration.  
In the development of optimal conditions for NMR experiments, first recorded 1H NMR spectra 
of SP in different solvents such as methanol, DMSO, water, water-D2O mixture, and D2O to 
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find the best solvent for the experiment. For DMSO fewer signals were observed for the 
concentrations used in this experiment. In the case of water, water signal interferes with 
chemical shifts of SP making the interpretation difficult. Very well resolved peaks were 
observed for spectra recorded in Methanol and D2O. Since all our experiments for substance P 
has been conducted in an aqueous medium, D2O was selected as the solvent. IR spectroscopy 
was used to check SP self-assembly in D2O before commencing NMR studies to confirm the 
suitability of D2O as the solvent.  
Both 1H and 13C chemical shift assignments for SP monomer (0.1% w/w SP) in D2O at 25 °C 
are tabulated in Tables 3.4 and 3.5.  
Table 3.4: 1H-NMR assignments for 0.1% w/w SP acetate in D2O at 25 °C. 
 
 
 
 
Residue αCH βCH γCH δCH Others 
1- Arg 3.98 1.70 1.58 3.11  
2- Pro 4.28 2.18 
1.75 
1.89 3.72 
3.51 
 
3- Lys 4.43 1.70 
1.60 
1.37 1.56 εCH2 - 2.87 
4- Pro 4.34 2.18 
1.75 
1.89 3.63 
3.46 
 
5- Gln 4.08 1.83 2.16   
6- Gln 4.08 1.72 2.0   
7- Phe 4.47 2.91 
2.80 
  2H – 7.13 
3,5H – 7.21 
4H – 7.16 
6H – 7.07 
8- Phe 4.47 3.04 
2.82 
  2H – 7.13 
3,5H – 7.21 
4H – 7.16 
6H – 7.07 
9- Gly 3.76 
3.67 
    
10- Leu 4.23 1.50 
0.88 
1.51 0.77 CH3 - 0.82 
11- Met 4.32 
 
1.98 
1.90 
2.49 
2.39 
1.95  
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Table 3.5: 13C-NMR assignments for 0.1% w/w SP acetate in D2O at 25 °C. 
Residue αC βC γC δC Others Carbonyl C 
1- Arg 51.3 29.4 23.6 40.6  156.7 
2- Pro 60.4 29.4 24.7 47.9  173.7 
3- Lys 51.6 29.6 21.9 26.4 εC- 29.1 172.0 
4- Pro 60.2 29.4 24.7 47.9  174.0 
5- Gln 53.1 26.7 31.0   172.8 
177.6 (side 
chain) 
6- Gln 53.1 27.0 30.9   172.2 
177.5 (side 
chain) 
7- Phe 54.8 37.1   1C - 136.2 
2,6C – 129.1 
3,5C – 128.7 
4C – 127.1 
172.3 
8- Phe 54.8 37.0   1C - 136.2 
2,6C – 129.1 
3,5C – 128.7 
4C – 127.1 
173.0 
9- Gly 42.4     171.1 
10- Leu 52.6 39.6 24.3 20.7 CH3 – 22.1 174.7 
11- Met 52.3 30.0 29.4 14.1  176.0 
 
1H assignments of the monomeric state of substance P in presents study are inconsistent with 
the previously reported 1H assignment patterns for substance P monomer [50, 51]. 1H chemical 
shifts were assigned to each proton using COSY, TOCSY and HMBC data. All the α-H were 
detected in 3.5-5 ppm, and aliphatic H was observed from the right extreme of the spectra to 
3.5 ppm as reported previously. Aromatic protons of phenylalanine residues were identified 
between 7-8 ppm. The 13C chemical shifts were assigned to each C with the aid of HSQC data, 
and proton assignments. Surprisingly, to the best of our knowledge, none of the reports have 
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been published on the regard of 13C chemical shifts of substance P. According to both 1H and 
13C NMR data obtained, significant changes in chemical shifts of monomeric SP and 
aggregated form of SP were not observed. Since chemical shifts are affected by the changes 
occur in the immediate environment, this finding indicates that the immediate environment of 
atoms is not changing due to the aggregation. However, according to the literature, in a native 
protein/peptide all the amino acids side chains are immersed into the solvent giving rise to 
similar chemical shift for multiple amino acid side chains with identical chemical structure. On 
the other hand, multiple amino acid side chains with identical chemical structure exhibit 
different chemical shifts for an aggregated protein/peptide due to the presence of different 
atoms in the immediate environment [48]. In the case of substance P, it is possible that SP 
monomer might be highly dynamic in solution due to its low molecular weight. Hence, 
irrespective of whether SP is aggregated or not the molecular structure in solution changes 
frequently. Another plausible explanation for this observation is that we were not dealt with 
the monomer at 0.1% w/w concentration, for instance, there might be several oligomers present 
in the solution which could also contribute to the structure. 
To further investigate the structural differences between the monomeric and aggregated state 
of substance P we performed NMR relaxation experiment and data were analyzed using T2 
analysis. This technique provides information about the decay of the NMR signal over time. 
The decay of the signal can be analyzed by two types of analysis: T1 and T2 analysis. The T2 
(spin-spin) analysis specifically measures the broadening of the signal. Firstly, the same 
concentrations as mentioned previously for both monomeric and aggregated states were used. 
However, monomeric state concentration (0.1% w/w) was not enough for this experiment. To 
overcome this limitation, we used 1% w/w concentration at 25 °C to obtain data for the 
aggregated state and then the temperature was increased up to 60 °C where aggregates melt 
leading to monomeric state. Prior to the relaxation experiment, we performed IR spectroscopy 
to detect the temperature that substance P assemblies become monomers. Since the temperature 
has an influence on chemical shift we again assigned proton chemical shifts to each H atoms. 
The T2 values obtained showed a significant difference between monomeric and aggregated 
states for the majority of amino acids. The rationale behind the lower values obtained for the 
monomeric state is that when an atom is included in aggregate their movement is limited. Each 
proton T2 value obtained for the monomeric state is presented as a percentage compared to that 
of the aggregated state in table 3.6.  
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Table 3.6: Percentage difference of T2 values of the monomeric state compared to the 
aggregated state of substance P. 
Residue αCH βCH γCH δCH Others 
1- Arg 250 %   20%  
2- Pro  82.35%  (3.72) 
17.72% 
(3.51) 
12% 
 
3- Lys 342.85%  66.67% -40%  
4- Pro -47.37% 82.35%  (3.63) 
211.11 
(3.46) 300 
 
5- Gln 108%  82.35%   
6- Gln 108%  40%   
7- Phe 181.82% (2.91) 
44.44% 
(2.80) 
211.11% 
  83.82% 
(aromatic 
ring) 
8- Phe 181.82% (3.04) 
222.22% 
(2.82) 
211.11% 
  83.82% 
(aromatic 
ring) 
9- Gly (3.76) 
81.82% 
(3.67) 
211.11% 
    
10- Leu 54.54%   125% 118.18% 
11- Met -47.37%  (2.49) 
64.52% 
(2.39) 
79.31% 
  
Note: When ≥2 protons are attached to a carbon atom percentage increase of T2 values are given for each proton 
with the corresponding chemical shift. 
According to the data present in table 3.6, the majority of atoms have shown more than 100% 
percent increase. Importantly, αH of arginine and lysine which are positively charged amino 
acids have shown a remarkable percentage increase compared to the aggregated state. The δH 
of proline at position 4 exhibits a 300% percentage increase compared to the aggregated state. 
In contrast, some of the atoms display negative percentages such as αH of proline (position 4) 
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and methionine. However, since T2 measurements are performed at two different temperatures 
for the soluble state and the aggregated state, temperature-dependent parameters like water 
density and peptide dynamics may change which could make these data non-comparable. 
Based on this percentage values I suggest that arginine (αH), lysine (αH) and proline (δH) 
(position 4) are directly involved in the core structure of substance P aggregates. However, 
more molecular level characterization, especially solid-state NMR studies are underway to 
confirm these results. 
3.4.2 LHRH forms β-sheet based self-assemblies as a function of the pH 
LHRH is a decapeptide with uncharged N- and C-termini (pGlu-His-Trp-Ser-Tyr-Gly-Leu-
Arg-Pro-GlyNH2) that contains two aromatic side chains (Trp and Tyr) and three ionizable 
residues Arg (pKa > 9), Tyr (pKa > 10) and His (pKa = 6.1) (Figure 3.9). 
 
 
Figure 3.9: Molecular structure of LHRH from the protein data bank [52] [53]. (a) LHRH molecule with 
details of amino acid side-chains and charges. (b) LHRH backbone conformation in solution with charges. (c) one 
letter sequence with charges. 
While Arg remains cationic for a wide range of pH, Tyr remains neutral for a wide range of 
pH. On the other hand, His can either be charged at low pH (below 6) or uncharged at high pH 
depending on the protonation state which could change the net charge of LHRH and thereby 
influence self-assembling properties of this peptide. 
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To determine the influence of histidine protonation on LHRH self –assembly, we studied 
LHRH self-assembly in the pH range of 5-8 using three different solvents: 150 mM NaCl (pH 
5.5), phosphate buffer saline (PBS) (pH=7.4) and phosphate buffer (pH=8). In a similar study 
conducted for LHRH analog, triptorelin has utilized ATR-FTIR to investigate the histidine 
protonation as a function of pH [16]. Figure 3.10A displays histidine protonation depending on 
pH as detected by IR spectroscopy (section 2.2.2). 
 
Figure 3.10: (A) ATR-FTIR spectra recorded for 45 % (w/w) LHRH acetate (one month old) at a pH range of 5.5 
– 8. The absorption bands at 1,091 and 1,105 cm-1 are characteristic to (HisH2)+ and (HisN3)H  ι-tautomer, that is, 
protonation of N3, respectively. ThT binding assay for (B) 3% (w/w) LHRH at pH 5.5 (C) 3% w/w LHRH at pH 
7.4 and (D) 3% LHRH at pH 8.  
 We found that assemblies formed at pH 5.5 and 7.4 have both charged and uncharged histidine 
residues, while high pH assemblies (pH 8) of LHRH possess only uncharged histidine residues 
(Figure 3.10A). The ATR-FTIR spectra of LHRH at pH 5.5 and 7.4 exhibit two vibrations at 
1091 and 1107 cm-1 whereas, that of at high pH exhibits one vibration at 1107 cm-1. The 
vibration at 1091 cm-1 is due to His protonation at low pH which gives rise to a positively 
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charged imidazolium group.  Deprotonated histidine at high pH, as a neutral and aromatic ι-
tautomer, gives rises to the vibration observed at 1107 cm-1 [16]. In sharp contrast to our results, 
triptorelin self-assemblies formed at low pH (<6.5) only possess protonated histidine, whereas 
that of at high pH (pH 8.5) possess both protonated and deprotonated histidine species.  
ThT binding assay was carried out to investigate the amyloid nature of LHRH self-assemblies 
and to study the self-assembling kinetics of LHRH as a function of pH (Figure 3.10B-D). 
LHRH self-assemblies formed at all three pHs exhibit increase of ThT fluorescence, however 
at different time points indicating the amyloid nature of these assemblies. The results were 
plotted against experiment time and fitted to a plateau followed by one phase association curve 
for assemblies at pH 5.5 and pH 7.4 as previously reported for similar systems [28, 29]. The 
rate constant for aggregation (kagg), lag time and plateau were calculated by GraphPad Prism 
7 software from the best fit kinetic traces and are given in table 3.7. 
Table 3.7: Lag time, Kagg and plateau fluorescence obtained for best-fit curves of LHRH self-
assemblies. 
pH Lag time (Days) Kagg (Days-1) Plateau 
pH 5.6  5 0.4147 ± 0.124 
 
64046.33 
pH 7.4 3 0.8496 ± 0.1739 
 
70948.23 
pH 8 0 α 77769.67 
 
In the beginning, very low ThT binding was observed for LHRH at pH 5.5 and 7.4 which could 
be due to the presence of small oligomers in the solution. In contrast, LHRH at pH 8 showed 
higher ThT fluorescence from the beginning without a lag phase indicating rapid aggregation 
of LHRH at pH 8. LHRH kinetic profiles at low pH and pH 7.4 show a lag phase prior to the 
aggregation. Further, LHRH at pH 7.4 shows the smallest lag phase and the highest aggregation 
rate constant (Kagg). Indeed, the higher fluorescence plateau value for LHRH at pH 7.4 and pH 
8 indicates the formation of more assemblies compared to pH 5.5. ThT results hence reveal 
that LHRH self-assemblies formed in the physiological range of pH possess amyloid 
architecture; however, pH 8 favors LHRH self-assembly followed by pH 7.4 and 5.5.  
The secondary structure of LHRH self-assemblies was investigated by FT-IR spectroscopy 
(Figure 3.11A). The secondary derivative spectra of LHRH self-assemblies at all three pHs 
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exhibit four well define vibrations that could be assigned for antiparallel β-sheet (1616 cm-1, 
1686 cm-1), parallel β-sheet (1633 cm-1) and random coil (1656 cm-1) based on previously 
reported data for similar systems [1]. The presence of antiparallel β-sheet network represents  
nanofibrils in solution [1]. According to previous reports, the parallel β sheet network observed 
at all three pHs arises due to the lateral association of nanofibrils/protofilaments to form 
nanofibers [1]. 
 
Figure 3.11: (A) Secondary derivatives of the spectra obtained for amide I vibrations for LHRH acetate 45 % 
w/w in the pH range of 5-8. (B) Synchrotron WAXS profiles of 45% (w/w) LHRH acetate in the pH range of 5-
8. 
It is noteworthy that LHRH analog triptorelin has been reported to possess β-sheet networks 
only at low pH assemblies. Further triptorelin β-sheet networks are composed only of 
antiparallel β-sheets, whereas LHRH self-assemblies at all three pHs studied are composed of 
both parallel and anti-parallel β-sheet networks. Differences observed in β-sheet content at high 
pH compared to triptorelin could be due to the presence of additional tryptophan residue in the 
triptorelin sequence. Two tryptophan residues in triptorelin sequence are situated in two 
different environments at high pH which led to the absence of β-sheet network in triptorelin 
assemblies formed at high pH [16].  
 
We also conducted synchrotron wide-angle X-ray scattering (WAXS) measurements to 
identify molecular symmetries within these self-assemblies (Figure 3.11B). WAXS profiles 
obtained for self-assemblies formed at all three pHs showed a reflection at 1.27 Å-1 (4.9 Å) 
which could be assigned to intramolecular β-sheet spacing indicating the presence of the cross-
β-sheet structure in LHRH self-assemblies. IR and WAXS data hence taken together reveal 
Chapter 3 
 
85 
 
that LHRH self-assemblies are composed of cross-β-sheet structures with both antiparallel and 
parallel β-sheets at all pHs studied. 
 
3.3.2.1 GnRH assemblies formed at the physiological range of pH are reversible  
The reversibility of LHRH self-assemblies formed at all three pHs was studied by the ThT 
binding assay upon dilution of the concentrated initial sample as previously reported for similar 
systems [54] (figure 3.12). 
 
Figure 3.12: ThT binding assays upon dilution, for LHRH at (A) pH 5.5, (B) pH 7.4 and (C) pH 8. Fluorescence 
intensity values just after dilution (blue scatters), and 24 h after dilution (red scatters) of an initial sample 
equilibrated for one week (highest concentration). 
 
At all three pHs, LHRH self-assemblies dissociated upon dilution showing the reversible 
property of hormone amyloids as reported previously for a few peptides/protein nanostructures, 
including LHRH analogs [2, 15, 29, 54]. 
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3.3.2.2 LHRH forms amyloid-like nanofibrils and hexagonal phases at a pH range 
of 5.5-8 
To observe the supramolecular structures formed in the pH range of 5-8, LHRH self-assemblies 
were imaged by electron microscopy (Figure 3.13) and atomic force microscopy (AFM) 
(Figure 3.14).  
 
 
Figure 3.13: Morphology of LHRH self-assemblies. TEM images of 5% w/w LHRH (a) pH 7.4, (b) pH 8 and (c) 
pH 5.5. (d) ESEM image of 15% w/w GnRH at pH 5.5. 
Qualitative analysis of both AFM (high concentration samples) and TEM images (low 
concentration samples) obtained for LHRH samples evidenced the formation of flexible 
homogenous nanofibrils at all three pHs studied. However, very few fibrils were detected for 
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LHRH samples at pH 8 in both AFM and TEM. According to TEM images, LHRH fibrils 
formed at pH 5.5 are longer than fibrils formed at other two pHs. Environmental scanning 
electron microscopy was also used to image LHRH assemblies. However, this technique only 
worked for LHRH assemblies formed at pH 5.5 displaying fibrillar morphology of LHRH 
assemblies (figure 3.13d).   
Figure 3.14: AFM images of LHRH self-assemblies formed at (A) pH 5.5 (B) pH 7.4 and (C) pH 8. Histograms 
showing the spread of fibril (D) diameters (measured from the AFM height data) and (E) contour length. 
 
A quantitative statistical analysis of the AFM height images was performed using the open 
source software FiberApp [38]. Figure 3.14D displays the diameter distribution of individual 
fibril formed at low pH, pH 7.4 and high pH. The fibrils formed at pH 7.4 had the highest mean 
fibril diameter (3.22 nm) followed by fibrils formed at low pH (1.91 nm) and high pH (1.64 
nm). Interestingly, the mean fibril diameter of fibrils formed at pH 7.4 is two times greater than 
that of high pH assemblies. In the case of counter length (Figure 3.14E), fibrils formed at low 
pH has the highest mean fibril counter length (3.9 µm) followed by fibrils formed at pH 7.4 (2 
µM) and high pH (1.5 µM). 
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All these morphological results taken together suggest that LHRH self-assemblies formed at 
low pH favors fibril extension (thin long fibrils), whereas that of pH 7.4 favors lateral 
association of protofilaments (short fibrils). Interestingly, both fibril extension and lateral 
association are disfavoured at high pH.  
 
Synchrotron small angle x-ray scattering (SAXS) measurements were performed to gain further 
insight into the molecular organization of LHRH self-assemblies formed in the physiological 
range of pH. Figure 3.15 shows two types of SAXS intensity profiles identified as a function 
of concentration. The SAXS profiles displayed in figure 3.15A were obtained from 10% (w/w) 
LHRH samples at pH 5.5/pH 7.4 during the lag phase and same concentration during very early 
stages of aggregation for pH 8 samples. Guinier analysis was conducted for figure 3.15A SAXS 
profiles to obtain values of the radius of gyration (Rg) which provides information about the 
size of the oligomers formed in the solution (Table 3.8).  
 
Figure 3.15: Synchrotron SAXS intensity profiles. (a) SAXS plots obtained for 10% (w/w) LHRH acetate in pH 
range of 5-8. (b) SAXS plots obtained for high concentration of LHRH acetate in pH range of 5-8 (pH 5.6 and pH 
8: 30% w/w LHRH and pH 7.4: 20% w/w LHRH). 
 
Table 3.8: Radii of gyration (Rg) obtained from Guiner analysis and calculated hexagonal 
parameter for LHRH assemblies. 
Sample Rg (Å) Hexagonal parameter (Å) 
pH 5.5 12.28 90.64 
pH 7.4 17.30 103.59 
pH 8 28.33 90.64 
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According to the Rg values calculated, LHRH at pH 8 forms larger oligomers compared to 
other two pHs. Oligomer size of LHRH at pH 8 is twice the size of that at pH 5.5. Rg data of 
LHRH oligomers hence suggest that alkaline pH promotes oligomerization of LHRH. The 
second type of SAXS intensity profiles was obtained for high concentrations (40% w/w) of 
LHRH at same pHs as above (3.15B). These SAXS intensity profiles exhibit Bragg reflections 
indicating the presence of a hexagonal network at all three pHs studied. Bragg reflections were 
observed at 0.08, 0.14 and 0.17 Å-1 corresponding to d-spacing of 78.5, 44.8 and 36.94 Å 
respectively for pH 5.5 and pH 8, whereas for pH 7.4 Bragg reflections were observed at 0.07, 
0.12 and 0,14 Å-1 corresponding to d-spacing of 89.7, 52.3 and 44.8 Å respectively. In addition, 
SAXS data analysis revealed the lattice parameter for hexagonal packing as 90.64 Å (9 nm) for 
pH 5.6 and 8, while that of 103.59 Å (10 nm) for pH 7.4 [55] (Table 3.8). Higher hexagonal 
parameter and higher Rg observed for LHRH self-assemblies formed at pH 7.4 could be due 
to the intercalation of divalent phosphate ions between fibrils/oligomers as previously shown 
for nanotube forming cationic peptides [56]. Overall the SAXS data indicates that LHRH 
nanofibrils have a 2D hexagonal packing with a lattice parameter which could be affected by 
the composition of the counterions present in the solution. 
 
3.3.2.3 Alkaline pH favours amyloid polymorphism 
Optical microscopy was performed to identify the liquid crystalline states of these self-
assemblies (Figure 3.16).  
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Figure 3.16: Optical microscopic images obtained for 30% w/w GnRH assemblies formed at (A), (B) pH 5.5, 
(C), (D) pH 7.4 and (E), (F) pH 8 (one month old). 
LHRH acetate spontaneously forms gels at 20% and 30% w/w onwards for pH 5.5/pH 7.4. and 
pH 8 respectively. Birefringence was observed under cross polarizer for LHRH self-assemblies 
formed at all three pHs studied without any specificity to the peptide concentration. Nemetic 
optical textures were obtained for 30 % (w/w) LHRH samples at all three pHs studied under 
cross polarizer indicating liquid crystalline nature of LHRH self-assemblies. Notably, at pH 
7.4 and high pH, birefringent aggregates were also observed along with liquid crystalline 
textures, suggesting amyloid polymorphism. AFM, TEM and optical microscopic results are 
taken together reveal that LHRH at low pH only forms fibrils, while that of at pH 7.4 and 8 
forms both aggregates and fibrils.  
3.5 Discussion 
According to recent findings, most of the peptide/protein hormones are stored as amyloid-like 
cross-β-sheet structures inside secretory granules in the brain [2]. Here we investigated the self-
assembly of two neuropeptides substance P and LHRH in conditions relevant to secretory 
granules. Substance P has sequence similarity to amyloid β (Aβ) peptide 25-35 which is 
previously shown to forms neurotoxic amyloid fibrils. When comparing results obtained for 
TANGO analysis of substance P in the present study with that of Aβ(25-35) as previously 
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reported indicates that both possess approximately similar percentage propensities to aggregate 
[27]. In both cases, aggregation-prone regions are situated towards C-terminal. According to 
our results, substance P self-assembles into liquid crystalline β-sheet rich nanotubes in 150 mM 
NaCl. These nanotubes are fitted to a core-shell cylinder with an internal diameter, a wall 
thickness, and a length. The nanotube diameter, length and wall thickness remain same 
irrespective of the peptide concentration. A previous study has shown that the positively 
charged somatostatin analogue lanreotide self-assembled into nanotubes and electrostatic 
repulsions between positively charged nanotubes play a vital role in the growth of these 
nanotubes [57]. As the peptide concentration increases, system become more ordered and less 
polydisperse. These findings are important since substance P is the first natural peptide reported 
to forms nanotubes. Substance P self-assembles without a lag phase prior to the aggregation 
showing a rapid kinetic profile. However, the majority of previously reported neuropeptides 
self-assemble with a lag phase prior to the aggregation in the absence of an aggregation helper 
including somatostatin, glucagon-like peptide I and β-endorphin. Notably, glucagon-like 
peptide II also self-assembles without a lag phase prior to the aggregation as previously 
reported [3]. However, glucagon-like peptide II requires more time (10 days) to complete the 
aggregation process than that of substance P (4 hours).  
The self-assembly of the native neuropeptide hormone LHRH into nanofibrils was studied as 
a function of the pH. In accordance with the FT-IR results of histidine protonation, at pH 5.5 
the monomeric solution contains both +2 and +1 charged species, while at pH 8 only +1 
charged species were detected. Interestingly, LHRH at pH 7.4 has +1 as the main species and 
+2 charge species to a lesser extent in the solution. LHRH at pH 8 forms large oligomers, fewer 
numbers of short and thin fibrils with aggregates/precipitates. This observation can be 
explained using steps involved in typical amyloid fibril formation pathway: step (i) soluble 
monomers gradually self-assemble to form oligomers/protofilaments (ii) protofilaments/fibril 
extension (iii) lateral association of fibrils. Due to less charge (+1) at pH 8, electrostatic 
repulsions between monomers are reduced leading to the rapid formation of large oligomers 
and precipitates consist of β-sheet networks as evidenced by ThT assay, IR spectroscopy, and 
optical microscopic results. Since most of the monomers are trapped inside the large oligomers 
and precipitates, the next two steps in the fibril formation process which are protofilament 
extension and lateral association by the addition of monomers are restricted. This leads to the 
formation of fewer thin short fibrils as detected by TEM and AFM data. In the case of pH 7.4, 
the solution contains both +1 and +2 charged LHRH species, however latter is present in a 
lesser extent leading to the formation of both fibrils and precipitates as imaged by optical 
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microscopy. However, fibril extension is less favored at pH 7.4 since some of the monomers 
are trapped inside the precipitates reducing the number of available monomer available for 
fibril extension. On the other hand, increased charge at pH 5.5 give rise to more electrostatic 
repulsions between fibrils which eventually leads to the formation of thin individual fibrils 
disfavouring lateral association of fibrils/protofilament to a lesser extent. 
3.6 Conclusion 
In this chapter, we show that two neuropeptides substance P and LHRH form functional 
amyloids. For the first time, this thesis reports the self-assembly of substance P into well-
defined liquid crystalline β-sheet rich nanotubes with a monodisperse diameter of 6 nm. As 
substance P concentration increases the degree of order in the self-assembly structures 
increases. Indeed, substance P counter ions within substance P nanotubes are directly involved 
in substance P structure. These nanotubes can be used as building blocks to develop 
biomaterials such nanoneedles for drug delivery [58-60]. However, further research needs to 
be performed to identify the structure of substance P nanotube wall. On the other hand, LHRH 
self-assembles into nanofibrils which arranged in a hexagonal network. Functional amyloid 
formation by native LHRH has never been reported before. Results obtained for LHRH self-
assembly indicate that peptide net charge is a key factor which determines the assembling 
kinetics, extent of fibrillization, architecture of nanostructures and equilibrium between 
ordered liquid crystalline structures and disordered precipitates. A similar result has been 
reported for LHRH-inspired peptide triptorelin which forms nanotubes with a pH-dependant 
diameter [16]. These results can be translated to the design of pH-responsive self-assembling 
peptides which are excellent candidates for targeted drug delivery especially in cancer therapy 
[18, 19]. 
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Chapter 4 
  
Interaction of glycosaminoglycans (GAGs)  
with functional amyloids: kinetic and structural 
effects  
4.1 Introduction 
Neuropeptides and peptide hormones are stored inside the secretory granules of the brain as 
amyloid-like structures that can release the monomeric peptide on demand into the extracellular 
space [1, 2]. Presence of several biological factors can affect the packing of neuropeptides and 
peptide hormones into secretory granules, including pH, ionic strength and molecules that are 
known to enhance aggregation, for instance,  glycosaminoglycans [3, 4].  
Glycosaminoglycans (GAGs) are a family of anionic polysaccharides present in the brain 
(Figure 4.1). GAGs were reported to induce the amyloid formation of a wide range of 
proteins/peptides in vitro [5]. Further, GAGs have been frequently found within amyloid 
plaques in the tissues of patients affected by amyloid diseases, indicating an association with 
the toxic amyloid formation in vivo [5].  
 
Figure 4.1: Structure of the glycosaminoglycans considered in this chapter: chondroitin sulphate and heparin. 
Abbreviations: GlcA - Glucuronic acid, IdoA - iduronic acid, GlcNAc - N-acetyl-glucosamine and GalNAc - N-
acetyl-galactosamine. Adapted from [6]. 
Scaffolding-based mechanisms are currently accepted for the molecular interactions between 
GAGs and amyloid-forming peptides or proteins. GAGs are thought to favour amyloid fibril 
nucleation and elongation by electrostatic interactions through their regularly spaced sulphate 
moieties [7, 8]. However, the effects of glycosaminoglycans on the amyloid aggregation 
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process and resulting assemblies are not well studied, [5, 9, 10]yet heparin is frequently used 
to induce peptide/protein aggregation in-vitro, sometimes with little mention in the study [1, 
11].  
In this context, the influence of the glycosaminoglycans heparin and chondroitin was studied 
on the self-assembling kinetics, molecular structure, nanostructure morphology, and 
macroscopic phases of three neuropeptides previously shown to form functional amyloids: 
somatostatin-14, substance P and luteinizing hormone-releasing hormone (LHRH) [11, 12]. 
Somatostatin-14 is a hypothalamic cyclic neuropeptide hormone with broad inhibitory effects 
including growth hormone inhibition [13]. According to literature somatostatin self-assembles 
into amyloid-like structures both in the presence and absence of heparin, however direct 
comparison of these two assembly processes has never been performed [11, 14]. Substance P 
is a neuromodulator that is widely distributed in the central and peripheral nervous systems and 
of many species [15]. Amyloid-like structure formation by substance P in the presence of 
heparin has been previously reported [12]. It was previously shown in this thesis that substance 
P forms nanostructures in the absence of heparin as well (Chapter 3). LHRH is a neuropeptide 
hormone that plays an important role in the development and normal functioning of the 
reproductive system [16]. It was previously shown in this thesis that LHRH self-assembles into 
amyloid-like nanostructures in the absence of heparin (Chapter 3).  
Chapter 4 focuses on characterizing the influence of the GAGs heparin and chondroitin on the 
kinetics of formation and structure of the functional amyloids formed by the three above human 
neuropeptides. Heparin sulphate was chosen because it is commonly employed in biophysical 
studies of amyloids and has biological relevance. Chondroitin sulphate was chosen because it 
bears fewer sulfation sites than heparin (Figure 4.1), hence allows us to directly compare the 
influence of GAG sulfation on neuropeptide self-assembly.  
4.2 Material and methods 
According to the literature, approximately equal amounts of protein/peptide and GAGs are 
present in dense-core vesicles [17]. The experiments hence included samples with an equimolar 
ratio of neuropeptide and GAGs, but also sub-equimolar ratio and excess of GAGs.  
4.2.1 Materials 
All the chemicals and reagents used for this study are given in section 2.1. 
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4.2.2 Methods 
4.2.2.1 Optical microscopy 
Polarized optical microscopy was used to observe the type of aggregates formed in the 
GAG/neuropeptide samples (Technique and protocol described in section 2.2.3). 
4.2.2.2 Thioflavin T (ThT) binding assay 
ThT is an amyloid-specific dye which binds to cross-β-sheet structures, however, not to the 
monomeric peptide [18, 19]. Upon binding to amyloids, ThT exhibits a significant increase in 
the fluorescence intensity. The rate constant of aggregation for all three peptides both in the 
presence and absence of GAGs were calculated by GraphPad Prism 7 software from the best 
fit kinetic (details in section 2.2.1) 
4.2.2.3 Transmission electron microscopy (TEM) and atomic force microscopy 
(AFM) 
To gain insights into the supramolecular structure of peptide-GAG assemblies, transmission 
electron microscopy (TEM) (section 2.2.5) and atomic force microscopy (AFM) (section 2.2.6) 
were performed at similar concentrations as the ThT assays. 
4.2.2.4 Cryo-scanning electron microscopy (Cryo-SEM) 
Cryo-SEM was performed to observed peptide-GAGs assemblies formed at high concentration 
of neuropeptides (details in section 2.2.7). 
4.2.2.5 Attenuated total reflectance Fourier-transform infrared spectroscopy 
(ATR-FTIR) 
To identify the secondary structures formed by self-assembly of pure neuropeptides and GAGs 
assisted assembly, FTIR spectroscopy was carried out at high concentrations (20%w/w) of 
neuropeptides (section 2.2.2). 
4.2.2.6 Synchrotron small angle x-ray scattering (SAXS) 
SAXS experiments were conducted at Australian synchrotron to identify different molecular 
species formed by pure neuropeptides and GAGs assisted assembly at different concentrations 
of neuropeptides (Protocols are described in section 2.2.4).  
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4.2.2.7 Monomer release assay 
Peptide fibrils formed in the presence and absence of heparin were investigated for their 
capability to release monomers [20]. Peptide samples were prepared both in the presence and 
absence of heparin. Peptide only sample was prepared and stored at 4°C for 3 days before the 
experiment to allow fibril formation. A peptide with heparin samples was prepared as the same 
concentration immediately before the experiment. All samples were prepared in 150 mm NaCl 
containing 0.01% sodium azide which was used to prevent microbial growth. Peptide acetate 
in NaCl medium gives pH around 5.6 which is the pH of secretory granules. PBS containing 
0.01% sodium azide was used as a release medium that provides 7.4 pH medium (extracellular 
pH). The dialysis unit system comprising dialysis regenerated cellulose and polypropylene 
membrane with a 3.5kDa cut-off (Thermo Fisher Scientific, USA) was used for the study. 
Samples were made in eppendorf tubes and transferred onto a dialysis membrane immediately 
before the experiment. Capped dialysis tubes were filled with PBS up to 45 ml mark. The 
assembled dialysis units were then placed in a shaking water bath at room temperature (25°C). 
An aliquot was taken from release medium at different time intervals for UV spectroscopy 
performed in Nanodrop. An equal amount of release medium was replaced immediately after 
the withdrawing. The experiment was performed in triplicate. Percentage release was 
calculated and plotted against experiment time. 
4.3 Results 
4.3.1 Pure peptide assemblies form liquid crystalline gels, while heparin-mediated 
peptide assemblies form precipitates  
Neuropeptide self-assembly in the presence and absence of heparin give rise to two distinct 
end products at a macroscopic level (Figure 4.2 (A) and (B)). Heparin mediated peptide self-
assembly leads to the rapid formation of precipitates immediately upon addition of heparin to 
the peptide solution at equimolar concentration, whereas pure peptides form gels with slower 
aggregation kinetics. These changes were noted for all peptides studied.  
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Figure 4.2. Photographs of somatostatin (1%w/w) assemblies in the (A) absence and (B) the presence of 
heparin in 150 mM NaCl.  
 
Both precipitates and gels formed at high concentrations (10-30% w/w) were observed by 
polarized optical microscopy (Figure 4.3). For both gels and precipitates, birefringence was 
observed for all three peptides under crossed polarized light at room temperature (Figure 4.3). 
Liquid crystalline nematic optical textures were only obtained for pure peptides at relatively 
high concentrations (≥10% w/w). For somatostatin, threaded like textures were observed as 
previously reported for somatostatin alone in both water and 150 mM NaCl [11]. In the case of 
substance P, threaded like textures together with cholesteric focal conic defects were observed 
as previously reported for amyloid fibrils [11, 21]. Liquid crystalline microfibrillar patterns 
were observed for pure LHRH assemblies. On the other hand, heparin assisted peptide 
assemblies were observed as birefringent micro-aggregates for all three peptides. These 
observations reveal that heparin prompt dramatic changes in peptide self-assembly forming 
structurally different end products at both macroscopic and microscopic levels. 
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Figure 4.3: Polarised light optical micrographs (A-F) of the peptide aggregates with/out heparin in 150 mM 
NaCl. (A) Liquid crystalline textures obtained for somatostatin 10% w/w 7 days old. (B) Birefringent aggregates 
observed for somatostatin 10% w/w with heparin 7 days old. (C) Liquid crystalline textures obtained for substance 
P 10% w/w 7 days old and (D) Birefringent aggregates observed for substance P 10% w/w with heparin 7 days 
old. (E) Liquid crystalline textures obtained for LHRH 30% w/w one month old. (F) Birefringent aggregates 
observed for LHRH 30% w/w with heparin one-month-old.  
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4.3.2 Influence of heparin on peptide aggregation kinetics 
Thioflavin T (ThT) assays were carried out to compare the self-assembling kinetics of the three 
peptides both in the presence and absence of heparin. In the present study, ThT fluorescence 
measurements were plotted against experiment time and fitted to a single exponential curve for 
all three peptides both in the presence and absence of GAGs (heparin and chondroitin) and are 
shown figure 4.4.  
 
Figure 4.4: ThT binding assays.  (A) Kinetic traces for Somatostatin acetate 1% w/w in presence of heparin, 
chondroitin or pure in 150 mM NaCl. (B) Kinetic trace of pure somatostatin acetate 1% w/w. (C) Corresponding 
rate constants of aggregation calculated from the best fits. (D) Kinetic traces for substance P 1% w/w in presence 
of heparin, chondroitin or alone in 150 mM NaCl. (E) Kinetic trace of substance P 1% w/w alone. (F) 
Corresponding rate constants of aggregation calculated from the best fits. (G) Kinetic traces for LHRH 3% w/w 
in presence of heparin, chondroitin or alone in 150 mM NaCl. (H) Kinetic trace of LHRH 3% w/w alone. (I) 
Corresponding rate constants of aggregation calculated from the best fits. 
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Main kinetic parameters such as lag phase, the rate constant of aggregation and fluorescence 
plateau for both GAG-peptide and pure peptide aggregation were tabulated in table 4.1. 
Table 4.1: Lag time, Kagg and plateau values for best-fit curves of peptide self-assemblies 
formed in the presence and absence of GAGs. 
 
Self-assemblies formed both with and without heparin showed an increase in ThT fluorescence 
with time. This result indicates the amyloid nature of the self-assemblies formed with or 
without GAGs. However, altered kinetic profiles were recorded upon addition of GAGs when 
compared to the pure peptides.  
 
 
 Lag time 
(hours) 
Kagg (S-1) Plateau  
 SST   
1% Pure SST 8.0 0.09×10-4±0.02×10-4 7560±563.5 
1% SST+heparin 0.0 18.32×10-4±1×10-4 17593±399.6 
1% SST+chondroitin  0.0 36.48×10-4±2×10-4 7007±135.2 
 Substance P   
1% Pure substance P 0.0 2.33×10-4±0.28×10-4 93884±2022 
1% Substance P+heparin 0.0 23.1×10-4±2×10-4 62362±1996 
1% Substance P+chondroitin  0.0 61×10-4±5×10-4 25616±467.9 
 LHRH   
3% Pure LHRH 120.0 0.05×10-4±0.01×10-4 57265±4153 
3% LHRH+heparin 0.0 59.77×10-4±4×10-4 100035±342.6 
3% LHRH+chondroitin 0.0 62.90×10-4±3×10-4 26687±245.5 
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Presence of a lag phase prior to the aggregation was observed for both pure somatostatin (8 
hours) and pure LHRH (5 days) (Table 4.1). The weak ThT fluorescence observed in the lag 
phase for pure somatostatin and pure LHRH is proposed to be due to the presence of small 
peptide oligomers in solution. In contrast, pure substance P showed no lag phase prior to the 
aggregation.  
Notably, in the presence of GAGs, all three peptides exhibited rapid aggregation kinetics 
without a lag phase prior to the aggregation. Both heparin and chondroitin assisted aggregation 
showed an increase in ThT fluorescence in a few seconds just after mixing of the peptide with 
GAGs, indicating their role in accelerating amyloid fibril formation. Pure LHRH aggregates 
with a lag phase of 5 days whereas; in the presence of both heparin and chondroitin no lag 
phase was observed prior to the aggregation. Addition of GAGs has increased rate constant of 
aggregation at least by two orders of magnitude for somatostatin and LHRH. Interestingly, in 
the presence of GAGs, Kagg for LHRH has increased by more than three orders of magnitude 
indicating the pivotal role of GAGs in the self-assembly of peptides with less amyloidogenic 
properties. However, substance P did not show a significant difference in constant of rate 
aggregation due to the addition of GAGs which suggest that heparin might be less actively 
involved in substance P fibril formation compared to somatostatin and LHRH. Interestingly, 
chondroitin showed slightly increased rate constant of aggregation values than heparin in all 
three cases (Table 4.1). On the other hand, when comparing plateau fluorescence of heparin 
and chondroitin (Table 4.1), heparin showed at least two times greater fluorescence plateau 
value than chondroitin in all cases revealing the formation of fewer aggregates in presence of 
chondroitin. In the case of peptide-heparin aggregation profiles, we observed higher standard 
deviations, especially in the case of substance P aggregation with heparin, which is due to the 
inhomogeneity of the solution caused by the formation of large aggregates.  
 
Figure 4.5 and table 4.2 show the effect of sub-equimolar concentration of heparin 
(Peptide:GAG, 1:0.7 molar ratio) on peptide self-assembling kinetics. In the presence of both 
equimolar and sub-equimolar heparin concentrations, all three peptides demonstrated increased 
ThT fluorescence with no lag phase prior to the aggregation. However, a slight increase in the 
rate constant of aggregation was observed for sub-equimolar concentration compared to the 
equimolar concentration of heparin (Table 4.2). In contrast, at least three times greater plateau 
fluorescence was observed for equimolar than subequimolar concentration of heparin (Table 
4.2) which indicates the formation of fewer assemblies at subequimolar concentration.  
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Figure 4.5: ThT binding assay: effect of different heparin molar ratios on peptide self-assembling kinetics. 
(A) Kinetic traces for Somatostatin 1% w/w in presence of heparin, equimolar concentration and subequimolar 
concentration in 150 mM NaCl (B) and their corresponding rate constant of aggregation calculated from the best 
fits. (C) Kinetic traces for Substance P 1% w/w in presence of heparin, equimolar concentration and subequimolar 
concentration in 150 mM NaCl (D) and their corresponding rate constant of aggregation calculated from the best 
fits. (E) Kinetic traces for LHRH 3% w/w in presence of heparin, equimolar concentration and subequimolar 
concentration in 150 mM NaCl (F) and their corresponding rate constant of aggregation calculated from the best 
fits. 
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Table 4.2: Kagg and plateau values for best-fit curves of peptide self-assemblies formed in the 
presence of different heparin to peptide molar ratios. 
 
 
 
 
 
 
 
 
 
 
 
 
 
ThT results hence reveal that all three peptides (i) adopt cross-β-sheet base structure both in 
the presence and absence of GAGs (ii) GAGs not only accelerate fibril formation but also 
increase the fibril yield (iii) electrostatic binding of positively charged peptide with negatively 
charged sulphate groups of GAGs occurs from the very early stage of aggregation and (iv) this 
electrostatic binding is the main driving and limiting factor in GAGs mediated aggregation. 
According to the published work on somatostatin derivative lanreotide, pure peptide self-
assembling process is limited by repulsive electrostatic interactions between charged peptides 
[22]. By analogy in regard of somatostatin, we propose that in the presence of GAGs, they 
screen repulsive interactions between charged peptides by directly binding to the positively 
charged side chains of peptide and thereby accelerating fibril formation.  
 
 
 Kagg (S-1) Plateau 
 SST  
1%SST+heparin 1.58×10-2±0.129×10-2 80653±1170 
1%SST+heparin_SE 1.73×10-2±0.202×10-2 30018±602.1 
 Substance P  
1%SP+heparin 0.23×10-2±0.018×10-2 62362±1996 
1%SP+heparin_SE 0.61×10-2±0.05×10-2 25616±467.9 
 LHRH  
3%LHRH+heparin 1.25×10-2±0.07×10-2 111700±1030 
3%LHRH+heparin_SE 4.06×10-2±0.57×10-2 24468±338.7 
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4.3.3 The presence of GAGs significantly alters the nanofibrils architecture 
Transmission electron micrographs obtained for peptide assemblies formed both in the 
presence and absence of heparin are shown in figure 4.6.  
 
Figure 4.6: Electron microscopy imaging of peptide assemblies. TEM images of one-week-old (A) 
somatostatin alone 1% w/w, (B) somatostatin 1% w/w with heparin. TEM images of five days old (C) Substance 
P alone 1% w/w (D) Substance P 1% w/w with heparin in 150 mM NaCl. TEM images of one-week-old (E) LHRH 
alone 5% w/w (F) LHRH 5% w/w with heparin in 150mM NaCl.  
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Peptide aggregates formed in the presence of heparin were too large and dense to be observed 
directly by TEM or AFM. These aggregates were hence broken down by centrifugation and 
then resuspended prior to the deposition on a suitable substrate as previously reported for toxic 
amyloid fibrils [23]. Nanofibrils were observed for all three peptides both in the presence and 
absence of heparin in TEM. However, pure peptides exhibit flexible and homogenous 
nanofibrils, which is consistent with the liquid crystalline nature of these assemblies and 
previously published data for somatostatin [11]. Even though peptide-heparin electron 
micrographs showed nanofibrillar morphology, these assemblies were observed to aggregate 
into clusters. Somatostatin self-assemblies formed in the presence and absence of heparin were 
further examined by cryo-scanning electron microscopy (cryo-SEM) (Figure 4.7) and AFM 
(Figure 4.8). 
Figure 4.7: Cryo-scanning electron microscopy images of somatostatin assemblies in the presence and absence 
of heparin. Microscopy images of three weeks old (A) somatostatin alone 20% w/w, (B) somatostatin 20% w/w 
with heparin.  
Cryo-SEM images of higher concentration (20% w/w) of somatostatin assemblies showed 
highly ordered arrays of laterally associated fibres for peptide alone (Figure 4.7A), whereas 
disordered, relatively short and rigid fibrillar aggregates were observed in the presence of 
heparin (Figure 4.7B). 
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Figure 4.8: AFM Imaging of SST assemblies. (A) AFM height images of pure SST assemblies, z-scale = 10 
nm, (B) AFM height image of SST with heparin, z-scale = 20 nm, (C) DMT modulus image of pure SST 
assemblies, z-scale = 30 GPa, (D) DMT modulus image of SST with heparin assemblies, z-scale = 30 GPa, all 
assemblies at [2.5% w/w], all scale bars = 500 nm. (E): Representative line scans used to calculate the modulus 
of the assemblies. (F) Histograms showing the spread of fibril diameters measured from the AFM height data. 
Adapted from [24]. 
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Table 4.3: Characteristic dimensions (image analysis using the open source software 
FiberApp), the elastic modulus of nanofibrils from QNM-AFM data and from persistence 
length calculations (Figure 4.8A and B) 
 
 
AFM images obtained for pure somatostatin assemblies exhibit homogenous nanofibrils as 
TEM images, while that in the presence of heparin exhibits heterogeneous needle-like 
nanofibrils. A quantitative statistical analysis of the AFM height images was performed using 
the open source software FiberApp [25]. Figure 4.8(E) displays the diameter distribution of 
individual fibrils formed both in the presence and absence of heparin. The fibrils formed in the 
presence of heparin exhibit a distribution of fibril diameters from 2–20 nm indicating the 
heterogeneous nature of nanofibrils formed. Pure somatostatin fibrils show a distribution of 
fibril diameters in a narrow range (from 1–4.5 nm). Notably, the mean fibril diameter of 
somatostatin-heparin fibrils (6.11 nm) is three times larger than that of pure somatostatin fibrils 
(1.97 nm). 
 
Quantitative Nanomechanical Atomic Force Microscopy (QNM-AFM) was used to obtain the 
nanoscale Young’s modulus (E) which provides information about the stiffness of the fibril 
surface. Average E was obtained by analysis of line scans of the modulus images from the 
QNM-AFM data. Interestingly, the average E of pure somatostatin nanofibrils (8.5 GPa) is 
only slightly larger than that of heparin-assisted nanofibrils (6.5 GPa) (Table 4.3). 
Approximately similar surface stiffness suggests that protofilaments of pure somatostatin and 
somatostatin-heparin have similar properties at this length scale which is possible since both 
types of assemblies look alike due to the cross-β-sheet structure. In contrast, persistent length 
(Lp) measurements indicate that heparin assisted fibrils are stiffer than pure somatostatin 
fibrils. The Lp is a basic mechanical property quantifying the stiffness of a polymer which 
includes contributions from both the E and the overall fibril architecture. The Lp of heparin 
assisted assemblies (12.71 µm) is more than three times greater than that of pure somatostatin 
 SST+heparin SST  
    
Mean fibril diameter 6.11 1.97  
Persistence length (BCF) (μm) 12.7±0.92 3.6±0.06  
E (QNM-AFM) (GPa) 6.5±1.55 8.5±0.75  
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assemblies (3.6 µm) which indicates that the heparin assisted fibrils are significantly stiffer 
than that of pure somatostatin fibrils (Table 4.3). This increased Lp for somatostatin-heparin 
nanofibrils must be to be due to a change in the fibril architecture (as we know E is more or 
less constant). It has been shown that the addition of heparin promotes thicker multifilamentous 
structure formation as evidenced by AFM (Figure 4.8F), TEM (Figure 4.6B) and cryo-SEM 
(Figure 4.7D), and it is likely this increase in fibril diameter which is causing the dramatic 
increase in Lp. Based on qualitative and quantitative morphological data we proposed that 
heparin binds to somatostatin protofilaments and promote their association until precipitation. 
 
4.3.4 Heparin hinders the formation of β-sheet networks between protofilaments. 
According to previously published reports, pure somatostatin assemblies are composed of both 
antiparallel β-sheet and parallel β-sheet networks. Importantly, parallel β-sheet networks which 
arise due to the lateral association of protofilaments/fibrils are detected towards the end of the 
aggregation process by ATR-FTIR spectroscopy for pure somatostatin [11]. In the present 
study, both antiparallel and parallel β-sheet networks were also observed in the case of pure 
LHRH and substance P self-assembly (chapter 3). In this context, we performed IR 
spectroscopy to identify and compare secondary structures formed in the presence of GAGs by 
peptides with pure peptides. Secondary derivative spectra of Substance P and LHRH 
assemblies formed in the presence and absence of heparin are shown in figure 4.9. In addition, 
detailed IR spectroscopic analysis was carried out for somatostatin assemblies formed both in 
the presence and absence of heparin (figure 4.10). 
 
In ATR-FTIR, amide I vibrations (1600-1700 cm-1) were used to identify the secondary 
structure of the peptide backbone. Amide I vibrations mainly arise from vibrational stretching 
modes of the backbone carbonyl groups. They can hence reveal information about the 
intermolecular and intramolecular H-bonds in which the backbone carbonyl groups are 
involved [26, 27]. When comparing secondary structures formed by pure somatostatin and 
heparin-somatostatin, in the absence of heparin, somatostatin assemblies are comprised of two 
types of β-sheet networks: anti-parallel (1625 cm−1 and 1680 cm−1) and parallel (1630 cm-1), 
while in the presence of chondroitin the latter vibration is present to a lesser extent and in the 
case of heparin the latter vibration is completely absent (figure 4.10). 
Chapter 4 
 
113 
 
 
Figure 4.9: Second derivative spectra of ATR-FTIR amide I vibrations for Substance P and LHRH 
assemblies. (A) Substance P 10% w/w in 150 mM NaCl with or without heparin (one-week old sample). (B) 
LHRH 20% w/w in 150 mM NaCl with or without heparin (Three weeks old). Blue and red colour arrows indicate 
the 1630 cm−1 vibration due to parallel β-sheet networks involved in protofilaments lateral association. 
 
Antiparallel β-sheets are formed between protofilaments at initial stages of fibril formation, 
whereas parallel β-sheet networks formed between fibrils leading to a well-ordered structure 
which could be detected towards the end of the aggregation process [11, 28]. A similar result 
was observed for LHRH assemblies formed in the presence and absence of heparin. In contrast 
to somatostatin and LHRH, in the case of substance P, peptide assemblies formed both in the 
presence and absence of heparin are consisting of both parallel and antiparallel β-sheet 
networks indicating less involvement of heparin in SP nanostructure formation which is also 
evidenced by the ThT assay results. Substance P self-assembles without a lag phase even in the 
absence of GAGs which demonstrate their high amyloidogenic propensity (chapter 3). 
Therefore, substance P self-assembly process might be completed prior to starting interactions 
with GAGs leading to the same secondary structures formed both in the presence and absence 
of heparin. 
 
According to somatostatin IR spectroscopic data, antiparallel β-sheet networks are formed 
within protofilaments both in the presence and absence of GAGs. However, the addition of 
GAGs provides numerous sulphate groups which prevent the formation of parallel β-sheet 
networks between fibrils explaining the disordered aggregates observed in the presence of 
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heparin. These parallel β-sheet networks were proposed to be located at the cationic N-terminal 
β-strand of the somatostatin molecule as previously reported. 
 
 
Figure 4.10: ATR-FTIR amide I vibrations for somatostatin 10% w/w in 150 mM NaCl with or without 
GAGs, at different time points. Arrows indicate the 1630 cm−1 vibration due to parallel β-sheet networks. A: 
Pure somatostatin at t = 0, t = 2day and t = 7days. B: Somatostatin with chondroitin at t = 0, t = 2day and t = 
7days. C: Somatostatin with heparin at = 0, t = 2day and t = 7days. D: Secondary derivatives of the spectra 
obtained at t = 7 days, for pure somatostatin and somatostatin with GAGs. Anti//= antiparallel β-sheet, //β= parallel 
β-sheet, R= random coil, T= turn. 
 
Since GAGs are negatively charged molecules, they hinder the formation of parallel β-sheet 
networks between protofilaments by binding to positively charged N-terminal which leads to 
loss of long-range order (parallel β-sheet networks) in heparin-assisted assemblies. 
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4.3.5 Both fibrillary liquid crystals and fibrillary precipitates are reversible 
According to the literature, functional amyloids release their monomer under suitable 
experimental conditions showing the reversibility of these assemblies which is a unique 
property possesses by functional amyloids [1, 29]. In addition, the reversibility of pure 
somatostatin assemblies has been previously reported by Maji and co-workers [14]. Based on 
our ThT, TEM, AFM, and IR data, the addition of GAGs to the pure peptides altered the 
aggregation kinetics and aggregate end-morphology. We were hence interested in studying 
whether these differences can cause any changes to their monomer release property. In this 
context, we studied the reversibility of peptide assemblies and heparin-peptide assemblies as 
previously reported for somatostatin [14]. Figure 4.11 shows the percentage peptide released 
for all three peptides, studied both in the presence and absence of heparin.  
 
Both types of assemblies released monomer when exposed to dialysis with phosphate buffer 
saline for all three peptides studied. However, less release was observed for heparin assemblies 
than pure peptide assemblies supporting the formation of less soluble aggregates in the 
presence of heparin which slows down monomer release. The presence of heparin increases 
fibril stability facilitating slow and gradual release of the monomer. A similar result was 
reported by Maji and co-workers for glucagon-like peptide 1 (GLP1) [9]. There was no 
significant difference either within pure peptides or peptide-heparin assemblies were observed. 
The percentage released for pure peptides was always observed as approximately between 4-
6% in the time frame studied, while that of peptide-heparin was approximately 1.8%. Slow 
release property of monomer by peptide self-assemblies has been utilized in designing of 
lanreotide liquid crystalline extended release formulation which is used in the treatment of 
acromegaly. Lanreotide is a somatostatin analog that forms liquid crystalline nanotubes [30]. 
This liquid crystalline gel has been developed into a depot formulation which is currently used 
in the management of acromegaly and neuroendocrine tumours.  
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Figure 4.11: Monomer release assay for pure peptide and peptide-heparin fibrils. (A) Percentage monomer 
release of 1% w/w somatostatin fibrils and somatostatin 1% w/w with heparin aggregates. (B) Percentage 
monomer release of 1% w/w substance P fibrils and substance P 1% w/w with heparin aggregates. (C) Percentage 
monomer release of 5% w/w LHRH fibrils and LHRH 5% w/w with heparin aggregates. 
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4.3.6 Pure assemblies of peptide form homogenous nanofibrils in solution whereas 
GAG associated assemblies form a heterogeneous mixture of aggregates. 
Somatostatin, substance P and LHRH self-assemblies formed both in the presence and absence 
of GAGs were characterized by synchrotron small angle X-ray scattering (SAXS). Three types 
of SAXS intensity profiles were detected as a function of peptide concentration for 
somatostatin (figure 4.12) and LHRH (figure 4.13). Additionally, figure 4.13 shows SAXS 
intensity profiles obtained for 5%, 10% and 20% of substance P assemblies.  
 
SAXS intensity profiles given in figure 4.12A were gained from supernatants of 10% (w/w) 
somatostatin aggregates formed in the presence of sub-equimolar concentrations of GAGs 
during the lag phase. Guinier analysis was conducted for those SAXS profiles to obtain the 
radius of gyration (Rg), which is a parameter that provides information about the size of species 
formed in solution [31, 32](Table 4.4). These Rg values were also compared with previously 
published Rg values for pure somatostatin monomer and somatostatin-heparin complexes 
obtained from all atom molecular dynamic (MD) simulations [14]. When comparing with MD 
simulation data, pure somatostatin forms dimers or small oligomers in solution. This 
observation is supported by previously reported work for somatostatin derivative lanreotide 
which states that the dimer is a thermodynamically stable intermediate in their self-assembly 
pathway [22]. According to the Rg values calculated herein, molecular species present within 
the supernatants of the GAG-peptide aggregates is almost four times greater than that of the 
pure somatostatin. In addition, Rg values obtained from MD simulation for the somatostatin-
heparin complex are similar to the Rg values calculated in this study. These data support the 
fact that high binding affinity of negatively charged GAG molecules to positively charged 
peptide leads to the formation of GAG bound aggregates which is the main species in the 
supernatants of GAG-somatostatin samples. 
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Figure 4.12: Synchrotron SAXS intensity profiles for Somatostatin assemblies. (A): SAXS plots obtained for 
supernatants of 10% w/w peptide-GAG samples with sub-equimolar heparin/chondroitin and during the lag phase 
of 10% w/w somatostatin. (B) SAXS plots for 1% w/w peptide samples with/without GAGs. (C) SAXS plots for 
5% w/w peptide samples with/without GAGs. (D) SAXS plots for 20% w/w samples with/without GAGs. 
 
Table 4.4: Radii of gyration (Rg) obtained from SAXS Guinier plots for somatostatin (Figure 
4.12A) and LHRH (Figure 4.13A) and reported from all atoms molecular dynamics for 
somatostatin [14]. 
 
 Guinier analysis (Rg, Å) Molecular dynamics (Rg, Å) 
Somatostatin 9.75 (90%) 5.5-7.0 (monomer)  
Somatostatin+chondroitin 22.22 (77%)  
Somatostatin+heparin 22.11 (77%) 23-32 (aggregates) 
LHRH 8.53 (87%)  
LHRH+chondroitin 9.14 (80%)  
LHRH+heparin 8.38 (93%)  
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Figure 4.13: Synchrotron SAXS intensity profiles for LHRH assemblies. (A): SAXS plots obtained for 
supernatants of 10% w/w peptide-GAG samples with sub-equimolar heparin/chondroitin and during the lag phase 
of 10% w/w LHRH. (B) SAXS plots for 5% w/w LHRH samples with/without heparin. (C) SAXS plots for 20% 
w/w Substance P with/without heparin. 
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Figure 4.14: Synchrotron SAXS intensity profiles for substance P assemblies formed in the presence and 
absence of heparin. SAXS intensity profile of 5%w/w substance (A) without (B) with heparin. SAXS intensity 
profile of 10%w/w substance (C) without (D) with heparin. SAXS intensity profile of 20%w/w substance (E) 
without (F) with heparin. 
Surprisingly, in the case of LHRH, we observed similar Rg values for pure LHRH (8.53 Å), 
LHRH-chondroitin (9.14 Å) and LHRH-heparin (8.38 Å) oligomers (Figure 4.13A). Since 
LHRH-GAGs aggregates are larger and heavier and insoluble it is possible that they might 
have fallen to the bottom of the capillary and have been missed by the X-ray beam, while pure 
LHRH oligomers are found in the top part of the capillary. We might hence not have captured 
LHRH-GAGs aggregates. 
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The second type of SAXS intensity profiles was obtained for somatostatin (1% and 5%) (Figure 
4.12B and 4.12C) and LHRH (5%) (Figure 4.13B) at an equimolar concentration of GAGs to 
peptide. These SAXS intensity profiles display a slope that leans towards q-x (x>0) in q range 
0.01-0.6 Å. These slopes are due to the scattering of nanoscale colloids in solution which 
provides information on their morphology such as fibrillar, crystals and aggregates. All 
calculated slopes and corresponding interpretation according to previous reports are tabulated 
in table 4.5.  
 
Table 4.5: Slope (q−x) of the SAXS intensity profiles at low scattering vector values: q in the 
range 0.01–0.02 Å−1 corresponding to distance in the range 310–630 Å (31–63 nm). 
 
Sample q-x min q-x max Interpretation [10] 
 Somatostatin   
1%SST 0.808 1.948 q-1: rod and q-2: flat 2D 
5%SST 0.771 0.828 q-1: rod 
1%SST+CS  3.602 4.048 q-4: unstructured/ spherical aggregates 
5%SST+CS 3.186 4.098 q-2: 2D flat and q-4: unstructured/spherical 
aggregates 
1%SST+hep 3.821 3.632 q-2: 2D flat and q-4: unstructured/spherical 
aggregates 
5%SST+hep 3.394 3.559 q-2: 2D flat and q-4: unstructured/spherical 
aggregates 
 LHRH   
5%LHRH 0.903 1.140 q-1: rod 
5%LHRH+CS 3.897 4.138 q-4: unstructured/ spherical aggregates 
5%LHRH+hep  3.340 3.365 q-2: 2D flat and q-4: unstructured/spherical 
aggregates 
 
 
According to the slope interpretation, somatostatin assemblies formed in the presence of GAGs 
mainly consist of unstructured or spherical aggregates, whereas pure somatostatin assemblies 
at the same concentration consist of rod-like (nanofibrils) and flat 2D structures (laterally 
associated fibrils). These results aligned with TEM and AFM data obtained for the same range 
of concentrations suggest that the presence of heparin leads to the precipitation of somatostatin 
protofilaments. Similar results were obtained for LHRH assemblies as well (Figure 4.12B). 
Pure LHRH assemblies consist of rod-like (nanofibrils) structures, while GAGs mediated 
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LHRH assemblies at the same concentration consist of unstructured or spherical aggregates 
(Table 4.5). 
 
Figure 4.12 (D) shows a third type of SAXS intensity profiles obtained for high concentrations 
of (20% w/w) somatostatin both in the presence and absence of GAGs. The correlation 
reflections observed for pure somatostatin are completely absent in the presence of heparin but 
present to a lesser extent in the case of chondroitin. These correlation peaks (6.3 nm and 12.5 
nm) are proposed to arise from inner symmetries within the self-assemblies. Based on fibril 
diameter obtained for pure somatostatin (1.5 nm) from AFM data, these distances can be 
interpreted as laterally-associated arrays of fibrils. These results are consistent with images 
obtained for pure somatostatin by cryo-SEM that showed fibre arrays. Indeed, this observation 
also supported by parallel β-sheet networks arises due to the lateral association of fibrils as 
identified by IR spectroscopy. The absence of correlation peaks in heparin-somatostatin 
assemblies aligns well with the results obtained by AFM and cryo-SEM, which showed 
disordered aggregates due to the loss of long-range order and loss of parallel beta-networks as 
detected by IR spectroscopy. The LHRH assemblies formed in the presence of heparin also 
display loss of reflections by SAXS, which typically arise due to the presence of a hexagonal 
network within the assembly (Figure 4.13D). LHRH-heparin SAXS intensity profile shows 
two other peaks corresponding to d-spacing of 27.3 Å and 10.6 Å which could be assigned to 
inner symmetries within the assembly and distance between β-sheet networks respectively. 
This result is also in accordance with IR spectroscopic results, which showed a loss of parallel 
β-sheet network for LHRH-heparin assemblies.  
 
In contrast to somatostatin and LHRH, in the case of substance P, oscillations for nanotubes 
were observed for both pure and heparin-assisted assemblies for all the concentrations studied 
(Figure 4.14). Substance P nanotubes formed both in the presence and absence heparin were 
fitted to a core-shell cylinder with an internal diameter (di), a wall thickness (twall) and a tube 
length (l). Table 4.6 displays modelled parameters of substance P nanotubes both in the 
presence and absence of heparin.  
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Table 4.6: Modelled parameters of substance P nanotubes 
 
SP concentration 
(w/w) 
Diameter/di (nm) 
Wall thickness/wallt 
(nm) 
Length/l (nm) 
5% 6.54 0.90 100.14 
5%+heparin 6.13 0.94 181.88 
10% 6.20 1.21 100.14 
10%+heparin 6.85 1.47 181.88 
20% 6.13 1.21 100.14 
20%+heparin 7.02 0.92 120 
 
Both pure substance P nanotubes and heparin assisted nanotubes show approximately similar 
diameter and wall thickness. However, at all concentrations studied heparin assisted tubes are 
longer than that of pure substance P nanotubes. The influence of concentration on tube internal 
diameter, wall thickness and length were not observed for both pure substance P and heparin 
assisted assemblies. These results suggest that heparin might not have an influence on nanotube 
growth as evidenced by similar tube diameter and wall thickness in both types of assemblies. 
However, heparin might influence tube length by making tubes longer.  
 
As previously reported for somatostatin analog lanreotide which is also a positively charge 
peptide, electrostatic repulsions between peptide nanotubes are important in tube growth [22]. 
Typically, interactions between positively charged amino acids in peptide structure and 
negatively charged sulphate groups in heparin molecules might screens repulsive interactions 
between peptide nanotubes. However, due to the lack of interactions between substance P and 
heparin, nanotubes formed at both cases show similar tube diameter. 
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4.4 Discussion 
4.4.1 Molecular mechanisms of aggregation 
With the combination of all our biophysical data mainly for somatostatin and previously 
published reports for somatostatin and lanreotide we were able to propose a mechanism of 
aggregation for somatostatin both in the presence and absence of GAGs (Figure 4.15). 
 
 
 
Figure 4.15: Model of somatostatin self-assembly alone (A) and with (B) heparin. (A) Somatostatin assembly 
into liquid crystalline protofilaments via antiparallel β-sheet networks. (A’) Lateral association of protofilaments 
into mature fibrils and liquid crystalline arrays via parallel beta-sheet networks and aromatic stacking. (B) 
Electrostatic bonding of somatostatin to heparin. (B’) Electrostatic bonding between somatostatin/ heparin 
complexes resulting in rigid protofilaments embedded into precipitates. Adapted from [24]. 
 
In the absence of GAGs, pure somatostatin gradually self-assembles into small oligomers and 
then protofilaments through the anti-parallel β-sheet network. These protofilaments in turn 
gradually laterally associate into multi-filamentous mature fibrils possessing highly ordered 
extended amyloid morphology. With time the further association of these highly ordered 
mature fibrils into ordered liquid crystalline arrays occurs via a parallel β-sheet network 
(4.15A). Apart from the parallel β-sheet network, π-π stacking arisen from the side chains of 
aromatic amino acids Phe and Trp on the fibril surface offer further stability as reported for 
somatostatin analog lanreotide [28]. Pure somatostatin self-assembly process hence leads to a 
well-structured and thermodynamically stable liquid crystalline end product. In the presence of 
GAGs, positively charged side chains of the peptide rapidly bind to the negatively charged 
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sulfate groups of the GAG molecules as demonstrated by 1H-NMR experiments [14]. Indeed, 
this complexation occurs within nanoseconds as shown by molecular dynamics [14]. This rapid 
complexation prevents the formation of the parallel β-sheet network and also screens repulsive 
charges between the fibrils resulting in the rapid precipitation of protofilaments intercalated by 
GAG molecules. With time this GAG assisted assembly process leads to the formation of 
relatively large and disordered precipitates in solution (4.15B). 
4.4.2 Common effects of GAG on the peptide assemblies  
Somatostatin, LHRH, and substance P are neuropeptides implicated in diverse biological 
functions of the human body. In the secretory pathway, these peptides are temporally stored in 
secretory granules as amyloids [1]. In other words, these peptides self-assemble into β-sheet 
rich nanostructures in vivo as a storage mechanism. However, upon physiological demand, 
these self-assemblies release their monomer to perform biological functions. 
Glycosaminoglycans are sulphated biopolymers co-localized with disease-associated amyloid 
deposits such as amyloid β deposits found in Alzheimer’s disease [5]. Glycosaminoglycans are 
also involved in hormone/neuropeptide aggregation in vivo [1, 33]. In this study, we used three 
neuropeptides (somatostatin, substance P and LHRH) which form functional amyloids without 
the help of aggregation inducing molecules to study the influence of glycosaminoglycans on 
functional amyloid formation mechanism and the structure of the self-assemblies formed since 
it is not clearly documented in the literature [11](chapter 3). 
 
All three peptides used for this study are positively charged at a physiological range of pH (pH 
5-7.4). According to previous reports pure somatostatin self-assembles into nanofibrils 
possessing both antiparallel and parallel β-sheet conformations [11, 28]. In the present study, 
we found that pure substance P self-assembles into β-sheet rich (antiparallel and parallel) 
nanotubes (chapter 3.1). In the case of pure LHRH, we demonstrated that it self-assembles into 
β-sheet rich (antiparallel and parallel) nanofibrils and hexagonal phases (chapter 3.2). 
Importantly, these three peptides have different rates of aggregation kinetics as demonstrated 
by ThT assay results for pure peptides (chapter 3): substance P –rapid aggregation kinetics, 
somatostatin – a medium rate of aggregation kinetics[14] and LHRH – a slow rate of 
aggregation kinetics.  
 
Results present in this chapter showed that GAGs accelerate amyloid fibril formation as 
previously reported for both functional and toxic amyloid systems [9, 14] [5, 34]. Apart from 
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that, the addition of GAGs also increases fibril yield. The subequimolar concentration of GAGs 
produces less fibril yield than that of equimolar concentration which is due to the availability 
of less binding sites for peptides to interact with GAG molecules. Reduction in fibril yield was 
also observed in the presence of less sulphated GAG, chondroitin when compared to that of 
heparin. In the presence of heparin, the peptide has more sulphate groups to bind than that of 
chondroitin which leads to less electrostatic interactions with chondroitin compared to heparin. 
These results indicate that electrostatic interactions between the peptide and sulphate groups of 
GAG molecules are the main driving and limiting factor in GAG mediated cationic peptide 
aggregation. Most importantly, our results show that structures of the self-assemblies formed 
in the presence of GAGs are different than that of pure peptide. Adamcik et al reported similar 
results for an amyloidogenic fragment of tau protein. According to their report, tau fragment 
self-assemblies into highly stable giant nanoribbons in the absence of heparin, while such 
structures were not observed in the presence of heparin [10]. In another study, conducted on 
heparin assisted aggregation of native neuropeptide β-endorphin showed that heparin 
incorporates into developing β-endorphin fibrils forming an integral component of their 
structure [35]. The above-mentioned studies and our results question the biological relevance 
of heparin-peptide systems use as biological models for amyloid systems.  
 
4.4.3 An influence of positive charge distribution in the peptide sequence? 
The addition of GAGs accelerated aggregation kinetics of all three peptides studied, however 
to a different extent. The difference observed in aggregation kinetics among three peptides 
could be due to the distribution of positive charges within the peptide sequence. All three 
peptides and their charge distribution along the amino acid sequence are shown in table 4.7. 
Both somatostatin (K4 and K9) and LHRH (H2 and R8) have two positively charged amino 
acids that are located distantly in their sequence. On the other hand, substance P has two 
positively charged amino acids (R1 and K3) that localized towards the N-terminal of the 
sequence 
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Table 4.7: Amino acid sequence of neuropeptides studied and their charge distribution. 
 
 
According to the previously published reports GAGs-peptide interactions occurs via binding 
of negatively charged sulphate groups of GAGs to positively charged amino acids in the 
sequence. In the case of substance P, since all positive charges are localized towards one end 
of the sequence, the rest of the sequence might not be actively interacting with heparin. Overall 
interaction of substance P with heparin hence might be poor. In contrast, previous reports have 
proposed that availability of a high number of basic residues and presence of basis-nonbasic-
basic (B-N-B) motif in the peptide/protein sequence facilitates strong peptide/protein-heparin 
interactions [9, 36, 37]. We argue that even though, substance P has a B-N-B motif (R1-P2-
K3) in their sequence, substance P contains fewer basic residues (2 basic residues) and more 
importantly, these two basic residues are localized towards one terminal resulting poor 
interactions of heparin with rest of the sequence. Other plausible explanation for the case of 
substance P could be that substance P converts to thermodynamically stable confirmation prior 
to the binding of GAG molecules leading to overall fewer interactions with heparin. In other 
words, during the self-assembly process substance P discover their thermodynamically stable 
conformation more promptly than somatostatin and LHRH without leaving time for heparin to 
bind. This assumption is supported by slower aggregation kinetics observed for somatostatin 
and LHRH and rapid aggregation kinetics observed for substance P in the absence of heparin. 
In the case of somatostatin and LHRH, heparin has sufficient time to bind to the peptide as they 
require more time to find their thermodynamically stable conformation. Since substance P has 
poor interactions with heparin, the molecular level arrangement of both substance P-heparin 
and pure substance P assemblies are similar as evidenced by the presence of parallel β-sheet 
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network detected by IR spectroscopy and similar form factor observed for nanotubes formed 
both in the presence and absence of heparin by SAXS. SAXS data also shows that heparin has 
no influence on the structure of substance P nanotubes as supported by similar diameter and 
wall thickness for both heparin-mediated nanotubes and pure substance P nanotubes. This 
finding supports our hypothesis that heparin has poor interactions with substance P and these 
interactions begin after substance P finding their thermodynamically stable conformation. In 
other words, heparin interacts with substance P towards the end of the self-assembly process. 
4.5 Conclusion 
In this work, we studied and compared the detailed mechanism of aggregation and amyloid 
formation by somatostatin both in the presence and absence of GAGs. In addition, self-
assembly of LHRH and substance P both in the presence and absence of GAGs were also 
examined and compared to a lesser extent. Our biophysical data suggest that GAGs possess a 
distinct effect on self-assembly of somatostatin, LHRH and substance P which we assume is 
due to the differences in positive charge distribution along their amino acid sequence. More 
importantly, our results indicate that heparin modifies not only aggregation kinetics but also 
the structure of the assemblies formed. A similar type of results has been reported lately by 
others. These data further confirm our postulate that heparin acts not as just an inert aggregation 
inducer, but significantly changes the molecular structure of most amyloid-forming systems. It 
is hence important to carefully consider the structural effects of GAGs on peptide/protein self-
assemblies when investigating amyloids and using such aggregation helpers, especially when 
concluding on structure-function relationships or when investigating amyloid-based 
nanostructures as bionanomaterials. 
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Chapter 5 
 
Interactions of neuropeptide 
self-assemblies with cells 
 
5.1 Introduction 
 
Amyloids are highly ordered cross-β sheet structures responsible for disease conditions, for 
instance, neurodegenerative diseases (Alzheimer’s diseases and Parkinson’s disease) [1] and 
biological functions of the host organism, such as melanin production in mammalians [2]. In 
both cases, soluble peptide/protein converts to insoluble nanostructures through the formation 
of intermediate species known as oligomers [3]. Lately, it has been shown that cellular toxicity 
observed in protein misfolding diseases is caused by oligomeric species rather than mature 
amyloid fibrils [4, 5]. On the other hand, nanostructures formed by functional amyloids are 
reported to be non-toxic and reversible, which makes them versatile building blocks for 
biomaterials [6, 7]. The presence of both charged and hydrophobic residues in peptide/protein 
structures contributes to the sticky properties of amyloid fibril surfaces [8-10]. This stickiness 
makes amyloid fibrils interact with small molecules and cell membranes in the extracellular 
matrix [11, 12]. However, limited literature is available on the interactions of molecular species 
formed by functional amyloids, with cell lines or model cell membranes [5, 6, 13].  
Neuropeptides are stored as amyloids in secretory granules within the brain [14]. Therefore, it 
is interesting to study how these neuropeptide assemblies interact with different types of brain 
cells. This work hence investigates the interactions of different types of molecular species 
formed in the neuropeptide self-assembly process, including species and mature fibrils, with 
two types of brain cells, neuroblastoma cells (SH-SY5Y) and microglia (BV2 cell line). In the 
literature, neuroblastoma cells were widely used as a model for neurons [15, 16]. Microglia is 
a type of glial cells which are also known as brain immune cells associated with Alzheimer’s 
disease. According to the literature, when amyloid β (Aβ) plaques are formed in the 
extracellular matrix of the brain, microglia get activated and recruited to the site to provide 
neuroprotective function [17-19]. Neuropeptide/hormone aggregation in the secretory pathway 
is regulated by several environmental factors, including the presence of aggregation helpers. 
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Glycosaminoglycans (GAGs) are a type of aggregation helper which may influence the 
aggregation of neuropeptides/hormones in vivo [14, 20]. It was shown in chapter 4 that the 
presence of GAGs significantly alters the structure of the end products formed by self-assembly 
of neuropeptides at both microscopic and macroscopic levels [21]. In this framework, the 
influence of the glycosaminoglycan heparin on the interactions between neuropeptide species 
and brain cells was also examined. 
5.2 Materials and methods 
5.2.1 Materials 
5.2.1.1 Chemical and reagents 
Dulbecco’s Modified Eagle Medium (DMEM) and Dulbecco's Modified Eagle Medium: 
Nutrient Mixture F-12 (DMEM/F12) were purchased from Invitrogen (Australia). Fetal bovine 
serum (FBS) sterile filtered (heat-inactivated) was purchased from Cellsera (Australia). Cell 
Proliferation Assay (MTS) kit was obtained from Promega (Australia). Cytopainter Cell 
Proliferation Staining Reagent-Green Fluorescence and Live/Dead cell assay were purchased 
from Abcam (Australia). 
5.2.1.2 Peptides 
Aβ(25-35) (Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-OH) was purchased from Creative 
Peptides (Australia) as powders and stored at -30°CAmyloidogenic peptide sequences 
(ILQINS, TFQINS, and IFQINS) were a gift of Dr. Nicholas Reynolds (Swinburne University, 
Australia). Details of the other peptides (substance P, somatostatin and LHRH) used in this 
chapter are given in chapter 2 section 2.1.2. 
5.2.1.3 Cell lines 
BV2 cells were a gift of Dr. Martin Stebbing (Florey Institute of Neuroscience and Mental 
Health, Australia). SH-SY5Y cell line was a gift of Prof. Peter McIntyre (RMIT University, 
Australia). 
5.2.2 Methods 
5.2.2.1 Preparation of peptide solutions 
A detailed description of sample preparation is given in chapter 2 section 2.2.12. Briefly, a 
weighed fraction of peptide powder was dissolved in cell culture media (DMEM/DMEM: F12) 
or Milli Q water for cell biology assays and CD experiments, respectively.  
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5.2.2.2 Biophysical techniques 
5.2.2.2.1 Transmission electron microscopy (TEM) 
To gain insights into the supramolecular structure of neuropeptide assemblies formed in cell 
culture media DMEM, transmission electron microscopy (TEM) (section 2.2.5) was performed 
at similar concentrations as the MTS assay (1% and 0.1%w/w). 
5.2.2.2.2 Attenuated total reflectance Fourier-transform infrared spectroscopy (ATR-
FTIR) 
To identify the secondary structures formed by self-assembly of pure neuropeptides and 
heparin assisted assembly, FTIR spectroscopy was carried out at 1%w/w the neuropeptide 
concentration (section 2.2.2). 
5.2.2.2.3 Circular Dichroism 
Spectra were acquired using a JASCO 810 instrument. All measurements were carried out at 
room temperature. Spectra were generally recorded over the wavelength range of 190–300 nm. 
The measurements were obtained at a speed of 50 nm/minute and 5 scans for each baseline and 
sample data. Water was used as the baseline. Data were smoothed with a 7-point Savitzky-
Golay filter according to the manufacturer’s instructions. 
5.2.2.5 Cell cultures 
Mouse BV2 and human SHSY5Y cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) and DMEM: F12 respectively, supplemented with 10% fetal bovine serum (FBS) 
and 1% antibiotics. The cell cultures were maintained in a 5% CO2 humidified atmosphere at 
37°C. 
5.2.2.6 MTS assay 
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) assay was carried out to evaluate the toxicity of neuropeptides, amyloidogenic 
peptides and Aβ(25-35) using SHSY5Y and BV2 cell lines [5, 6]. BV2 and SHSY5Y cells 
were seeded at a density of 2500 and 10,000 cells per well, respectively on 96-well plates 
coated with poly-lysine in 100 µL medium. After 24 hours of incubation, the old culture 
medium was replaced with fresh medium containing the peptide samples and cells were further 
incubated for 24 hours at 37°C. After incubation of 20 hours, 10 µL of MTS was added to each 
well and the incubation was continued for another 4 hours. Absorbance values at 490 nm were 
determined using a Clariostar microplate reader [22]. The growth medium without peptide 
samples and MTS dye in growth medium were used as negative control and blank, respectively. 
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Staurosporine at 0.5µM concentration was used as a positive control [23-25]. The percentage 
of cell viability was calculated using the equation below:  
% 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑐𝑐𝑣𝑣𝑣𝑣𝑣𝑣 = 𝐴𝐴𝑣𝑣𝐴𝐴𝐴𝐴𝐴𝐴𝑣𝑣𝑣𝑣𝐴𝐴𝑐𝑐𝑐𝑐 𝐴𝐴𝑜𝑜 𝑣𝑣ℎ𝑐𝑐 𝐴𝐴𝑣𝑣𝑠𝑠𝑠𝑠𝑐𝑐𝑐𝑐 − 𝐴𝐴𝑣𝑣𝐴𝐴𝐴𝐴𝐴𝐴𝑣𝑣𝑣𝑣𝐴𝐴𝑐𝑐𝑐𝑐 𝐴𝐴𝑜𝑜 𝑣𝑣ℎ𝑐𝑐 𝑐𝑐𝐴𝐴𝐴𝐴𝑣𝑣𝐴𝐴𝐴𝐴𝑐𝑐
𝐴𝐴𝑣𝑣𝐴𝐴𝐴𝐴𝐴𝐴𝑣𝑣𝑣𝑣𝐴𝐴𝑐𝑐𝑐𝑐 𝐴𝐴𝑜𝑜 𝑣𝑣ℎ𝑐𝑐 𝑐𝑐𝐴𝐴𝐴𝐴𝑣𝑣𝐴𝐴𝐴𝐴𝑐𝑐  
Two protocols were used: either cells placed at the bottom of the plate and peptide solutions 
on top or peptide solutions at the bottom of the plate and cell added on top. 
5.2.2.7 Live and dead cell assay 
BV2 and SHSY5Y cells were seeded at a density of 50,000 cells per well on 96-well plates 
coated with polylysine in 100 µL medium. After 24 hours of incubation, the old culture medium 
was replaced with fresh medium containing the peptide samples and cells were further 
incubated for 24 hours at 37°C. Next, live and dead cell ratios were identified using live and 
dead cell assay (Abcam, Australia) according to the manufacturer’s protocol. Briefly, cells 
were trypsinized and centrifuged to obtain a cell suspension. A working solution of live and 
dead dye was mixed with each cell suspension and incubated for 10 minutes at room 
temperature in the dark. Finally, cells were analysed by flow cytometry using a FACS CANTO 
II flow cytometer (BD Biosciences, Australia). Staurosporine at 0.5µM concentration was used 
as the positive control for dead cells [24, 25]. 
5.2.2.8 Cell proliferation assay 
Cell proliferation assay was conducted using a Cell Proliferation Staining Reagent-Green 
Fluorescence kit (Abcam, Australia) according to the manufacturer’s protocol. Briefly, cells 
were seeded at a density of 2×106 cells per well after labelling with the green fluorescence dye 
at day 0. On the same day, 100 µL of cell suspension from each well was used for flow 
cytometry analysis and the rest were incubated at 37°C for 24 hours. At day 1, an aliquot of 
cells was used for flow cytometry analysis and the rest were subculture at 1:1 ratio. Peptide 
solutions were added to the cells at this stage, by replacing the old culture media, and incubated 
for another 24 hours at 37°C. On day 2, peptide treatments were removed and an aliquot of 
cells (1:1 ratio) were used for flow cytometry analysis. Staurosporin at 0.5 µM concentration 
was used as the positive control [25]. Flow cytometry data were analysed by flowJo software. 
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5.3 Results 
5.3.1 Biophysical characterization of neuropeptide molecular species in cell 
media 
A typical amyloid-like peptide self-assembly process comprises three main types of distinct 
molecular species: (i) soluble monomer, (ii) soluble oligomers and (iii) fibrillar aggregates 
[26]. Chapter 3 and 4 described district molecular species obtained in simple aqueous media 
for somatostatin, substance P and LHRH. For instance, somatostatin and LHRH form 
oligomers at low concentrations and nanofibrils at higher concentration, as demonstrated by 
synchrotron small angle x-ray scattering experiments (chapter 4), while substance P forms 
nanotubes (chapter 4) [21]. For cell studies, a peptide concentration gradient was used to screen 
the effect of different molecular species, from soluble species to fibrillary aggregates. All 
neuropeptide concentrations were prepared both in the presence and absence of aggregation 
helper, heparin. According to the work described in chapter 4, the presence of heparin can alter 
the properties of molecular species formed. (chapter 4)[21]   
The molecular species formed by somatostatin, substance P and LHRH were characterized in 
the cell media by optical microscopy (Figure 5.1), electron microscopy (Figure 5.2 and 5.3), 
circular dichroism (CD) (Figure 5.4) and IR spectroscopy (Figure 5.5). 
Substance P and somatostatin 1% w/w solutions prepared in cell culture media DMEM in both 
in the presence and absence of heparin showed precipitates while that of LHRH remained 
isotropic. These solutions containing precipitates were observed by polarized optical 
microscopy (Figure 5.1). 
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Figure 5.1: Photographs and optical micrographs of somatostatin and substance P solutions at 1% w/w. (A) 
1%w/w somatostatin in DMEM. (B) 1%w/w somatostatin with heparin in DMEM. (C) 1% w/w substance P in 
DMEM (D) 1% w/w substance P with heparin in DMEM.  
Optical microscopy images exhibit birefringent micro-aggregates in peptide solutions of 
somatostatin and substance P both with and without heparin. In contrast, pure somatostatin and 
substance P showed liquid crystalline textures in simple aqueous media but similar micro-
aggregates when in the presence of heparin (chapter 4).  
When preparing TEM grids, these aggregates were broken down by centrifuging prior to 
negative staining. Figure 5.2 and 5.3 show TEM images of molecular species formed by 
functional amyloids at a concentration of 1% and 0.1%, respectively.  
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Figure 5.2: Transmission electron micrographs of 1%w/w neuropeptide self-assemblies formed in DMEM both 
in the presence and absence of heparin. (A) 1%w/w somatostatin in DMEM 24 hours old. (B) 1%w/w substance 
P in DMEM 24 hours old (C) 1%w/w LHRH in DMEM 24 hours old (D) 1%w/w somatostatin with heparin in 
DMEM 24 hours old. (E) 1%w/w substance P with heparin in DMEM 24 hours old (F) 1%w/w LHRH with 
heparin in DMEM 24 hours old. 
TEM images show that at 1%w/w of peptide concentration both somatostatin and substance P 
form precipitated nanofibrils in DMEM, with and without heparin. In contrast, LHRH at 1% 
w/w in DMEM did not exhibit precipitates in solution but, however, showed nanofibrils in the 
presence of heparin. LHRH at the same concentration without heparin did not display any 
fibrillar morphology. 
For 0.1% of peptide concentration, nanofibrils were not observed for any of the peptides 
studied both in the presence and absence of heparin. 
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Figure 5.3: Transmission electron micrographs of 0.1%w/w neuropeptide self-assemblies formed in DMEM both 
in the presence and absence of heparin. (A) 0.1%w/w somatostatin in DMEM 24 hours old. (B) 0.1%w/w 
substance P in DMEM 24 hours old (C) 0.1%w/w LHRH in DMEM 24 hours old (D) 0.1%w/w somatostatin with 
heparin in DMEM 24 hours old. (E) 0.1%w/w substance P with heparin in DMEM 24 hours old (F) 0.1%w/w 
LHRH with heparin in DMEM 24 hours old. 
The characterization of neuropeptide self-assemblies formed in the presence and absence of 
heparin at 0.01%w/w of peptide concentration was investigated by CD. Milli Q water was used 
to prepare samples for CD experiments due to supersaturation of CD signal by sodium ions 
present in DMEM. Figure 5.4 displays CD spectra recorded for 0.01%w/w of neuropeptide 
concentration. Both somatostatin and LHRH at 0.01% w/w in water showed a large minimum 
close to 200 nm, while substance P at same concentration displayed a large minimum at 190 
nm, indicating the presence of random coil in all three cases. Hence the three peptides are not 
organised at this concentration. 
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Figure 5.4: CD spectra of neuropeptide assemblies. (A) 0.01%w/w somatostatin (B) 0.01%w/w substance P (C) 
0.01%w/w LHRH (D) 0.01%w/w somatostatin with heparin (E) 0.01%w/w substance P with heparin (F) 
0.01%w/w LHRH. All peptide assemblies are 24 hours old. 
Figure 5.5 shows the secondary derivative spectra of the FTIR spectra of both somatostatin and 
substance P precipitates formed at 1%w/w in DMEM. The amide I region (1600 -1700 cm-1) 
of an infrared spectrum provides information about secondary structures formed by the peptide 
backbone [27]. In the case of pure somatostatin, antiparallel β-sheet (1625 cm-1, 1694 cm-1), 
parallel β-sheet (1643 cm-1), random coil (1658 cm-1) and turn (1682 cm-1) secondary structures 
were identified as shown in Figure 5.5A. However, somatostatin in the presence of heparin 
does not possess parallel β-sheet networks, similarly to our previous results in 150 mM NaCl 
(chapter 4 [21]). Substance P both in the presence and absence of heparin exhibits antiparallel 
β-sheet (1626, 1674 cm-1), parallel β-sheet (1636 cm-1) and random coil (1654 cm-1) secondary 
structures, similarly to our previous results in 150 mM NaCl. 
Chapter 5 
 
142 
 
 
Figure 5.5: FTIR spectra of somatostatin and substance P assemblies formed in the presence and absence of 
heparin in DMEM cell culture media. (A) 1%w/w somatostatin in DMEM. (B) 1%w/w somatostatin with heparin 
in DMEM. (C) substance P in DMEM (D) substance P with heparin in DMEM.  
All these results taken together indicate that at 1% w/w of peptide concentration, both 
somatostatin and substance P self-assemble into nanofibrils in DMEM, either as pure peptides 
or in the presence of heparin. However, in both cases, these nanofibrils are not liquid crystalline 
but precipitates. These aggregates formed in cell culture media (DMEM) is similar to 
precipitates obtained from heparin-induced aggregation in 150 mM NaCl. LHRH at 1% w/w 
in DMEM with heparin forms nanofibrils, while pure LHRH in DMEM at the same 
concentration forms soluble species. All three neuropeptides at 0.1% and 0.01% concentrations 
give rise to soluble species, which can either be oligomers or monomers.  
Table 5.1 summarized the distinct molecular species formed by the studied neuropeptides in 
different media (150 mM NaCl, water and DMEM) in the presence and absence of heparin. 
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Table 5.1: Different molecular species formed by the neuropeptides studied. 
Type of amyloid Peptide Molecular species formed in water/150 mM NaCl 
and DMEM [21, 28] (chapter 3 and 4) 
Functional 
amyloids 
 -heparin +heparin 
 Somatostatin-14 
0.01%w/w 
 
Soluble species 
 
Soluble species 
0.1%w/w Soluble species Soluble species 
1%w/w Water/150mM NaCl- 
Liquid crystalline 
nanofibrils  
DMEM – fibrillary 
precipitates 
Fibrillary precipitates 
 Substance P 
0.01%w/w 
 
Soluble species 
 
Soluble species 
0.1%w/w Soluble species Soluble species 
1%w/w Water/150mM NaCl- 
Liquid crystalline 
nanotubes  
DMEM – 
Precipitated 
nanotubes 
Precipitated nanotubes 
 LHRH 
0.01%w/w 
 
Soluble species 
 
Soluble species 
0.1%w/w Soluble species Soluble species 
1%w/w Soluble species Liquid crystalline nanofibrils 
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5.3.2 Concentration-dependent cytotoxicity of somatostatin and substance P 
 
5.3.2.1 Peptide controls used for cell assays 
In contrast to functional amyloids, disease-associated amyloids form typical amyloid fibrils 
which are not liquid crystalline [29, 30]. Due to the fact that Aβ (25-35) forms typical amyloid 
fibrils and retain neurotoxic properties of Aβ-40, Aβ (25-35) was used as a control in this study 
to compare results obtained for functional amyloids [31, 32]. Aβ (25-35) is a short peptide 
fragment (10 amino acids) which matches well with the size of the neuropeptides (10-14 amino 
acids) examined in this study as well. The amyloidogenic peptides ILQINS, IFQINS, and 
TFQINS are derived from hen egg-white lysozyme, human lysozyme and a mutant form of the 
peptide responsible for hereditary systemic amyloidosis, respectively [33]. These hexapeptides 
self-assemble into amyloid fibrils, crystals or both depending on the sequence [33]. These 
peptides were also used as control toxic peptides in the cell assays. Table 5.2 summarized the 
different concentrations of each peptide used in cell-based assays. 
Table 5.2: Different peptide concentrations used for cell biology assays and biophysical 
characterization 
 
5.3.2.2 Results of live and dead stain assay 
Live and dead cell assays were carried out to investigate the toxicity of the molecular species 
formed by the studied neuropeptides towards two types of brain cells: microglia (BV2 cells) 
and neuroblastoma cells (SH-SY5Y) using flow cytometry. The peptide samples were directly 
prepared in the cell culture medium (DMEM). Except samples containing pure neuropeptides 
which were left to self-assemble for 24 hours prior to the experiments, other peptide samples 
(heparin-mediated neuropeptide aggregates and toxic peptide amyloids) were prepared 
Peptide Concentrations  
Neuropeptides  
(somatostatin (SST), substance P (SP) 
and LHRH) 
%w/w SP (mM) SST 
(mM) 
LHRH 
(mM) 
1.0 7.50 mM  5.80 8.40 
0.1 0.75 0.58 0.84 
0.01 0.07 0.05 0.08 
Amyloidogenic peptides  
(ILQINS (IL), IFQINS (IF)and 
TFQINS (TF)) 
%w/v IL IF TF 
0.1 0.02 mM 0.01 mM 0.01 mM 
0.05 0.01mM 5 µM 5 µM 
0.01 2 µM 1 µM 1 µM 
Aβ(25-35) 20 µM (0.002%), 200 µM (0.02%) and 2mM (0.2%) 
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immediately before adding to cell lines given their rapid aggregation kinetics (chapter 4). 
Staurosporine (0.5 µM) was used as the positive control [23, 34]. All peptide samples were 
incubated with cell lines at 37°C for 24 hours before flow cytometry analysis. Live and dead 
cell assays rely on the principle that live cells exhibit intact plasma membranes and intracellular 
esterase activity, which allows green dye staining, whereas dead cells exhibit non-intact plasma 
membranes and absence of esterase activity, which allows red dye staining.  
Figure 5.6 and figure 5.7 display the percentage of live cells for BV2 cells (microglia) and 
SHSY5Y cells (neuroblastoma) treated with neuropeptides, respectively.  
Chapter 5 
 
146 
 
 
Figure 5.6: Percentage of live cells of BV2 cell line (microglia) treated with (A) neuropeptides, (B) amyloidogenic 
peptides compared to (C) controls. 
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Figure 5.7: Percentage of live cells of SH-SY5Y cell line (neuroblastoma) treated with (A) neuropeptides, (B) 
amyloidogenic peptides compared to (C) controls. 
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Both cell lines without treatment (DMEM only) showed over 98% of live cells. Cells treated 
with staurosporin (toxic control) exhibited 30% and 26% of live cells for BV2 (microglia) and 
SHSY5Y cells (neuroblastoma), confirming cytotoxicity. Aβ(25-35) displayed over 90% of 
live cells for BV2 cells, while 50% of cytotoxicity for SH-SY5Y cells. Cytotoxic behaviour 
showed by Aβ(25-35) towards SH-SY5Y cells well aligned with previously reported data [6]. 
Neuroprotective activity of Aβ(25-35) towards microglial cells has already been reported [35]. 
All neuropeptides studied at 0.1%w/w of concentration showed approximately 90% of cell 
viability towards both cell lines. LHRH at the concentration of 1%w/w both in the presence 
and absence of heparin also displayed more than 90% of viable cells, indicating their non-toxic 
behaviour towards both cell lines. However, at 1%w/w both somatostatin and substance P with 
and without heparin exhibit approximately 20% of cell viability. Amyloidogenic peptides 
displayed less viable cells in the case of BV2 cell line compared to that of SH-SY5Y cells, 
indicating their mild cytotoxicity towards BV2 cells. When compared results obtained for 
somatostatin and substance P at the concentration of 1%w/w with that of staurosporine indicate 
that somatostatin and substance assemblies formed at 1% are cytotoxic. Interestingly, in most 
cases, the percentage of cytotoxicity showed by both somatostatin and substance P at 1%w/w 
concentration is higher than that of staurosporine. Indeed, cytotoxicity exhibit by somatostatin 
and substance P is greater than that of Aβ(25-35) amyloid fibrils with respect to SH-SY5Y 
cells. Amyloidogenic peptides showed non-cytotoxic behaviour compared to somatostatin and 
substance P at 1%w/w of concentration.  
Results obtained for LHRH and 0.1%w/w somatostatin and substance P indicate that soluble 
species and liquid crystalline nanofibrils formed by neuropeptides are non-toxic, whereas 
fibrillary precipitates formed by somatostatin and substance P at high concentration can cause 
cytotoxicity to both BV2 and SH-SY5Y cell lines.  
5.3.2.3 Results of MTS assays (protocol 1 – peptide samples on top of cells) 
To further study the interactions between neuropeptide species and model brain cells, MTS 
assay was carried out. A similar protocol was used as the live and dead stain assay to prepare 
the neuropeptide solutions. Heparin assisted neuropeptides, amyloidogenic peptides and 
Aβ(25-35) concentrations were prepared immediately prior to the assay. All peptide species 
were incubated with cell lines at 37°C for 24 hours before measuring MTS reduction. Two 
protocols were used, either – protocol 1 (Figure 5.8) or protocol 2 (Figure 5.11). Figures 5.9 
and 5.11 show the percentages of cell viability for both SHSY5Y (neuroblastoma) and BV2 
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(microglia) cell lines treated with different peptide species following protocol 1. These values 
were calculated with respect to the buffer (DMEM). In protocol 1 the cells have adhered to the 
bottom of the 96-well plate before the addition of peptide solutions.  
 
Figure 5.8: Schematic presentation of MTS assay protocol 1. 
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Figure 5.9: Percentage of cell viability of BV2 (microglia) and SH-SY5Y (neuroblastoma) cell lines in the 
presence of peptide species (0.01%, 0.1% and 1%) examined by MTS assay. Percentage cell viability of BV2 cell 
line in the presence of(a) somatostatin (c) substance P and (e) LHRH self-assemblies with respect to buffer. 
Percentage cell viability of SH-SY5Y cell line in the presence of (b) somatostatin (d) substance P and (f) LHRH 
self-assemblies with respect to buffer.  
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Figure 5.10: Percentage cell viability of BV2 and SH-SY5Y cell lines in the presence of amyloidogenic peptides 
(ILQINS, TFQINS, and IFQINS) and Aβ(25-35) assemblies examined by MTS assay. Staurosporine was used as 
the positive control at concentration of 0.5 µM. 
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Both 0.01%w/w and 0.1%w/w of neuropeptide concentrations showed percentage cell viability 
closer to 100% for both cell lines. LHRH at all three concentrations studied showed percentage 
cell viability between 90-100%, indicating non-cytotoxic behaviour towards both cell lines. 
Somatostatin and substance P exhibited very high cell viability (>>100%) at the concentration 
of 1%w/w for both cell lines compared to the toxic control staurosporine.  
Amyloidogenic peptides exhibited moderate cytotoxicity towards microglial cells, whereas 
Aβ(25-35) exhibited approximately 50% cytotoxicity towards neuroblastoma cells. Notably, 
Aβ(25-35) showed more than 80% percentage cell viability towards microglia which is also in 
accordance with previously published reports [36]. Among three concentrations studied for 
amyloidogenic peptides (0.1%, 0.05%, and 0.01%), 0.05% showed the highest cytotoxicity 
towards microglia for all three peptides which are 47%, 45% and 30% for IFQINS, ILQINS, 
and TFQINS, respectively. In contrast, amyloidogenic peptides exhibited more than 80% 
percentage cell viability towards neuroblastoma cells. The results obtained for Aβ(25-35) and 
amyloidogenic peptides from MTS assay are consistent with the results obtained from live and 
dead stain assay. 
Maji and co-workers reported that self-assemblies formed by substance P in the presence of 
heparin at 0.2%w/v concentration are non-toxic to SHSY5Y cells, which is in accordance with 
our results obtained for SHSY5Y cells treated with 0.1%w/w substance P. On the other hand, 
a study conducted in examining cytotoxicity of oligomeric species formed by N-terminal 
domain of the E. coli HypF protein (HypF-N) showed that their oligomers are cytotoxic to 
SHSY5Y cells, while native protein exhibited non-toxic behaviour [5]. Our results are partially 
consistent with results obtained for HypF-N protein and oligomers. 
The MTS assay results obtained for somatostatin and substance P at 1%w/w of concentration 
contrast with the results obtained by live and dead stain assay. The high cell viability 
percentages are likely to arise from artefacts from dead cells, as suggested by the previous MTS 
assays [37, 38]. 
5.3.2.4 MTS assays (protocol 2 – cells on top of peptide samples) 
To further examine the cytotoxic behaviour of somatostatin and substance P at high 
concentrations, we again used MTS assay however with a different protocol. This protocol has 
been widely used to test the influence of amyloid hydrogel on cell growth previously [39-41]. 
In the first attempt (protocol 1, figure 5.8), cells were placed on the bottom of the plate and 
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peptide solution was added on top. In this case (protocol 2, figure 5.11), the peptide solution 
was placed at the bottom of the plate and cells were added on top. 
 
Figure 5.11: Schematic presentation of MTS assay protocol 2. 
 
Figure 5.12 and 5.13 show percentage cell viability of BV2 and SHSY5Y cells in the presence 
of neuropeptides, amyloidogenic peptides and Aβ(25-35) examined by MTS assay protocol 2.  
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Figure 5.12: Percentage cell viability of BV2 and SH-SY5Y cell lines in the presence of neuropeptides assemblies 
examined by MTS assay protocol 2. Percentage cell viability of BV2 cell line in the presence of (A) somatostatin, 
(C) substance P, (E) LHRH. Percentage cell viability of SH-SY5Y cell line in the presence of controls (B) 
somatostatin, (D) substance P, (F) LHRH. 
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Figure 5.13: Percentage cell viability of BV2 and SH-SY5Y cell lines in the presence of amyloidogenic peptides 
and Aβ(25-35) assemblies examined by MTS assay protocol 2. Percentage cell viability of BV2 cell line in the 
presence of (A) ILQINS, (C) IFQINS, (E) TFQINS, and (G) Aβ(25-35). Percentage cell viability of SH-SY5Y 
cell line in the presence of (B) ILQINS), (D) IFQINS, (F) TFQINS, and (H) Aβ(25-35). 
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MTS assay protocol 2 also exhibited similar results as MTS assay protocol 1. Low 
concentrations (0.01% and 0.1%w/w) of all neuropeptides and 1%w/w of LHRH display 
percentage cell viability of more than 90%. Both somatostatin and substance P showed very 
high (>>100%) percentages of cell viability with and without heparin for both cell lines at 
1%w/w concentration. Aβ(25-35) showed 46% cytotoxicity towards neuroblastoma cells, 
whereas high cell viability cell towards microglia. Amyloidogenic peptides showed 
approximately 40% cytotoxicity towards microglia, while a higher percentage cell viability 
towards neuroblastoma cells.  
The MTS assay results obtained for somatostatin and substance P at 1%w/w concentration 
suggest either they have an influence on cell growth or it is an overestimation of cell viability 
due to the presence of aggregates in peptide solutions at high concentrations [37, 38]. To 
address this question, cell proliferation assays were performed, which can estimate the number 
of cell cycles during the treatment period. 
 
5.3.2.5 Results of cell proliferation assay 
Cytopainter cell proliferation assay is based on the use of green fluorescence dye which 
incorporates DNA and passed to daughter cells when cells proliferate. The dye hence gets 
diluted with each cell division leading to decrease fluorescence at each cell cycle. Both BV2 
and SHSY5Y cells were labelled with green fluorescence dye on day0 and then a portion of 
the culture was subjected to flow cytometry analysis. After 24 hours, cells were passed through 
1:1 serial dilution for 2 days. Fluorescence intensity was measured by flow cytometer at each 
day. The cells were treated with peptides solutions on Day1 and incubated for 24 hours before 
performing flow cytometry.  
Figure 5.13 and 5.14 show flow cytometry analysis of dye diluted with each cell division for 
BV2 cells and SHSY5Y cells, respectively.  
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Figure 5.12: Flow cytometry analysis of proliferation assay for BV2 cell line. (A) Histograms of the daily green 
fluorescence dye intensity of BV2 cells treated with (A) DMEM. (B) 1%w/w somatostatin (C) 1%w/w substance 
P (D) 1%w/w somatostatin with heparin (E) 1%w/w substance P with heparin (F) 1%w/w LHRH (G) 1%w/w 
LHRH with heparin and (H) 0.5µm staurosporine (control). Note: D0=day 0, D1=day 1, D2=day 2. 
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Figure 5.13: Flow cytometry analysis of proliferation assay for SHSY5Y cell line. (A) Histograms of the daily 
green fluorescence dye intensity of SHSY5Y cells treated with (A) DMEM. (B) 1%w/w somatostatin (C) 1%w/w 
substance P (D) 1%w/w somatostatin with heparin (E) 1%w/w substance P with heparin (F) 1%w/w LHRH (G) 
1%w/w LHRH with heparin and (H) 0.5µm staurosporine (control). Note: D0=day 0, D1=day 1, D2=day 2. 
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Cells treated only with DMEM demonstrated three successive generations of both BV2 and 
SHSY5Y cells during the study period. Over time, for each cell cycle fluorescence intensity 
decreases demonstrating the proliferation of cells. Staurosporine (control) treated cells 
exhibited a population of dead cells at day 2 and three successive generations of BV2 cells by 
day 2. In sharp contrast to MTS assay results, we observed a population of dead cells for both 
somatostatin and substance P treated cells at day 2 for 1%w/w of peptide concentration. LHRH 
treated cells showed three successive generations by day 2 which is similar to DMEM (buffer) 
treated cells which aligned with MTS assay results. Results obtained for somatostatin and 
substance P at 1%w/w of peptide concentration are thus consistent with the results obtained for 
staurosporine indicating cytotoxic behaviour of these two peptides at 1%w/w concentration. 
These results are well aligned with results obtained for live and dead cell assay. 
Results obtained by cell biology assays taken together with TEM and IR data suggest that 
cytotoxicity of somatostatin and substance P is due to the presence of precipitates in solution. 
This assumption is supported by the fact that 1%w/w of LHRH showed no cytotoxicity in the 
presence of heparin which has a few fibrils in TEM images, however, did not form precipitates 
in the solution. Based on live and dead cell assay and proliferation assay results, the 
cytotoxicity of neuropeptides depends on the peptide concentration as well as molecular 
species present in the solution since depending on the peptide concentration different molecular 
spices could be present in the solution (Table 5.1). 
 
5.3.3 Activation of microglia by neuropeptides 
It has been widely demonstrated that microglia get activated in the presence of Aβ plaques 
composed of Aβ-42 or Aβ25-35 [35]. Since functional amyloids also possess typical amyloid 
morphology, we were interested to discover whether microglia get activated in the presence of 
assemblies formed by the neuropeptides as well. BV2 cells were hence imaged in the presence 
of peptide assemblies formed at the concentration of 0.1%w/w to observe morphological 
changes with respect to the buffer and Aβ(25-35) (0.002%w/v/20 µM). Figure 5.14 and 5.15 
display images of microglial cells obtained by fluorescence microscopy in the presence of 
peptide assemblies formed at 0.1%w/w and 0.01%w/w of peptide concentration. BV2 cells 
were treated with peptide assemblies and incubated for 24 hours before imaging. On activation, 
microglia change their cellular morphology by displaying processes out [36].  
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Figure 5.14: The effect of peptide nanostructures on BV2 cell morphology. (A) BV2 cells treated with 0.1%w/w 
somatostatin (B) BV2 cells treated with 0.1%w/w somatostatin with heparin (C) BV2 cells treated with 0.1%w/w 
substance P (D) BV2 cells treated with 0.1%w/w substance P with heparin (E) BV2 cells treated with 0.1%w/w 
LHRH (F) BV2 cells treated with 0.1%w/w LHRH heparin (G) BV2 cells treated with 0.002%w/w (20 µM) 
Aβ(25-35) (H) BV2 cells treated with DMEM (buffer). 
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Figure 5.15: The effect of neuropeptide nanostructures formed at 0.01%w/w of peptide concentration on BV2 
cell morphology. BV2 cells treated with (A) 0.01%w/w somatostatin (B) 0.01%w/w somatostatin with heparin 
(C) 0.01%w/w substance P (D) 0.01%w/w substance P with heparin (E) 0.01%w/w LHRH (F) 0.01%w/w LHRH 
heparin (G) 0.002%w/v (20 µM) Aβ(25-35) (H) DMEM (buffer). 
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BV2 cells incubated with DMEM (buffer) exhibit an oval shape, although occasional ramified 
cells were also identified. On the other hand, BV2 cells treated with 20 µM Aβ(25-35) display 
cells with prolonged processes indicating microglia activation. Among activated BV2 cells, 
most of the cells showed bipolar-like morphology. However, very few cells exhibited 
multipolar morphology. Interestingly, cells treated with neuropeptides at a concentration of 
0.1%w/w also showed bipolar morphology to different extents. This phenomenon is observed 
in BV2 cells treated with 0.1%w/w pure somatostatin to a greater extent compared to the other 
neuropeptides at a similar concentration. Pure somatostatin treated BV2 cells display bipolar 
morphology with prolonging processes along with a few multipolar morphologies. However, 
BV2 cells treated with neuropeptides at the concentration of 0.01%w/w only display oval shape 
cells indicating no activation of microglial cells. The differences observed with respect to the 
neuropeptide concentration might be due to the presence of distinct molecular species in the 
peptide solution. At 0.01%w/w of peptide concentration, less oligomerized species can be 
expected compared to the 0.1%w/w peptide concentration.  
These observations reveal that microglia get activated even in the presence of functional 
amyloids with concentration increase. It suggests that larger than smaller oligomers activate 
microglia. 
5.4 Discussion 
In the past decade, a wide range of peptide sequences including biologically important peptides 
has been shown to self-assemble into amyloid-like structures in vitro, which provided model 
systems to study protein misfolding diseases and templates for biomaterial fabrication [6, 7, 
28, 42]. This chapter investigated the effect of different molecular species formed by functional 
amyloids both in the presence and absence of an aggregation helper, heparin, on different types 
of brain cells. The human brain is composed of mainly two types of cells: neurons and glial 
cells. This study used neuroblastoma cells (SH-SY5Y) and microglia (BV2cells) as models for 
neurons and glial cells, respectively [15, 43]. Microglia were chosen as a model for glial cells 
over the other two types (astrocytes and oligodendrocytes) due to their association with the 
pathophysiology of Alzheimer’s disease and Parkinson’s disease [44]. To compare the results 
obtained for functional amyloids and amyloidogenic peptides derived from diseases associated 
proteins/peptides, the toxic Aβ(25-35) fragment was used. 
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The findings first support the assumption that functional amyloids are non-cytotoxic, however 
depending on the molecular species present in the solution. Indeed, the present study 
unexpectedly showed concentration-dependent cytotoxicity of somatostatin and substance P 
neuropeptides, which were previously shown to possess a higher self-assembling propensity 
than LHRH (chapter 3 and 4) [6, 21, 28]. Finally, these results indicate that the type of 
molecular species formed by the neuropeptides in their assembling pathway plays a vital role 
in determining the cytotoxicity of neuropeptide-based functional amyloids.  
Cells treated with both somatostatin and substance P at 1%w/w of concentration showed a very 
high percentage of cell viability (more than 100%) compared to that of buffer DMEM, in the 
MTS cell viability assay. According to previously published reports, particles/aggregates could 
interfere with background absorbance in MTS assays, leading to an overestimation of cell 
viability [37, 38]. Notably, our findings highlight the danger of using MTS related assays in 
testing cytotoxicity in amyloid-based systems without any complementary assays. In this 
context, flow cytometry provides an extra set of advantages over MTS assays, including the 
ability to specifically sort cells as a function of their size, which excludes the contribution from 
micro-aggregates to the fluorescence measurement [45]. As we previously described in chapter 
3 and 4, nanostructures formed by pure neuropeptides in simple aqueous media are liquid 
crystalline, while in the presence of heparin, the neuropeptides can self-assemble into micro-
aggregates. However, in the cell culture media DMEM, both pure somatostatin and substance 
P at 1%w/w self-assemble into micro-aggregates when incubated at 37 °C overnight. This 
observation suggests that ingredients in the complete cell culture media (DMEM, fetal bovine 
serum and antibiotics), possibly sulphate ions or macromolecules such as serum proteins, might 
have an influence on peptide aggregation leading to the formation of precipitates, which cause 
cytotoxicity.  
Chiti and co-workers have reported that surface hydrophobicity and size of the oligomers play 
an important role in determining cytotoxicity [5]. High surface hydrophobicity and a low size 
could contribute to oligomer toxicity. The fibrillary precipitates formed by neuropeptides at 
1%w/w in DMEM are insoluble, hence hydrophobic. This might be the reason behind the 
observed cytotoxicity of somatostatin and substance P assemblies in the present study.  
Recent findings revealed that oligomers formed in the early stages of amyloid formation 
processes are the potential cytotoxic species found in neurodegenerative diseases [4, 5]. In this 
context, this thesis examined the cytotoxicity of soluble species formed during the self-
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assembly pathway of functional amyloids. In contrast to what has been reported for diseases 
associated amyloids, our results have shown that soluble species formed during self-assembling 
of functional amyloids are non-toxic to neurons and glial cells. Another study has previously 
shown that HypF protein produced by E coli, which also forms functional amyloids produce 
toxic oligomers [5, 46]. However, in this case, native protein showed non-cytotoxic properties 
[5].  
To summarize (Figure 5.16), all results in the account of functional amyloid cellular toxicity 
reveal that different molecular species formed by functional amyloids are nontoxic, except 
when precipitates are present. Since all three neuropeptides have shown non-cytotoxicity 
towards neuroblastoma cells and microglia at low concentrations, this nontoxic property of 
functional amyloids is neither cell-specific nor sequence-specific.  
 
 
Figure 5.16: Schematic representation of molecular species formed by neuropeptides and their cytotoxic 
behaviour. 
The amyloidogenic peptides ILQINS, TFQINS, and IFQINS have exhibited approximately 
40% cytotoxicity towards microglia, compared to no cytotoxicity towards neuroblastoma cells 
in MTS assays, suggesting that cytotoxicity of diseases associated amyloids is cell-specific. 
Live and dead cell assay results also support moderate cytotoxicity of amyloidogenic peptides 
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towards microglia. The amyloidogenic peptides ILQINS, TFQINS, and IFQINS self-assemble 
into distinct nanostructures [47]. Among these three hexapeptides, the highest cytotoxicity was 
shown by IFQINS followed by ILQINS and TFQINS. While both IFQINS and ILQINS have 
been reported to self-assemble into typical amyloid fibrils, TFQINS self-assembles into 
crystals [33]. The cell assays here performed suggest that cytotoxicity is triggered by the 
amyloid fibril morphology rather than the formation of crystals. Results obtained for Aβ(25-
35) also fuel the finding that cytotoxicity of disease-associated peptides is cell-specific by 
displaying cytotoxicity specifically towards neuroblastoma cells. Our results are consistent 
with previous reports published on Aβ(25-35) cytotoxicity [6]. 
Microglia play a vital role in neurodegenerative diseases, for instance Alzheimer’s disease and 
Parkinson’s disease. Microglia are known as brain immune cells, which get activated in such 
diseases and provide neuroprotection to a certain extent [44]. Upon activation, microglia 
display their prolong processes and release specific biomarkers, such as the macrophage 
antigen complex-1 (MAC-1) and cytotoxic molecules such as reactive oxygen species (ROS), 
NO and a variety of proinflammatory cytokines [35, 44, 48]. Activation of microglia in the 
presence of Aβ plaques formed by either Aβ42 or Aβ(25-35) has already been reported. Here, 
it is showed that microglial cell activation is not only triggered by Aβ42/Aβ(25-35) but also by  
oligomers formed by neuropeptides. Since both functional and diseases associated amyloids 
possess similar biophysical characteristics, for instance, secondary structure i.e β-sheets, it is 
not totally surprising that functional amyloids have the ability to trigger microglial activation.  
5.5 Conclusion 
The present study demonstrates the non-cytotoxic properties of soluble species and liquid 
crystalline nanofibrils formed by neuropeptide functional amyloids. However, cytotoxicity 
displayed by somatostatin and substance P assemblies formed in complete cell culture media 
is concentration and structure-dependent. These data together with previous reports suggest 
that higher surface hydrophobicity of fibrillary precipitates formed at higher neuropeptide 
concentrations contributes to the cytotoxicity. Due to the presence of similar morphologies as 
disease-associated amyloids, functional amyloids have an ability to activate microglia. 
Amyloidogenic peptides used in this study fuel the assumption that cytotoxicity caused by 
diseases associated amyloids are cell-specific. Importantly, this work highlights the danger of 
using single-cell viability assay, especially MTS related assays, without other complementary 
methods to examine cytotoxic properties of amyloids-based systems. 
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Chapter 6 
 
Functional amyloids as templates and catalysts  
for inorganic material synthesis 
 
6.1 Introduction 
Nature provides numerous examples of organic-inorganic hybrid materials, which 
hierarchically self-assemble from nanoscale building blocks [1-3]. Peptides and proteins are 
essential components in the majority of natural composite biomaterials, including mother of 
pearl, bones, and cartilage [4]. Peptides and proteins have the ability to form nanostructures 
via different self-assembling and folding pathways, and as such, are important building blocks 
for bio-materials and composite materials fabrication [5, 6]. In the past decade, considerable 
efforts have been applied to the development of nanomaterials using amyloid-based systems. 
Peptide/protein amyloid fibrils possess unique properties which make them versatile building 
blocks for the fabrication of nanomaterials, including their high mechanical strength similar to 
silk and steel [7], their capability to produce highly ordered structures at both nanoscale and 
microscale [8], their tunable physicochemical properties of the resulting nanostructures by 
sequence mutation [9] and their ability to interact with various chemicals via their amino-acid 
side chains [10, 11]. Amyloid-based systems are widely used in designing bio-inspired 
nanomaterials with a diverse set of applications, including drug delivery [9], stem cell 
differentiation  [12, 13], water purification [5] [14], sensors [15] and antibacterial materials 
[16]. In this context, functional amyloids may provide an extra set of advantages over disease-
associated amyloids, for instance, non-toxicity and reversibility. 
Functional amyloids can be formed under suitable conditions in vitro by converting monomeric 
peptide/protein into rod-like liquid crystalline structures with nematic properties such as 
nanofibrils formed by pure somatostatin [17], β endorphin [18] and GnRH analogs [9]. These 
liquid crystalline systems could be used as templates for the fabrication of functional materials 
[9, 19]. Some of the amino acid side-chains have high affinity to interact with inorganic 
substances: for instance, the interactions of histidine with Zn2+ [18] and cysteine with gold 
surfaces [11], or the reducing capacity of tryptophan [20] and acidic amino acids for noble 
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metal ions [11, 21, 22], which are important in inorganic nanoparticle synthesis and 
stabilization of nanoparticle dispersions [23, 24]. Specific interactions between inorganic 
substances and amyloid fibrils have been used to produce functional materials, including silica 
nanotubes [25] organic light-emitting diodes [26], biosensors [27], water purification systems 
[5] and gold aerogels [28]. Inspired by these biomaterials, this chapter explores the potential 
of functional amyloids formed by somatostatin, substance P and LHRH for the synthesis of 
bio-inorganic materials. The self-assembly of these peptide hormones into nanostructures has 
been fully characterized in the previous chapters of this thesis. 
6.2 Materials and methods 
6.2.1 Materials 
In addition to the peptides (sources detailed in chapter 2 section 2.1.2), tetraethyl Orthosilicate 
(TEOS), calcium carbonate (ACS reagent, assay≥99.0%), gold (III) chloride trihydrate 
(assay≥99.9% trace metal basis) and Tris-buffered saline tablets were purchased from Sigma-
Aldrich (Australia). Silver nitrate (assay≥99.5%) was obtained from Chem Supply (Australia).  
6.2.2 Methods 
6.2.2.2 Synthesis of silica nanotubes 
Silica nanotubes were prepared using a previously published method for a similar system [25]. 
A substance P gel (2%w/w and 10%w/w) was prepared in water and stored at 4°C for a few 
days allowing substance P to self-assemble into nanotubes. TEOS solution (30 % w/w) was 
prepared in water 24 hours prior to use. Silica-substance P hybrid nanotube formation was 
carried out in 1.5 mL Eppendorf tubes and quartz glass capillaries with 1.5 mm outer diameter. 
At first, an aliquot of substance P gel was added to the Eppendorf tube/capillary and then the 
same volume of TEOS solution was added on top. The reaction was carried out at room 
temperature for 48 to 72 hours. Substance P-silica hybrid structures were observed as white 
fibres appearing after 48 hours of reaction time at the interface between the substance P gel 
and TEOS solution. These white fibres were removed using a pipette and extensively washed 
with water to dissociate and eliminate substance P. After several washing cycles, the resulting 
silica fibres were observed by transmission electron microscopy (TEM) and characterized by 
small-angle x-ray scattering (SAXS), using the protocols described in Chapter 2, section 2.2.5 
and 2.2.4. 
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6.2.2.3 Synthesis and characterization of calcium carbonate crystals in the 
presence of substance P nanotubes  
A calcium carbonate solution was prepared using a previously published method [29]. Briefly, 
a supersaturated calcium carbonate solution was prepared by dissolving calcium carbonate in 
water. The resulting solution was stirred continuously using a magnetic stirrer while dry ice 
was added to continuously bubbled carbon dioxide through the solution for 90 minutes. 
Hereafter, the solution was rapidly filtered using filter paper (Whatman filter paper, grade 1) 
and a glass funnel to remove excess calcium carbonate. The resulting solution was again stirred 
continuously while bubbling carbon dioxide through the solution for another 60 minutes. Then, 
the solution was filtered using a 0.2 µm filter adapted to a 10 mL syringe. The resulting solution 
is known as the Kitano solution or calcium carbonate growth solution. An aliquot of calcium 
carbonate growth solution (20 µL) was placed on a glass slide and left to air dry, allowing the 
precipitation and/or crystallization of pure calcium carbonate as a control. The following 
chemical reaction describes the equilibrium between calcium carbonate solid-state and calcium 
carbonate ionic state:  
𝐶𝐶𝐶𝐶𝐶𝐶𝑂𝑂3 (𝑠𝑠) + 𝐶𝐶𝑂𝑂2 (𝑔𝑔) + 𝐻𝐻2𝑂𝑂(𝑙𝑙) ↔ 𝐶𝐶𝐶𝐶2+ (𝐶𝐶𝑎𝑎) + 2 𝐻𝐻𝐶𝐶𝑂𝑂3− (𝐶𝐶𝑎𝑎) 
After adding calcium carbonate growth solution to the glass slide, an equal volume of substance 
P nanotube solution was added on top and kept open to the air to obtain a dried thin layer. Layer 
by layer deposition of calcium carbonate growth solution and substance P nanofibrils was 
imaged by optical microscopy, using the protocol described in Chapter 2 section 2.2.3. 
6.2.2.4 Synthesis and characterization of gold particle dispersions in the presence 
of peptide nanostructures 
Two different protocols were used to obtain gold particle dispersions in the presence of 
peptides. Protocol 1 uses peptide nanostructures (anisotropic samples), while protocol 2 uses 
isotropic peptide solutions (monomers or small peptide oligomers) as a control. 
Protocol 1 using peptide nanofibrils - A previously published method was used to prepare gold 
particle dispersions, with modifications [30]. Both substance P and somatostatin samples were 
prepared in water and stored at 4°C for a few days to form nanostructures. Different peptide 
concentrations were used ranging from 2% w/w to 20% w/w. A gold chloride solution was 
prepared by dissolving gold (III) chloride trihydrate in Tris buffer at pH 7.6. A 2:5 molar ratio 
of peptide to gold salt was determined to be the most efficient (see results section). Firstly, an 
aliquot of peptide nanostructure solution/gel was added to a 1.5 mL Eppendorf tube and then 
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the same volume of gold salt solution was added on top. The reaction was left overnight at 
room temperature and protected from light by covering the sample with aluminium foil. The 
resulting gold particle dispersions were characterized using optical microscopy, electron 
microscopy, UV-Vis spectroscopy and scanning electron microscopy following protocols 
described in Chapter 2 section 2.2.3, 2.2.5, chapter 6 section 6.2.2.7 and 6.2.2.8, respectively. 
Protocol 2 using isotropic peptide samples – A gold chloride solution was prepared by 
dissolving gold (III) chloride trihydrate in Tris buffer at pH 7.6 as described above. A weighed 
fraction of peptide acetate powder was dissolved in the gold salt solution to reach a peptide: 
gold ratio of 2:5. The reaction was left overnight at room temperature and protected from light 
as in the above protocol. The resulting gold particle dispersions were characterized by optical 
microscopy and UV-Vis spectroscopy, using protocols described in Chapter 2, section 2.2.3 
and chapter 6 section 6.2.2.7, respectively. 
6.2.2.5 Synthesis and characterization of silver particle dispersions in the 
presence of peptide nanostructures 
Silver particles were synthesized according to a previously reported method, with 
modifications [6]. Peptide nanofibril solutions/gels (2%w/w – 10%w/w) were prepared in 
water and stored at 4 °C for a few days to form nanostructures. A silver nitrate solution was 
prepared by dissolving silver nitrate powder in water. Different molar ratios of the peptide to 
silver salt were attempted (1:1, 1:10 and 1:25). However, 1:25 was determined as the most 
effective ratio based on reaction time (see results section). Firstly, an aliquot of peptide 
nanostructure solution/gel was placed at the bottom of an Eppendorf tube and an equal volume 
of silver salt solution was added on top. The reaction mixture was left overnight at room 
temperature. As synthesized silver particle dispersions were characterized by optical 
microscopy, electron microscopy, and small-angle x-ray scattering, following protocols 
described in Chapter 2 section 2.2.3, 2.2.5 and 2.2.4, respectively. 
6.2.2.6 Scanning electron microscopy (SEM) 
SEM was performed on a FEI Quanta 200 ESEM microscope under low vacuum without 
sputter coating the samples. An aliquot of the sample was mounted on a stub of metal with 
adhesive and left to dry for a few minutes before observation. Then the metal stub with the 
sample was placed on the sample holder inside the sample chamber. The sample was imaged 
at 30 kV accelerating voltage and working distance of 7-8 mm.  
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6.2.2.7 UV-Vis spectroscopy 
UV-Vis spectroscopy was performed on 10x diluted samples for gold nanoparticle dispersions 
using ClarioStar fluorimeter equipped with a plate reader. Spectra were recorded in the range 
400–900 nm and plotted using Prism graph pad as wavelength (nm) against absorbance (AU). 
6.3 Results 
6.3.1 Self-assembled β-sheet based peptide nanotubes as templates to synthesize 
silica nanotubes 
As described in chapter 3, neuropeptide substance P self-assembles into hollow nanotubes. 
Peptide nanotubes can be used as templates to generate mineralized nanotubes, including silica 
nanotubes as previously reported for the somatostatin derivative Lanreotide [25, 31]. A similar 
protocol to the Lanreotide nanotube mineralization was used to attempt mineralizing the 
substance P nanotubes by silica, as described in the material and methods section of this chapter 
(section 6.2.2.2). Briefly, substance P hydrogels in the concentration range 2-10%w/w in water 
were placed in contact with a 30% w/w tetraethylorthosilicate (TEOS) solution in water.  
Such samples were observed to evolve over 48 hours (Figure 6.1). The reaction kinetics and 
structures formed in each phase of the samples were monitored by small-angle x-ray scattering 
(Figure 6.2). The structures formed at the interface between the initial peptide hydrogel and the 
TEOS solution were pipetted, washed, negatively stained by uranyl acetate and observed by 
transmission electron microscopy (Figure 6.3).   
Figure 6.1 shows representative time-dependent changes that occurred in the bottom phase 
(peptide hydrogel), interface (contact peptide hydrogel/TEOS solution) and the upper phase 
(TEOS solution) of a capillary initially containing 10% w/w substance P hydrogel and TEOS 
solution. 
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Figure 6.1: Pictures of capillary during the reaction between substance P nanotubes formed at 10%w/w of the 
peptide concentration and TEOS solution at different time intervals (A-30 minutes, B-6 hours, C-24 hours and D-
48 hours). 
Immediately after adding the TEOS solution to the substance P hydrogels, the bottom phase – 
the peptide hydrogel containing nanotubes - showed turbidity, as expected for an anisotropic 
solution, while the upper phase – the TEOS solution - appeared clear, as expected for an 
isotropic solution (Figure 6.1A). Over a few hours to a few days, part of the bottom phase 
turned into a clear solution while the hydrogel/TEOS interface showed turbidity and 
precipitates (Figure 6.1 B, C, D). All substance P concentrations studied (2%, 5% and 10%w/w) 
exhibited a similar behaviour after the addition of TEOS solution. 
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Figure 6.2: SAXS diffraction patterns obtained during the mineralization process of substance P nanotubes 
formed at 10%w/w of the peptide concentration at different time intervals along the capillary. 
From the beginning of the reaction, the bottom phase is consisting of highly ordered substance 
P nanotubes as evidenced by correlation peaks exhibited by the SAXS pattern obtained for the 
bottom phase. Presence of correlation peaks indicates that substance P nanotubes are very well 
aligned in water. Over time, the SAXS pattern at the interface changes from low q diffusive 
patterns assigned to peptide soluble species (Chapter 3) - to Bessel-like oscillations, assigned 
to nanotubes (Chapter 3). These SAXS results support that the substance P nanotubes are first 
dissociated into soluble species before re-assembling into nanotubes while binding silica. Such 
a process was previously described for Lanreotide silica nanotubes [25].  
After 48 hours of reaction time, the interface was removed and washed with water repeatedly. 
This step was conducted to dissolve peptide nanotubes and obtain mainly silica nanotubes. 
Theses silica nanotubes were characterized by transmission electron microscopy (TEM) and 
SAXS. Figure 6.3 shows electron micrographs and SAXS pattern obtained for the washed silica 
nanotubes. 
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Figure 6.3: Characterization of silica nanotubes. (a) The TEM image of silica nanotubes fabricated from 2%w/w 
substance P nanotubes. Note: red colour arrow – silica nanotubes with a diameter in the range of 12-14 nm. (b) 
Histogram displaying inner diameter distribution of silica nanotubes fabricated from 2%w/w substance P 
nanotubes. (C) SAXS pattern of silica nanotubes fabricated from 10% w/w substance P. (D) SAXS pattern and 
the fit obtained for 10%w/w of pure substance P (chapter 3). 
Electron micrographs evidenced the fabrication of silica nanotubes from 2% w/w substance P 
gel. The histogram shows that the inner diameter of silica nanotubes is centred around 5 nm, 
with a majority of nanotubes (66%) with a diameter in the range of 4-5 nm. The mean diameter 
was calculated as 5.05±1.87 nm. However, 3% of the nanotubes showed a diameter in the range 
of 12-14 nm (red colour arrow 6.3A). 
 
6.3.2 Calcium carbonate crystal formation in the presence of peptide 
nanostructures 
According to literature, macromolecules for instance peptides/proteins with secondary 
structures [32] [33] and self-assembled monolayers [34] have been used to control the 
crystallization process of calcium carbonate. 
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A calcium carbonate supersaturated solution was used to obtain calcium carbonate crystals 
using the Kitano method [29]. Layer by layer deposition of the calcium carbonate 
supersaturated solution and substance P hydrogel was carried out at room temperature on a 
glass slide and observed by optical microscopy. Here, we observed that calcium carbonate 
crystal size is affected by substance P concentration (Figure 6.4, Table 6.1).  
 
Figure 6.4: Optical micrographs (bright field) of calcite calcium carbonate crystals in the presence of different 
concentrations of substance P. (A) Pure calcite calcium carbonate crystals (control) obtained from drying the 
Kitano supersaturated calcium carbonate solution. (B) Calcite calcium carbonate crystals obtained in the presence 
of 2% w/w substance P. (C) Calcite calcium carbonate crystals obtained in the presence of 5% w/w substance P. 
(D) Calcite calcium carbonate crystals obtained in the presence of 10% w/w substance P. Small red circle – calcite 
calcium carbonate crystals showing rhombohedron shape. Large red circle – an aggregate of calcite rhombohedron 
shape crystals. 
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Table 6.1: Variation of calcium carbonate crystal size in the presence of different 
concentrations of substance P nanotubes. 
 
 
 
 
Typical calcium carbonate calcite crystals are rhombohedral in shape as shown in figure 6.4.A 
(small red circle) [35]. In this control sample, the majority of crystals are single crystals, 
however, occasionally crystal aggregates were also identified. Calcium carbonate crystal size 
was measured using Image J open software and presented in Table 6.1. The mean crystal size 
was measured as 4.93 µm for pure calcium carbonate crystals. 
In the presence of substance P, calcium carbonate crystals showed the same crystal shape, 
which is rhombohedral for all peptide concentrations studied. Interestingly, crystal aggregates 
were identified in higher frequency than in the absence of substance P, in particular for 10% 
substance P concentration. According to the tabulated data, as the peptide concentration 
increases calcium carbonate crystal size decreases. The highest mean crystal size (13.30± 3.28 
µm) was observed for the lowest peptide concentration studied (2% w/w) followed by the other 
two concentrations 5% w/w (9.66± 3.61 µm) and 10% w/w (5.17± 1.54 µm), respectively. The 
mean crystal size obtained for 2% w/w substance P is more than twice greater than that of pure 
calcium carbonate. No significant difference was observed in crystal size obtained in the 
presence of 10% w/w the peptide concentration (5.17± 1.54 µm) compared to that of pure 
calcium carbonate crystals (4.93± 1.42 µm).  
Calcium carbonate crystals exist in three types of polymorphs which are calcite (rhombohedral 
shape), vaterite (disk or floret shapes) and aragonite (rods or needles) ) [36] [35]. Vaterite crystals 
were observed to coexist with the calcite (rhombohedral) described above, in the presence of 
substance P. Figure 6.5 shows vaterite crystals observed in the presence of substance P at 2 % 
w/w, which were identified as disk shape (figure 6.5B) and floret shape (figure 6.5C) [37, 38] 
crystals. Disk type crystals are the early stage of floret shape crystals [37].  
Substance P concentration (w/w) Calcium crystal size (µm) 
No peptide (control) 4.93± 1.42 
2% 13.30± 3.28 
5% 9.66± 3.61 
10% 5.17± 1.54 
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Figure 6.5: Optical images of vaterite calcium carbonate crystals obtained in the presence of substance P. (A) 
Pure calcium carbonate crystals showing typical calcite rhombohedral shape obtained in the absence of substance 
P (negative control) (B) Vaterite disk shape crystals obtained in the presence of 2%w/w substance P (C) Vaterite 
floret shape crystals obtained in the presence of 2%w/w substance P and (D) Vaterite disk shape crystals obtained 
in the presence of 5%w/w substance P. 
Vaterite crystals were observed in the presence of 2% and 5% of substance P, however to a 
different extent. This type of crystals was prominently observed at 2%w/w of peptide 
concentration. Indeed, crystal size is also larger in 2%w/w peptide concentration (9.20±1.64 
µm) than 5%w/w of concentration (3.12±0.64 µm). Interestingly, floret shape crystal 
aggregates were only observed at 2%w/w peptide concentration. In the absence of substance 
P, vaterite crystals were not observed.  
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Mann et al have reported that in the presence of stearic acid monolayers, calcium carbonate 
crystallization leads to the formation of vaterite crystals, whereas in the absence of stearic acid 
monolayers, calcium carbonate crystallized to rhombohedral calcite crystals [37]. Further, 
aspartic acid-rich proteins with β-pleated sheets have been shown to control the crystal growth 
of calcium carbonate [33]. Our results are consistent with previously published work revealing 
that an organized macromolecular structure which is β-sheet rich, substance P nanotubes in our 
case, has an ability to control crystal growth through confinement [33] However, 
biomineralization of the peptide structures was not achieved, which is attributed to the lack of 
aspartic acid residues and the cationic charge of the peptide, which likely repels the calcium 
ions.  
 
6.3.3 Functional amyloid templated gold materials. 
The method used for gold synthesis was adapted from previously published reports with 
modifications [28, 30, 39]. Chloroauric acid was used as the gold source, while neuropeptides 
were used to generate nanostructures. Both substance P and somatostatin were allowed to self-
assemble into nanostructures in water. As the final step, the neuropeptide nanostructures and 
chloroauric acid solution were mixed at a molar ratio peptide: gold of 2:5. The reaction was 
left overnight at room temperature and protected from light. During the development stage of 
the protocol, two molar ratios of the peptide to gold salt was attempted (1:1 and 2:5). Among 
those two ratios, the latter showed promising results with faster kinetics. On the other hand, the 
molar ratio of 1:1 showed slower kinetics with less quantity of resulting gold materials. The 
colour of the reaction mixture changed into yellow after one to three days of the reaction time. 
The reaction mixture comprises of 2%w of substance P turned into yellow after one day. 
However, the other two concentrations (5%w/w and 10%w/w) underdo colour change 
approximately after three days. Optical microscopy images evidenced the presence of gold 
crystals at all three concentrations of substance P used. These observations suggest that reaction 
time is very slow with 1:1 peptide to gold salt molar ratio. This might be due to the limited 
availability of gold salts to interact with the peptide nanostructures which reduce gold ions into 
gold. 
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6.3.3.1 Influence of the presence of peptide monomer on gold material synthesis 
To identify the role of peptide monomer in the synthesis of gold materials, we used native 
neuropeptide soluble species such as monomers or oligomers instead of nanofibrils and 
followed the same procedure and molar ratios. Four different neuropeptides were utilized for 
this study: (i) somatostatin, (ii) substance P (iii) luteinizing hormone-releasing hormone 
(LHRH) and (iv) oxytocin. Chapter 3 and 4 describe the soluble species forms by somatostatin, 
substance P and LHRH. Substance P SAXS profile obtained for 1%w/w 10 days aged samples 
showed a slope of -1.66 indicating the presence of 2D flat structures which could be nanofibrils 
(chapter 4). However, in this experiment, we used 2%w/w of substance P which probably gives 
monomer or small oligomers. On the other hand, somatostatin forms dimers at 1%w/w of 
concentration.   LHRH at a concentration of 10%w/w self-assembles into oligomers in size 
range of 20-30 Å. Hence at 2%w/w of concentration, LHRH might remain as the monomer or 
forms small oligomers. However, oxytocin has never been reported to self-assembled into β-
sheet rich nanostructures [40], while other three peptides are able to from nanostructures 
containing β-sheets. Our preliminary data for oxytocin showed that oxytocin has a potential to 
self-assemble into small oligomers for instance dimers (appendix A).  
Immediately after mixing peptide powder with gold chloride solution, all these peptides 
showed coloured precipitates at the bottom of the Eppendorf tube indicating a higher tendency 
to aggregate and precipitate than in the presence of nanofibrils. After 24 hours of incubation 
time, these suspensions were characterized using UV-Vis spectroscopy (figure 6.6) and optical 
microscopy (figure 6.7). 
White/very light red, yellow, light green and orange colours were observed for somatostatin, 
substance P, LHRH, and oxytocin-mediated assembly, respectively. All four suspensions 
display major UV-Vis absorbance in the range of 570-600 nm. This absorbance peak is due to 
the presence of gold nanoparticles in the suspensions.  However, LHRH suspension exhibits 
another pronounced absorbance peak at 732 nm. Oxytocin suspension also showed similarly 
but to a lesser extent. Both somatostatin and substance P suspensions also exhibit similar peak 
however not to the extent as LHRH and oxytocin. According to previously published reports, 
peak emerged in the near-infrared region is due to the presence of gold crystals (triangle, 
hexagonal or other crystal shapes) [41, 42]. Thus, triangle and hexagonal-shaped crystals 
contribute to the peaks observed in 730-740 nm.   
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Figure 6.6: Photographs and UV-Vis spectra of the suspensions obtained neuropeptide monomers. (A) The gold 
suspension obtained from 2%w/w somatostatin. (B) The gold suspension obtained from 2%w/w substance P. (C) 
Gold suspension obtained from 2%w/w LHRH. (D) The gold suspension obtained from 2%w/w oxytocin. 
 
Optical microscopy images show both gold crystal and particle morphologies. Notably, 
suspensions obtained from oxytocin and LHRH monomers display cubic shape crystals. Even 
though oxytocin suspension showed all three types of crystal shapes (hexagonal, triangle and 
cubic), LHRH only displays cubic shape crystals. None of the LHRH suspension images 
showed triangle or hexagonal shape crystals. Optical microscopy and UV-Vis data taken 
together thus reveal that peak arises at 732 nm in spectrum of LHRH suspension are due to the 
presence of cubic shape crystals.  
 
Chapter 6 
 
 
184 
 
 
Figure 6.7: Optical microscopy images of the suspensions obtained using neuropeptide soluble species (A) Gold 
suspension obtained from 2%w/w substance P. (B) Gold suspension obtained from 2%w/w somatostatin. (C) The 
gold suspension obtained from 2%w/w LHRH. (D) The gold suspension obtained from 2%w/w oxytocin. 
 
6.3.3.2 Substance P nanostructure templated gold material 
Figure 6.8 shows photographs of gold materials obtained from different concentrations of 
substance P (2, 5 and 20%w/w) for reactions with gold salts at 2:5 peptide to gold molar ratios. 
Different forms of gold assemblies were observed as a function of substance P concentration. 
The lowest concentration studied (2%w/w) gave rise to precipitates (Figure 6.8A), while higher 
peptide concentrations (5 and 20%w/w) catalysed the formation of gold clusters of a few 
millimetres in substance P hydrogels (Figure 6.8B-E).  
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Figure 6.8: Photographs of gold materials obtained using substance P nanotubes. (A) Gold materials obtained 
from 2%w/w (B, D, and E) 5%w/w and (C) 20%w/w SP.  
Figure 6.9 shows the UV-Vis spectrum obtained for 2% w/w substance P sample with gold, 
after reaction (overnight).  
 
Figure 6.9: UV-Visible spectrum of gold particles synthesized from 2%w/w substance P nanofibrils. 
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The spectrum displays a major peak at 583 nm and a minor peak around 740 nm. Typical UV-
Vis absorbance wavelength of gold nanoparticles is 520 nm. However, depending on the size 
of gold nanoparticles, the presence of gold crystals and shape of the crystals, the absorbance 
wavelength can be shifted to the right side of the spectrum [43, 44]. According to previously 
published reports, gold absorbance in the near-infrared region is due to the presence of gold 
crystals (triangle, hexagonal or other crystal shapes) [41, 42]. Thus, gold nanoparticles and 
crystals contribute to the above spectrum. The UV-Visible spectrum was only recorded for 
gold dispersions obtained from 2%w/w of substance P. Due to the formation of thick gold gels 
by other two concentration it was impossible to record an UV-Visible spectrum for these 
concentrations.  
The samples were further characterized by optical microscopy (figures 6.10 and 6.11), scanning 
electron microscopy (figure 6.12) and transmission electron microscopy (figure 6.13), for gold 
materials synthesized using different substance P concentrations.  
The optical micrographs showed the presence of gold particles and crystals for all three 
substance P concentration studied. Optical image 6.10D provides the evidence for the presence 
of both substance P nanofibrils and gold crystals in this assembly. 
Figure 6.11 shows the gold particle/crystal size distribution as a function of substance P 
concentration measured from optical micrographs. Particle size was measured using Image J 
open software.  
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Figure 6.10: Optical micrographs of gold material obtained in the presence of substance P nanostructures with a 
peptide: gold molar ratio of 2:5. (A) 2%w/w substance P (bright field) (B) 5%w/w substance P (bright field) (C) 
20%w/w substance P (bright field) and (D) 20% w/w substance P (polarised light with crossed polarisers). 
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Figure 6.11: Gold particle (AuP) size distribution obtained from analysis of optical micrographs for different 
concentrations of substance P. 
Table 6.2: Mean particle size of substance P nanostructures templated gold materials.  
SP concentration (w/w) AuP size (µm) 
2% 3.9±1.4 
5% 2.8±1.1 
20% 2.3±0.8 
 
The highest mean particle size (3.9±1.4 µm) was observed for gold particles synthesized from 
2%w/w SP, while the lowest mean particle size (2.3±0.8 µm) was displayed by gold amyloid 
gel synthesized from 20%w/w SP. Particle size distribution data indicate that as peptide 
concentration increases particle size decreases. All these histograms show that gold particle 
size is distributed in a wide range. These results are consistent with the near-infrared 
absorbance recorded by UV-Vis spectrometry (Figure 6.9) [43, 44]. 
Figure 6.12 shows the scanning electron micrographs for the substance P/gold samples.  
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Figure 6.12: Scanning electron micrographs of gold material formed in the presence of substance P. (A) 
Triangle shaped and (B) hexagonal-shaped crystals synthesized from 2%w/w SP. (C and D) Gold crystals 
obtained from 5%w/w SP.  
Scanning electron microscopy exhibits the presence of gold particles/nanoparticles and 
crystals. Mainly hexagonal and triangle-shaped crystals were observed in different sizes. SEM 
images provide evidence for the existence of nanoparticles in gold materials synthesized using 
substance P which was not captured by optical microscopy. Figure 6.12C displays the 
coexistence of matrix which could be substance P nanostructures together with gold crystals 
supporting the formation of gold amyloid hybrid gels. Figure 6.13 shows the distribution of 
gold particles/nanoparticles in gold gel synthesized using 5%w/w of substance P. These 
measurements were carried out to measure the particles in nanometre range which is not 
covered by optical microscopy image analysis. 
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Figure 6.13: Particle size distribution obtained by SEM images of gold particles synthesized using 5%w/w of 
substance P concentration. 
Majority of the particles are situated in the nanometre range. However, very few showed 
micromere size as well (1-1.25 µm). 
 
Figure 6.14: Transmission electron micrographs of gold material obtained from (A) 2%w/w SP and (B) 5%w/w 
SP and (C) 20%w/w SP. 
Transmission electron micrographs showed the presence of gold particles in all three 
concentrations of substance P. Indeed, when substance P concentration increases particle size 
decreases as shown by TEM images. Large gold particles were observed for both 2%w/w and 
5%w/w of substance P concentrations which are in align with the results obtained by particle 
size distribution using optical microscopy images.  
According to optical, SEM and TEM micrographs, the gold material synthesized in the 
presence of substance P comprised gold crystals (triangle and hexagonal shaped) and gold 
nanoparticles for all peptide concentrations, which is consistent with the two values of UV 
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absorbance recorded for these samples. The lowest peptide concentration (2% w/w) favoured 
the formation of gold crystals while increasing peptide concentration favoured gold 
nanoparticle formation.  
 
3.3.2 Somatostatin catalysed gold material 
To study the effect of neuropeptide sequence on the fabrication of gold materials, somatostatin 
nanofibrils were used to synthesize gold materials. Similar reaction protocol as substance P 
was utilized. Gold particles were observed as red colour precipitates in the bottom of the 
Eppendorf tubes shown in figure 6.15 as an insert. When a force was applied to this red colour 
precipitate which was dispersing on a glass slide and covered by a coverslip gave rise to gold 
colour material (6.15 insert). Figure 6.15 shows UV-Vis spectrum obtained for gold dispersion 
obtained using somatostatin. 
 
Figure 6.15: UV-Visible spectrum and photographs (inserts) of gold materials synthesized from 2%w/w 
somatostatin nanofibrils. 
UV-Vis spectra exhibited a peak at 575 nm indicating the presence of gold particles with large 
size [43, 44]. This observation is similar to gold materials obtained from substance P which 
showed UV-Vis absorbance at 583 nm.  
 
Optical microscopy images (6.16A-C) evidence the presence of both gold nanoparticles and 
gold crystals.  
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Figure 6.16: Optical microscopic images (A-C) and (D) particle size distribution of gold particles and crystals 
synthesized from 2%w/w somatostatin nanofibrils. 
Triangle, pentagonal and hexagonal crystal shapes were observed in this case. Figure 6.16D 
shows particle size distribution obtained from measuring gold nanoparticle and crystals 
obtained from optical microscopy using Image J open software. Mean particle size was 
calculated as 2.7±1.1 µm. However, gold nanoparticles and crystals are distributed in a wide 
range (1-6 µm). Majority of particles lie between size range of 1.5-3.5 µm. 
Figure 6.17 shows TEM and SEM images of gold materials synthesized from 2%w/w 
somatostatin nanofibrils. 
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Figure 6.17: TEM (A, B) and SEM (C, D) images of gold particles and crystals synthesized from 2%w/w 
somatostatin nanofibrils. 
Both hexagonal and triangle-shaped crystals were displayed by TEM and SEM images. 
Importantly, SEM images show round gold nanoparticles along with crystals. However, with 
optical microscopy images, it was impossible to measure the size of nanoparticles. Most of the 
measurements were performed on crystals. To overcome this issue gold nanoparticle size was 
measured using SEM images for somatostatin (2%w/w) mediated gold materials. Figure 6.18 
histograms display particle size distribution of gold assemblies synthesized from 2%w/w 
somatostatin. 
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Figure 6.18:  The size distribution of gold particles synthesized from 2%w/w somatostatin nanofibrils. 
 
Majority of the nanoparticles are lying between 150-550 nm. The mean gold nanoparticle size 
was determined as 322.22±67.78 nm. These results taken together with optical microscopic 
analysis indicate reveal that somatostatin templated gold materials are composed of gold 
crystals with a size range of 1-6 µm (Figure 6.16D), while that of the gold nanoparticle is from 
0.15-0.55 µm. On the other hand, substance P based gold nanoparticles are two times greater 
than that of somatostatin, whereas crystals are approximately in the same micrometre range as 
somatostatin. These differences are might be due to the variations in the peptide sequence. 
Somatostatin has more amino acids which has the potential to reduce gold ions into gold 
(tryptophan, glycine and threonine) than substance P. According to the literature , peptides that 
give rise to typical red colour gold nanoparticle dispersions require strong reducing power 
compared to others [30]. 
Comparison of these results with peptide monomer mediated gold material synthesis reveals 
that gold materials generated in the presence of nanostructures are well organized, particularly 
for substance P. However, both gold crystal and particle morphologies were observed in both 
cases. Notably, reaction kinetics was rapid in the presence of soluble species than 
nanostructures. In the presence of soluble species, gold ions have more opportunities to interact 
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with the amino acids than in the presence of nanostructures. At molecular level nanostructures 
are well organized which makes difficult for gold ions to reach amino acids.  
 
6.3.4 Functional amyloid templated silver materials 
The synthesis of silver material was investigated using substance P and somatostatin 
nanostructures as templates. A previously published method was used with modifications [6]. 
First, somatostatin and substance P acetate powders were dissolved in water and allow to self-
assemble into nanostructures before mixing with silver nitrate. The silver nitrate (AgNO3) to 
peptide molar ratio was fixed as 1:25 after optimization of the protocol, detailed in section 
6.2.2.5. After adding silver salt to the peptide nanostructures, the reaction mixture was 
incubated at room temperature for 24 hours. After 24 hours, the reaction mixture displayed 
orange/brown colour precipitates for substance P catalysed silver synthesis (inserts in Figure 
6-19). Figure 6.19 shows photographs and optical microscopy images of the silver material 
obtained with the substance P nanostructures.  
 
Figure 6.19: Optical micrographs and SEM/TEM micrographs of substance P catalysed silver material. (A) 
Polarised light micrograph of 5% SP catalysed silver material. (B) Polarised light micrograph of 10% SP catalysed 
silver material  
Optical micrographs of substance P mediated silver synthesis display birefringent clustered 
fibres for both substance P concentrations studied (Figure 6.19), with larger aggregates for 10% 
substance P.  
Figure 6.20 shows scanning electron microscopic images obtained for silver substance P hybrid 
nanowires. 
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Figure 6.20: Scanning electron microscopic images of silver nanowires synthesized using substance P nanotubes. 
(A) 5%w/w substance P mediated silver nanowires. (B) 10%w/w substance P mediated silver nanowires. 
At both concentrations of substance P, SEM images exhibit nanowire morphology. However, 
at 5%w/w of substance P concentration, silver nanowires are more aligned forming nanowire 
arrays. AS described in chapter 3, substance P forms laterally associated nanotubes at higher 
concentrations (5-20% w/w). Notably, samples were not sputter coated (metal coating) during 
the sample preparation procedure for SEM. Therefore, we hypothesized that silver 
nanoparticles are quoted along the length of substance P nanotubes fabricating arrays of silver 
nanowires at 5%w/w of concentration. In contrast, figure 16.20A shows silver nanowires 
obtained for 10%w/w of substance P concentration which is single nanowires.  
Precipitates obtained after the reaction with silver salts and substance P were extensively 
washed with water before making TEM grids to avoid oxidation of copper grids. TEM images 
obtained for washed silver precipitates are shown in figure 6.20.  
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Figure 6.21: TEM images and particle size distribution of substance P nanofibrils template silver nanoparticles 
and crystals. TEM image (A) and particle size distribution (C) of 5% substance P nanostructure catalysed silver 
material. TEM images (B) and particle size distribution (D) of 10% substance P nanostructure catalysed silver 
material.  
TEM images display silver nanoparticles instead of nanowires. These nanoparticles are closely 
associated with substance P nanostructures, as shown in Figure 6.20B. One plausible 
explanation for this observation is that washing of silver precipitates might disperse silver 
nanoparticles packed along the length of the substance P nanotubes. Mean particle size for 
10%w/w of substance P treated samples is 11.40 ± 2.21 nm, while that of 5%w/w substance P 
treated sample is 68.10 ± 14.98 nm. These results indicate that lower substance P 
concentrations give rise to larger nanoparticles. Therefore, TEM images and particle size 
distribution reveal that due to the washing of silver precipitates, silver nanowires dissociate to 
silver nanoparticles. 
Silver material was also synthesized using somatostatin nanofibrils using the same protocol as 
above to study the influence of peptide sequence on silver materials synthesis. After 24 hours 
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of reaction time, the sample was observed as a dark brown gel as shown in figure 6.21 as an 
insert. Apart from that, figure 6.21 shows optical microscopy and scanning electron 
microscopic images obtained for somatostatin mediated silver materials. 
 
Figure 6.22: Photograph, and microscopic images of the silver materials synthesized using 5%w/w of 
somatostatin nanofibrils. (A) Optical microscopy image of silver somatostatin gel (B) SEM image of silver 
somatostatin gel.  
Both optical microscopy and SEM showed that this hybrid gel is composed of silver particle 
aggregates (Figure 6.21). Besides, SEM images exhibit fibrillar morphology which suggests 
that silver materials are trapped inside the somatostatin gel. Characterization of this gel by 
optical microscopy and SEM was performed without washing the gel. 
Figure 6.21 displays small-angle x-ray scattering pattern observed for somatostatin silver gel.  
 
6.23: SAXS intensity profile of silver nanoparticle dispersion in 5%w/w somatostatin hydrogel. 
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These measurements were also conducted without washing the dispersion prior to the 
measurements. SAXS data showed two correlation peaks at 36.9 Å and 17.9 Å which could be 
due to inner symmetries within the hybrid assembly.  
Figure 6.23 displays TEM image of somatostatin silver gel. Notably, due to the thickness, it 
was impossible to record a good TEM image without dilution. In addition, to prevent oxidation 
of copper grids by silver, the dispersion was washed before mounting on the TEM grid. 
 
Figure 6.24: (A) TEM image of silver nanomaterials obtained from 5%w/w somatostatin hydrogel and (B) 
corresponding particle size distribution 
The TEM image of silver gel displays silver nanoparticles along with a few silver nanocrystals. 
Somatostatin fibrils can also be observed together with silver nanoparticle which indicates the 
assembly of somatostatin silver hybrid material. Silver nanoparticle size distribution data show 
that particles are distributed in the range of 15-65 nm. Mean particle size was calculated as 
33.38±10.23 nm. On the other hand, at the same concentration, substance P gives rise to a 
larger particle size (68 nm). Use of different peptide sequence leads to distinct silver 
nanomaterials such as silver nanowires (substance P) and silver gels (somatostatin). 
6.4 Discussion 
Lately, amyloids are widely been used to fabricate functional nanomaterial such as 
multifunctional composites [45], sensors [15] and cell scaffolds [10] [46] to name a few. This 
chapter shows the use of functional amyloid nanostructures to synthesize organic-inorganic 
hybrid materials, for instance, silica nanotubes and gold/silver particle dispersions. 
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6.4.1 Peptide templated synthesis of silica nanotubes 
Substance P nanotubes formed in water were used as a template to synthesize silica nanotubes 
using a silica precursor, TEOS. For this reaction, substance P nanotubes were formed in water 
instead of 150 mM NaCl or phosphate-buffered saline, as ionic strength was observed to 
prevent silica formation. This observation reveals the role of electrostatic interactions in the 
formation of silica. Upon addition of TEOS solution to substance P gel, substance P nanotubes 
dissociate and diffuse into the upper phase as soluble species. These species in the upper phase 
start assembling into nanotubes again. Both silica polymerization and substance P assembly 
processes occur simultaneously giving rise to substance P silica hybrid nanotubes, as 
previously reported for another system, Lanreotide-silica nanotubes [25]. SAXS patterns 
evidenced the formation of hybrid nanotubes at the interface between TEOS solution and 
substance P gel. However, a similar study has reported that the formation of lanreotide silica 
hybrid nanotubes occurs in the upper phase which is a TEOS solution [25]. A plausible 
explanation for our observation is that due to the high weight of substance P nanotubes they 
could fall into the interface. Another possibility is that due to the fast reaction kinetics between 
substance P and silica the available time might not be sufficient for them to reach the upper 
phase. Photographs obtained during the reaction supports fast reaction kinetics between 
substance P and silica precursor by showing cloudiness after 30 minutes of the reaction begins. 
Indeed, SAXS data also supports the latter explanation by displaying nanotube form factor after 
30 min of the starting point. During the reaction, the only portion of substance P nanotubes 
diffuses into the upper phase leading to the formation of silica substance P hybrid nanotubes at 
the interface. Remaining substance P nanotubes are still present in the bottom phase 
contributing to correlation peaks observed by SAXS for the bottom phase. Correlation peaks 
arise due to the inner symmetries between substance P nanotubes. 
Pouget et al have proposed a mechanism to explain the growth of silica-peptide hybrid 
nanotubes which can also apply to explain the formation of substance P silica hybrid nanotubes 
[25]. As already highlighted, both peptide self-assembly and silica condensation processes 
occur simultaneously. In other words, hybrid nanotubes form as a result of synergy between 
peptide self-assembly and biomineralization. Both processes start from the beginning of 
peptide self-assembly. The peptide is self-assembling while silica precursor is condensing to 
silica. In this situation, both inner and out surface of peptide nanotube is accessible to silica 
precursor to a similar extent. However, TEM images of silica nanotubes templated by substance 
P nanotubes only display outer coating of silica. Since substance P nanotubes are very small in 
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diameter (6 nm) it might be impossible for silica to polymerise within the nanotube. The main 
driving force behind this synergy process is that the electrostatic interactions between 
positively charged substance P nanotube surface and slightly negatively charged silica 
precursor. Condensation of silica precursor to silica gives rise to slightly negatively charged 
silica deposits as a result of the unreacted silanol group [47]. Biomineralization reaction stops 
when charge neutralization occurs between negatively charged silica and positively charged 
substance P wall surface leading to the production of hybrid silica-substance P nanotubes. 
Washing of white colour hybrid nanotubes with water for several times dissociates substance 
P nanotubes resulting in silica replica of substance P nanotubes which is observed by TEM and 
SAXS data. 
6.4.2 Peptide templated crystallisation of calcium carbonate 
Growth of calcium carbonate crystals was monitored in the presence of substance P nanofibrils 
formed at different concentrations of substance P. Crystallization of calcium carbonate from a 
supersaturated calcium carbonate growth solution occurs according to the following 
equilibrium. 
𝐶𝐶𝐶𝐶𝐶𝐶𝑂𝑂3 (𝑠𝑠) + 𝐶𝐶𝑂𝑂2 (𝑔𝑔) + 𝐻𝐻2𝑂𝑂(𝑙𝑙)  ↔ 𝐶𝐶𝐶𝐶2+ (𝐶𝐶𝑎𝑎) + 2𝐻𝐻𝐶𝐶𝑂𝑂3− (𝐶𝐶𝑎𝑎) 
Outgassing of carbon dioxide from calcium carbonate growth solution leads to calcium 
carbonate crystallization. Results obtained from optical microscopy shows that calcium 
carbonate crystal size increases as a function of substance P concentration. Lowest substance 
P concentration studied displayed the highest calcium carbonate crystal size. Indeed, in the 
presence of a low concentration of substance P (2%w/w) different calcium carbonate 
polymorphs (vaterite crystals) were observed compared to the control which only displays 
calcite crystals. Effect of substance P on calcium carbonate crystal size is more likely due to 
the secondary structure of substance P nanofibrils. According to the literature, organized 
organic macromolecular substrates such as β-pleated sheets, α-helix, phospholipid vesicles, 
and stearic acid monolayers possess the ability to catalyse the growth of inorganic minerals 
[33, 37, 48-51]. This catalytic effect is due to electrostatic and stereochemical interactions 
occur at the organic-inorganic interface. Acidic peptides and peptide sequences rich with 
aspartic acid induce calcium carbonate crystal growth through electrostatic interaction between 
negatively charged amino acids and positively charged calcium ions [52-54]. However, 
substance P does not contain any negatively charged amino acids. On the other hand, Picker et 
al. showed that chemistry of side chains of amino acids plays a vital role in protein/peptide-
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mediated calcium carbonate crystallization especially in the early stages of crystallization [55]. 
Glutamine with a side chain ending with an amide and methionine which contains mercapto 
functional groups in their side-chain influences crystal growth. Presence of two glutamine 
residues and one methionine residue in substance P structure could contribute the increase in 
calcium carbonate crystal size. Birchall and co-workers have reported that in the presence of 
organized steric acid monolayers, vaterite calcium carbonate crystals are formed, while in 
control sample only rhombohedral calcite crystals are formed [37]. In another study, the 
presence of ovalbumin protein alters calcite crystal morphology, whereas in the absence of 
ovalbumin well define rhombohedral calcite crystals are formed [54]. These findings well align 
with our results which shows that the presence of substance P leads to the formation of both 
calcite and vaterite crystals, while the control sample only forms rhombohedral calcite crystals. 
Always more prominent effects of substance P has been observed with the lowest concentration 
(2%w/w) studied. This might be due to the fact that at low concentrations, nanofibrils are 
separated and therefore calcium ions can easily access amino acid side chains in the wall 
surface. However, at higher concentrations, since substance P nanotubes are laterally 
associated and well-aligned, it is possible that calcium ion may not be able to interact with 
amino acid side chain as effectively as low concentrations. To support these findings, x-ray 
scattering needs to be performed. 
6.4.3 Peptide templated gold and silver synthesis 
Gold materials were fabricated using both neuropeptide soluble species and aggregated 
nanostructures. Typically, the inorganic nanoparticle is synthesized using harsh reducing 
agents and extreme conditions such as high temperature, high pressure, and extreme pHs. The 
method described in this thesis hence provides a green synthetic protocol to fabricate gold 
materials. Gold materials obtained in the presence of neuropeptide nanostructures are well-
organized than that of neuropeptide monomers. The schematic illustration shown in figure 6.25 
explains the formation of gold materials by both neuropeptide nanofibrils and monomers. 
Substance P self-assembles into β-sheet rich nanotubes, while that of somatostatin forms 
nanofibrils. Both nanostructures are well-organized at the molecular level which leads to the 
synthesis of organized gold materials. On the other hand, neuropeptide monomers give rise to 
typical gold material suspensions. Electrostatic interactions between amyloid fibrils and gold 
nanoparticles/crystals govern the interactions of these two species. Both somatostatin and 
substance P nanostructures templated the synthesis of gold nanoparticles and gold crystals. 
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Figure 6.25: Schematic illustration of preparation of gold materials from (A) neuropeptide soluble species and 
(B) neuropeptide nanostructures. 
According to a recently published report, gold nanoparticle dispersions showing red colour 
require strong reducing power to reduce Au(III) to Au(0) [30]. This suggests that somatostatin 
has a stronger reducing power than substance P, which could be explained by the presence of 
amino acid with reducing properties such as tryptophan, glycine and two threonine residues in 
its sequence [22, 56] [21]. 
The results presented in this thesis suggest that the particle size of gold material can be 
controlled by peptide concentration. Higher peptide concentrations lead to smaller particle size. 
This observation can be explained by the fact that at high peptide concentrations, 
nanostructures are more organized giving rise to stable liquid crystalline structures which may 
reduce the opportunity of interactions with gold ions.  
The presence of gold nanocrystals gives rise to an additional peak in the near-infrared range. 
Lately, gold nanoplates/nanocrystals have attracted more attention in biomedical applications 
such as plasmonic photothermal therapy, biosensing and cell imaging owing to their high 
anisotropy, increased cellular uptake and enhance surface plasmon resonance [42, 57-59]. 
Since the synthetic procedure described in this thesis is an environmentally friendly, safe and 
simple approach, modification of synthetic protocol to enhance yield especially nanocrystal 
yield would definitely provide significant advantages to develop biomedical applications. 
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Silver nanoparticles, silver nanowires, and silver dispersions were developed using substance 
P and somatostatin nanostructures according to a green synthetic approach. The procedure used 
to develop silver nanowires is illustrated in figure 6.26. Self-assembly of substance P leads to 
the formation of β-sheet rich hollow nanotubes which reduced Ag(I) ion to Ag(0). Both SEM 
and optical microscopy data evidenced the formation of silver nanowires. To obtained silver 
nanowires, silver nanoparticles arrange tightly along the nanotube wall in a vertical direction. 
Dilution of this well-packed assembly leads to a relaxing of such arrangement giving rise to 
both free nanoparticles in the solution and some nanoparticles still attached to the nanotube 
wall. Due to strong antimicrobial properties and low cytotoxicity, silver nanowires have been 
proposed to use in coating of the surface of catheters [60] and combining with chitosan 
biocompatible polysaccharide to develop metal nanostructures that can be used in drug 
delivery, wound healing and medical devices [1, 61, 62].  
Figure 6.26: Schematic illustration of silver nanowire synthesis using substance P nanotubes.  
In the case of somatostatin, β-sheet rich somatostatin nanofibrils produced a silver dispersions 
which has the potential to develop into antibacterial gels and wound healing dressings [6]. 
Silver nanoparticles are trapped inside the somatostatin gel giving rise to a somatostatin-silver 
dispersion. Our results for the silver assembly show that nanostructure and peptide sequence-
dependant silver materials can be obtained by following the synthetic protocol described in this 
thesis.  
6.5 Conclusion 
This chapter explores the potential of developing organic-inorganic hybrid nanomaterials using 
neuropeptide’s self-assembling properties. We were able to develop a green synthetic method 
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which is effective, environmentally friendly, safe and simple to produced gold materials. Both 
neuropeptide monomer and nanostructures could reduce gold salt into gold and generate gold 
materials. However, in the presence of neuropeptide nanostructures well define gold materials 
are formed. As a function of peptide concentration different size of gold particles can be 
obtained. Silver nanowires and silver nanoparticle dispersions are synthesized by using 
functional amyloid fibrils which has the potential to develop into antibacterial materials. 
Moreover, silica nanotubes were successfully generated using substance P nanotubes as 
templates which has applications in nano-optics and electronics. Nanostructures formed by 
functional amyloids could influence the crystal size and shape of calcium carbonate which 
aligns well with previous reports published on similar systems. All these findings open a new 
path for functional amyloid templated biomaterials. To the best of our knowledge very few 
attempts have been performed to develop such materials. 
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Chapter 7 
General discussion, conclusions and perspectives 
This thesis focused on studying functional amyloid formation by three neuropeptides: 
somatostatin-14, substance P and luteinizing hormone-releasing hormone (LHRH) under 
conditions relevant to secretory granules, including mildly acidic pH, high peptide 
concentrations, high ionic strength and presence of aggregation helpers in vitro. Indeed, 
cytotoxicity of these neuropeptide self-assemblies towards model neuronal cells and glial 
cells was investigated. Finally, explored the potential of developing bionanomaterials using 
functional amyloids based on neuropeptides. The structure and properties of assemblies 
formed by model neuropeptides were elucidated using a multidisciplinary approach 
combining biophysical and cell biology techniques.  
Substance P self-assembly without an aggregation helper, heparin has not been reported 
previously [1]. This thesis, for the first time, reports that neurotransmitter substance P 
intrinsically self-assembled into liquid crystalline nanotubes with a diameter of 6 nm. 
Although significant changes were not observed in NMR chemical shifts between substance 
P soluble state and aggregation state, indicating no change in the immediate environment of 
atoms, relaxation spectral data support that positively charged amino acids play a role in 
substance P aggregation. These data suggest the direct structural involvement of substance P 
counterions within the substance P nanotubes. These results are important as this is the first 
natural neuropeptide shown to form nanotubes. Despite the achieved progress in studying of 
substance P nanotube formation and their structure further studies are necessary to reveal the 
wall structure of nanotubes to proposed 3D structural model for substance P nanotubes. Since 
substance P is a natural neuropeptide implicated in diverse functions in humans, these 
findings could provide important insights into its biological function. In addition, structural 
information of substance P nanotubes could deliver new knowledge to the field of functional 
amyloids providing a better understanding of concepts in this field. 
LHRH is a natural neuropeptide hormone which has been previously reported not to form 
functional amyloids [2]. However, this thesis report for the first time that LHRH self-
assembles into liquid crystalline nanofibrils arranged in a hexagonal network. Since LHRH 
bear histidine residue in their structure, self-assembling properties of LHRH is pH dependent. 
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Alkaline pH favours aggregation kinetics, while slightly acidic pH favours longer nanofibril 
formation. Recently, LHRH analogs have been developed into long-acting depot formulations 
using functional amyloid properties to treat conditions involved in reproductions and related 
functions [2-6]. However, due to the very slow aggregation kinetics and low nanofibril yield 
observed for native LHRH at the physiological range of pH it would be impossible to develop 
such formulations from Native LHRH. However, results obtained on both substance P and 
LHRH intrinsic aggregation expand the understating of functional amyloid formation 
mechanisms and their properties. 
As this thesis highlights, amyloid aggregation inducers like heparin not only influence 
aggregation kinetics but also alter the structure of the assemblies formed. In particular, this 
finding is important when drawing conclusions about structure-activity relationships in 
fundamental amyloid studies. The heparin effect is mainly due to the electrostatic interactions 
between the positively charged peptide and negatively charged sulfate groups of heparin 
molecule. Besides promoting aggregation kinetics, heparin influences the formation of very 
stable amyloid fibrils as indicated by monomer releases studies. In the context of functional 
amyloids, the current belief is that amyloids are the storage form of neuropeptides and 
peptide/protein hormones where they dissociate into monomeric peptide/protein upon 
appropriate stimulation [7]. With this in mind, findings of this thesis question the 
applicability of heparin-mediated functional amyloids as a type of functional amyloids 
formed in neuropeptide/hormone aggregation in vivo.  
Heparin influence was studied using three neuropeptides which possess different aggregation 
kinetic profiles: somatostatin-14, substance P and LHRH. Among these three neuropeptides, 
substance P aggregation does not significantly influence by the addition of heparin. This 
finding raised the question that is heparin influence is universal for all neuropeptides and 
hormones which form functional amyloids? If it’s not, then what are the factors determining 
heparin influence? As this thesis indicates peptide structure and distribution of positive 
charges along with the structure could be certain factors governing heparin influence. 
Another question opens up by these findings is that if heparin significantly alters the structure 
of final assemblies formed, is it appropriate to use heparin as a model to study the influence 
of glycosaminoglycans on functional amyloid formation? This statement is supported by the 
results obtained for chondroitin sulfate which is also a glycosaminoglycan with fewer sulfate 
units. The structure of the final assemblies acquired with chondroitin sulfate resembles 
assemblies obtained from pure neuropeptide to a greater extent compared to heparin.  
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Cell biology studies conducted to determine the cytotoxicity of neuropeptide self-assemblies 
towards neuronal cells reveal concentration- and structure-dependent cytotoxicity of 
neuropeptide self-assemblies. Peptide soluble species and liquid crystalline arrays of 
neuropeptide nanostructures are non-toxic. However, amorphous aggregates/precipitates 
formed at high neuropeptide concentration in cell culture media were correlated to 
cytotoxicity towards neuroblastoma cells and microglia. This study questions the use of MTS 
and related assay as the only experiment to determine cell viability. In the context of both 
disease-associated and functional amyloids, appropriate cell biology assays to examine cell 
viability would be experiments involved with flow cytometry which has a feature to select 
particles/cells based on size. In addition, the use of DMEM cell culture media to prepare 
peptides has drawbacks as shown in this thesis such as precipitate formation by pure 
neuropeptides in the presence of DMEM. Most important finding reported by this thesis in 
regard of cell-based assays is that soluble neuropeptide species and liquid crystalline arrays 
of neuropeptide nanostructures are non-cytotoxic to neuronal cells, while fibrillary 
precipitates formed in the presence of heparin and DMEM causes cytotoxicity to neuronal 
cells. This finding again questions the use of heparin as a model system to study the influence 
of glycosaminoglycan on functional amyloid formation. Apart from that, another question 
arises from these findings is that biological relevance of heparin in functional amyloid 
formation which is also supported by the fact that heparin is not reported to located in the 
brain [8].  
As this study clearly demonstrates functional amyloids can be used as templates to develop 
organic-inorganic nanomaterials which have a wide range of applications in diagnostic tools, 
nanoelectronics, antibacterial materials, and drug delivery to name a few [9-12]. These 
materials offer novel perspectives of sol-gel synthesis pathways for inorganic nanostructures 
under soft conditions. This thesis discovered the formation of silica nanotubes using 
substance P nanotubes as templates. Indeed gold-amyloid hybrid gels and gold crystals were 
developed using functional amyloid nanostructures and a gold source. Silver substance P 
hybrid nanowires and silver amyloid hybrid gels were synthesized using functional amyloid 
nanofibrils and silver salts. Typical synthetic protocols use to fabricate gold nanoparticles 
involves the use of harsh chemicals (strong reducing agents) and extreme conditions (high 
pH, high pressure and extreme pHs). Notably, this thesis presents a novel protocol to 
synthesise gold crystals and gold amyloid hybrid gels using a green synthetic approach, 
which is effective, safe, simple and environmentally friendly. Organic-inorganic 
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nanomaterials developed in this thesis open the pathway for further research to develop an 
application. In this context, silica nanotubes replicated from substance P nanotubes has the 
potential to be developed into nanoneedle employed in drug delivery. The fabrication of 
aligned arrays of nanotubes can be obtained by vapor deposition technique as reported 
previously for a similar system; however, the protocol should be optimized to align with 
requirements of our system [13]. Lately, gold nanoplates/nanocrystals have attracted more 
attention in biomedical applications such as plasmonic photothermal therapy, biosensing and 
cell imaging owing to their high anisotropy, increased cellular uptake and enhance surface 
plasmon resonance [14-17]. Since the synthetic procedure described in this thesis is safe and 
simple, modification of synthetic protocol to enhance the yield especially nanocrystal yield 
would provide significant advantages to develop biomedical applications. 
To conclude, this thesis reports functional amyloid formation by two neuropeptides substance 
P and LHRH for the first time. However, further research needs to be conducted to develop a 
3D structural model for substance P nanotubes. To the best of our knowledge, this is the first 
natural neuropeptide shown to form non-toxic nanotubes. Heparin mediated aggregation of 
neuropeptides reveal that heparin not only accelerates peptide self-assembly but also alters 
the structure of the assemblies formed. Indeed, this work highlights the danger of using 
heparin in fundamental amyloid research, especially when studying structure-activity 
relationships. Cell biology experiments clearly demonstrate that cytotoxicity of functional 
amyloids towards neuronal cells are both structure and concentration dependent. Importantly, 
this study questions the use of MTS and related assays without any complementary method to 
determine cell variability, particularly in amyloid research. Overall, the results presented in 
this thesis contribute to enhancing the current understanding of functional amyloid formation. 
Finally, this thesis explored the use of functional amyloids as templates to fabricate organic-
inorganic hybrid nanomaterials. By further research, inorganic-organic hybrid materials 
discovered in this thesis could be developed into nanotechnology applications, for instance, 
nanoneedles for drug delivery and inorganic nanomaterials for diagnostic tools or 
nanoelectronics. 
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Self-assembly of neuropeptide oxytocin 
Oxytocin (sequence: Cyclo-Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2, MW 1007 Da) is a 
neuropeptide hormone produced by the hypothalamus and released by the posterior pituitary. 
It has implicated in diverse functions of the body, including stimulating contractions of uterine 
smooth muscles, postpartum haemorrhage, lactation and social bonding [1, 2]. The self-
assembling tendency of neuropeptide Oxytocin was investigated using ThT assay, TEM and 
mass spectrometry (MALDI-TOF). Figure A1 show short fibrils formed by oxytocin over the 
period of two weeks in 150 mM NaCl (A1.A) and PBS (A1.B). 
 
Figure A1: TEM images of 5%w/w Oxytocin assemblies formed at (A) 150 mM NaCl and 
(B) PBS. 
However, ThT assay failed to provide a conclusive result about oxytocin aggregation kinetics.  
Mass spectroscopic experiments performed at three different temperatures showed that 
oxytocin can oligomerized up to trimers (Figure A2-A4). Oxytocin assemblies formed at room 
temperature only display the monomer, while higher temperatures showed up to the trimer. 
Methods 
Peptide sample preparation 
Oxytocin acetate powered was dissolved in different solvents (water, PBS and 150 mM NaCl) 
according to the detail protocol provided in section 2.1.4. 
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Transmission electron microscopy (TEM) 
TEM experiments were carried out to investigate the nanostructures formed by oxytocin in 
different buffers (detail protocol 2.2.5). 
Thioflavin T assay 
Oxytocin self-assembling kinetics was determined using ThT assay as per the protocol given 
in 2.2.1. 
Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-
TOF MS) 
A weighed fraction of oxytocin was dissolved in water to obtain a final concentration of 20%w/w. The 
resulting solution was diluted until the concentration of 0.2%w/w before the experiment. THAP (2,4,6-
Trihydroxyacetophenone) matrix (9 µL) was mix with 1 µL of the sample in a microcentrifuge 
tube. Then 1-2 µL of sample/matrix was transferred on to the plate and subsequently loaded to 
the Bruker AutoFlex MALDI-TOF MS to record the spectra.
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Figure A2: MALDI-TOF mass spectrum of 20%w/w oxytocin in water incubated for two weeks at 37°C. 
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Figure A3: MALDI-TOF mass spectrum of 20%w/w oxytocin in water incubated for two weeks at room temperature. 
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Figure A4: MALDI-TOF mass spectrum of 20%w/w oxytocin in water incubated for two weeks at 4°C.
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Solution state NMR spectra of substance P (chapter 3) 
 
Proton NMR of aggregated state substance P 
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Proton NMR of soluble state substance P 
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13C-NMR of soluble state substance P 
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COSY-NMR of soluble state substance P 
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HSQC-NMR of soluble state substance P 
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HMBC-NMR of soluble state substance P 
 
 
